var title_f11_45_11984="Complete fracture reduction A";
var content_f11_45_11984=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F63133&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F63133&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Complete fracture reduction: Reestablish length",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panels A and B) Use of the thumb to push the distal fragment hyperdorsiflexed 90 degrees (black arrow) until length is reestablished. Counteraction is applied in the opposite direction (white arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Waters PM, Mih AD. Fractures of the distal radius and ulna. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_45_11984=[""].join("\n");
var outline_f11_45_11984=null;
var title_f11_45_11985="Breech delivery using forceps for aftercoming head";
var content_f11_45_11985=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/OBGYN/73745/Bre_del_using_forcep_conv.mp4?title=Breech+delivery+using+forceps+for+aftercoming+head\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Breech delivery using forceps for aftercoming head",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rafik Mansour, MD and the STRATUS Center for Medical Simulation at Brigham and Women's Hospital, Boston, MA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_45_11985=[""].join("\n");
var outline_f11_45_11985=null;
var title_f11_45_11986="Patient information: Supraventricular tachycardia (SVT) (The Basics)";
var content_f11_45_11986=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86463\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/42/9888\">",
"         Normal heart",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/63/7154\">",
"          Person having an ECG",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?20/32/20994\">",
"         Patient information: Atrial fibrillation (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/51/25395\">",
"         Patient information: ECG and stress test (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/34/5666\">",
"         Patient information: Tachycardia (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/17/33042\">",
"         Patient information: Vagal maneuvers and their responses (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?0/16/261\">",
"         Patient information: Atrial fibrillation (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Supraventricular tachycardia (SVT) (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H101255819\">",
"      <span class=\"h1\">",
"       What is supraventricular tachycardia (SVT)?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Supraventricular tachycardia, also called &ldquo;SVT,&rdquo; is a heartbeat that is faster than normal. It usually starts and stops suddenly, without warning. SVT is also called &ldquo;paroxysmal supraventricular tachycardia&rdquo; or PSVT. (Paroxysmal means a sudden attack.)",
"     </p>",
"     <p>",
"      SVT happens because of a problem with the heart&rsquo;s electrical system. It starts in the upper chambers of the heart, called the &ldquo;atria&rdquo; (",
"      <a class=\"graphic graphic_figure graphicRef56936 \" href=\"UTD.htm?9/42/9888\">",
"       figure 1",
"      </a>",
"      ). The fast heartbeat can last from a few minutes to hours, but usually lasts for 10 to 15 minutes. It often happens when you are at rest. But in some people, exercise triggers it.",
"     </p>",
"     <p>",
"      The 3 main types of SVT are called:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Atrioventricular nodal reentry tachycardia (AVNRT)",
"       </li>",
"       <li>",
"        Atrioventricular reentry tachycardia (AVRT)",
"       </li>",
"       <li>",
"        Atrial tachycardia",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H101255851\">",
"      <span class=\"h1\">",
"       What are the symptoms of SVT?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You might not have symptoms. But you might feel that your heart is beating too fast, beating hard, or seems to skip a beat. These kinds of heartbeat changes are called &ldquo;palpitations.&rdquo;",
"     </p>",
"     <p>",
"      You might also feel:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Lightheaded",
"       </li>",
"       <li>",
"        Dizzy",
"       </li>",
"       <li>",
"        Very tired",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you also have coronary heart disease, you might also:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have trouble breathing",
"       </li>",
"       <li>",
"        Feel a tightness in your chest",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H101255866\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have trouble breathing or have chest pain that lasts for more than a few minutes, call 9-1-1 for an ambulance.",
"     </p>",
"     <p>",
"      If you do not have these problems, but you often feel your heart beating fast or irregularly, talk to your doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H101255881\">",
"      <span class=\"h1\">",
"       Is there a test for supraventricular tachycardia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will do a test called an electrocardiogram, also known as an &ldquo;ECG&rdquo; or &ldquo;EKG.&rdquo; This test measures the electrical activity in your heart (",
"      <a class=\"graphic graphic_figure graphicRef53145 \" href=\"UTD.htm?6/63/7154\">",
"       figure 2",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Other possible tests include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Holter monitor - This is a small, portable machine you wear that records all the heart&rsquo;s electrical activity over 1 or 2 days.",
"       </li>",
"       <li>",
"        Event or loop monitor &ndash; These are similar to Holter monitors but smaller, because they don&rsquo;t record all the time. Instead, you start the monitor when you feel symptoms. Your doctor will likely have you wear 1 of these monitors every day for about a month.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H101255896\">",
"      <span class=\"h1\">",
"       How is supraventricular tachycardia treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The treatment depends on the cause of the tachycardia. When your heartbeat is very fast, your doctor might suggest ways to slow it down. He or she might have you cough, or bear down as if you&rsquo;re having a bowel movement. He or she might also suggest that you put an ice pack on your face. Doing these things can affect the nerve that helps control your heartbeat.",
"     </p>",
"     <p>",
"      Other treatments can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines to control the speed or rhythm of your heartbeat",
"       </li>",
"       <li>",
"        A treatment called &ldquo;cardioversion&rdquo; that involves applying a mild electrical current to the heart to fix its rhythm",
"       </li>",
"       <li>",
"        Treatments called &ldquo;ablation.&rdquo; Ablation treatments use heat (called &ldquo;radiofrequency ablation&rdquo;) or cold (called &ldquo;cryoablation&rdquo;) to destroy the small part of the heart that is sending the abnormal electrical signals.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H101255911\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/34/5666?source=see_link\">",
"       Patient information: Tachycardia (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=see_link\">",
"       Patient information: ECG and stress test (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/17/33042?source=see_link\">",
"       Patient information: Vagal maneuvers and their responses (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/32/20994?source=see_link\">",
"       Patient information: Atrial fibrillation (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/16/261?source=see_link\">",
"       Patient information: Atrial fibrillation (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?11/45/11986?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86463 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-6F4C19BDB0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_45_11986=[""].join("\n");
var outline_f11_45_11986=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H101255819\">",
"      What is supraventricular tachycardia (SVT)?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H101255851\">",
"      What are the symptoms of SVT?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H101255866\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H101255881\">",
"      Is there a test for supraventricular tachycardia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H101255896\">",
"      How is supraventricular tachycardia treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H101255911\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86463\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/42/9888\">",
"      Normal heart",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/63/7154\">",
"       Person having an ECG",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/16/261?source=related_link\">",
"      Patient information: Atrial fibrillation (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/32/20994?source=related_link\">",
"      Patient information: Atrial fibrillation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=related_link\">",
"      Patient information: ECG and stress test (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/34/5666?source=related_link\">",
"      Patient information: Tachycardia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/17/33042?source=related_link\">",
"      Patient information: Vagal maneuvers and their responses (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_45_11987="Lymphangitic cancer CT II";
var content_f11_45_11987=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F79160&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F79160&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT appearance of asymmetric lymphangitic carcinomatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 375px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Asymmetric lymphangitic spread of bronchogenic carcinoma, primarily involving the right lung. Thickened bronchovascular bundles and a fine reticular pattern are seen and probably represent thickened interlobular and intralobular septae. Polygon formation is seen in the anterior and medial aspect of the right lung. Several thickened interlobular septa are present, abutting the medial pleura of the right lung.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_45_11987=[""].join("\n");
var outline_f11_45_11987=null;
var title_f11_45_11988="C-section (cesarean delivery)";
var content_f11_45_11988=[" <h1 id=\"patTopicTitle\">",
"  Patient information: C-section (cesarean delivery) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?11/45/11988/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/45/11988/contributors\" id=\"au2171\">",
"       Vincenzo Berghella, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?11/45/11988/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/45/11988/contributors\" id=\"se4723\">",
"       Charles J Lockwood, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?11/45/11988/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/45/11988/contributors\" id=\"de4555\">",
"       Vanessa A Barss, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?11/45/11988?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     A cesarean delivery (also called a surgical birth) is a surgical procedure used to deliver an infant (",
"     <a class=\"graphic graphic_figure graphicRef63791 \" href=\"UTD.htm?30/10/30880\">",
"      figure 1",
"     </a>",
"     ). It requires regional (or rarely general) anesthetic to prevent pain, and then a vertical or horizontal (&lsquo;bikini line&rsquo;) incision in the lower abdomen to expose the uterus (womb). Another incision is made in the uterus to allow removal of the baby and placenta. Other procedures, such as tubal ligation (sterilization), may also be performed during cesarean delivery. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/28/7620?source=see_link\">",
"      \"Patient information: Permanent sterilization procedures for women (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Cesarean deliveries may be performed because of maternal or fetal problems that arise during labor, or they may be planned before the mother goes into labor. More than 30 percent of births in the United States occur by cesarean delivery.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      REASONS FOR CESAREAN DELIVERY",
"     </span>",
"    </p>",
"    <p>",
"     Some women who intend to deliver vaginally will eventually require cesarean delivery. The following list describes some reasons cesarean might be needed:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Labor is not progressing as it should. This may occur if the contractions are too weak, the baby is too big, the pelvis is too small, or the baby is in an abnormal position. If a woman's labor does not progress normally, in many cases, the woman will be given a medication",
"       <span class=\"nowrap\">",
"        (Pitocin&reg;/oxytocin)",
"       </span>",
"       to be sure that contractions are adequate for several hours. If labor still does not progress after several hours, a cesarean delivery may be recommended.",
"      </li>",
"      <li>",
"       The baby's heart rate suggests that it is not tolerating labor well.",
"      </li>",
"      <li>",
"       The baby is in a transverse (sideways) or breech position (buttocks first) when labor begins.",
"      </li>",
"      <li>",
"       Heavy vaginal bleeding. This can occur if the placenta separates from the uterus before the baby is delivered (called a placental abruption).",
"      </li>",
"      <li>",
"       A medical emergency threatens the life of the mother or infant (see",
"       <a class=\"local\" href=\"#H9\">",
"        'Emergency cesarean delivery'",
"       </a>",
"       below)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      PLANNING CESAREAN DELIVERY",
"     </span>",
"    </p>",
"    <p>",
"     A planned cesarean delivery is one that is recommended because of the increased risk(s) of a vaginal delivery to the mother or her infant. Cesarean deliveries that are done because the woman wants, but does not",
"     <strong>",
"      require",
"     </strong>",
"     , a cesarean delivery are called \"maternal request cesarean deliveries\". (See",
"     <a class=\"local\" href=\"#H8\">",
"      'Maternal request cesarean delivery'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     There are a number of medical and obstetric circumstances that a healthcare provider would recommend scheduling a cesarean delivery in advance. Some of these circumstances are listed below:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The mother has had a previous cesarean delivery or other surgery in which the uterus was cut open. A vaginal delivery is possible after cesarean delivery in some, but not all cases. (See",
"       <a class=\"local\" href=\"#H15\">",
"        'Future deliveries'",
"       </a>",
"       below.)",
"      </li>",
"      <li>",
"       There is some mechanical obstruction that prevents or complicates vaginal delivery, such as large fibroids or a pelvic fracture.",
"      </li>",
"      <li>",
"       The infant is unusually large, especially if the mother has diabetes. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?10/45/10966?source=see_link\">",
"        \"Patient information: Care during pregnancy for women with type 1 or 2 diabetes mellitus (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       The mother has an active infection, such as herpes or HIV, that could be transmitted to the infant during vaginal delivery. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?36/3/36916?source=see_link\">",
"        \"Patient information: Genital herpes (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?7/29/7635?source=see_link\">",
"        \"Patient information: HIV and pregnancy (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       The birth involves multiple gestation (twins, triplets, or more).",
"      </li>",
"      <li>",
"       The woman has cervical cancer.",
"      </li>",
"      <li>",
"       The infant has an increased risk of bleeding.",
"      </li>",
"      <li>",
"       The placenta is covering the cervix (called placenta previa).",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     There is some controversy about the preferred method of delivery in certain situations. These include some birth defects, such as spina bifida and fetal abdominal wall defects, and some maternal medical problems.",
"    </p>",
"    <p>",
"     One of the most important factors in scheduling a cesarean delivery is making certain that the baby is ready to be delivered. In general, cesarean deliveries are not scheduled before the 39th week of pregnancy. An amniocentesis may be recommended to determine if the baby's lungs are fully developed, especially if cesarean is planned before 39 weeks of pregnancy.",
"    </p>",
"    <p>",
"     Most women will meet with an anesthesiologist before planned surgery to discuss the various types of anesthesia available and the risks and benefits of each. Instructions about how to prepare for surgery will also be given, including the need to avoid all food and drinks for 10 to 12 hours before the surgery.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Advantages of planned cesarean",
"     </span>",
"     &nbsp;&mdash;&nbsp;The advantages of a planned cesarean delivery include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       It allows parents to know exactly when the baby will be born, which makes issues related to work, childcare, and help at home easier to address.",
"      </li>",
"      <li>",
"       It avoids some of the possible complications and risks to the baby.",
"      </li>",
"      <li>",
"       It avoids the possibility of postterm pregnancy, in which the baby is born two or more weeks after its due date.",
"      </li>",
"      <li>",
"       It helps ensure that a pregnant woman's obstetrician will be available for the delivery.",
"      </li>",
"      <li>",
"       It may offer a more controlled and relaxed atmosphere, with fewer unknowns such as how long labor and delivery will last.",
"      </li>",
"      <li>",
"       It may minimize injury to the pelvic muscles and tissues and the anal sphincters. These injuries sometimes occur during vaginal delivery, which may increase the risk of urinary or anal incontinence.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The benefits of planned cesarean delivery must be weighed against the risks. Cesarean delivery is a major surgery, and has associated risks.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Risks",
"     </span>",
"     &nbsp;&mdash;&nbsp;Because cesarean delivery involves major surgery and anesthesia, there are some disadvantages compared to vaginal delivery.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Cesarean delivery is associated with a higher rate of injury to abdominal organs (bladder, bowel, blood vessels), infections (wound, uterus, urinary tract), and thromboembolic (blood clotting) complications than vaginal delivery.",
"      </li>",
"      <li>",
"       Cesarean surgery can interfere with mother-infant interaction in the delivery room.",
"      </li>",
"      <li>",
"       Recovery takes longer than with vaginal delivery.",
"      </li>",
"      <li>",
"       Cesarean delivery is associated with a higher risk that the placenta will attach to the uterus abnormally in subsequent pregnancies, which can lead to serious complications.",
"      </li>",
"      <li>",
"       Cutting the uterus to deliver the baby weakens the uterus, increasing the risk of uterine rupture in future pregnancy. This risk is small and depends upon the type of uterine incision.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h3\">",
"      Infant risks",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are few risks of cesarean delivery for the infant. One risk is birth trauma, which is rare. Temporary respiratory problems are more common after cesarean birth because the baby is not squeezed through the mother's birth canal. This reduces the reabsorption of fluid in the infant's lungs.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Potential complications",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most common complications related to cesarean delivery include infection, hemorrhage (excessive bleeding), injury to pelvic organs, and blood clots.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Infection &mdash; The risk of postoperative uterine infection (endometritis) varies according to several factors, such as whether labor had started and whether the water was broken. Endometritis is treated with antibiotics.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Wound infection, if it occurs, usually develops four to seven days after surgery, but sometimes appears during the first day or two. In addition to antibiotics, wound infections are sometimes treated by opening the wound to allow drainage, cleansing with fluids, and removing infected tissue if needed.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Hemorrhage &mdash; One to two percent of all women having cesarean deliveries require a blood transfusion because of hemorrhage (excessive bleeding). Hemorrhage usually responds to medications that cause the uterus to contract or procedures to stop the bleeding In rare cases, when all other measures fail to stop bleeding, a hysterectomy (surgical removal of the uterus) may be required.",
"      </li>",
"      <li>",
"       Injury to pelvic organs &mdash; Injuries to the bladder or intestinal tract occur in approximately one percent of cesarean deliveries.",
"      </li>",
"      <li>",
"       Blood clots &mdash; Women are at increased risk of developing blood clots in the legs (deep vein thrombosis or DVT) or the lungs (pulmonary embolus) during pregnancy and the postpartum period. This risk is further increased after cesarean delivery. The risk can be reduced by using a device that gently squeezes the legs during and after surgery, called an intermittent compression device. Women at high risk of DVT may be given an anticoagulant (blood thinning) medication to reduce the risk of blood clots.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      MATERNAL REQUEST CESAREAN DELIVERY",
"     </span>",
"    </p>",
"    <p>",
"     The concept of requesting a cesarean delivery is relatively recent. In the United States and most Western countries, pregnant women have the right to make choices regarding treatment, including how they will deliver their child.",
"    </p>",
"    <p>",
"     A woman who wants to request a cesarean delivery should discuss this decision with her healthcare provider. He or she can provide information about each method of delivery and can help to relieve common fears about pain, the expected process of labor, as well as the woman's right to determine how she will deliver. The woman should also discuss the risks and benefits of maternal request cesarean delivery; in general, the risks are the same as those of a planned cesarean delivery (see",
"     <a class=\"local\" href=\"#H5\">",
"      'Risks'",
"     </a>",
"     above). The woman should also discuss the possible need for a cesarean delivery with future pregnancies (see",
"     <a class=\"local\" href=\"#H15\">",
"      'Future deliveries'",
"     </a>",
"     below).",
"    </p>",
"    <p>",
"     Regardless of a woman's decision, it is possible to reconsider the decision at any time based upon a change in circumstances.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      EMERGENCY CESAREAN DELIVERY",
"     </span>",
"    </p>",
"    <p>",
"     In some cases, cesarean delivery is performed as an emergency surgery, after attempting a vaginal delivery. Time may be of the essence, depending upon the situation. Cesarean deliveries performed due to concerns about the mother's or infant's health are started as quickly as possible.",
"    </p>",
"    <p>",
"     In contrast, if a cesarean is performed because labor has not progressed normally or for other, less serious concerns about the baby's wellbeing, the surgery is usually begun within 30 to 60 minutes.",
"    </p>",
"    <p>",
"     If an epidural was placed before the attempted vaginal delivery, it can be used to administer anesthesia for the cesarean delivery (a larger dose is necessary for cesarean delivery versus vaginal delivery). Otherwise, spinal anesthesia (or rarely general anesthesia) is given. (See",
"     <a class=\"local\" href=\"#H11\">",
"      'Anesthesia'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      PROCEDURE",
"     </span>",
"    </p>",
"    <p>",
"     After being admitted to the hospital, a woman may be given an oral dose of an antacid to reduce the acidity of the stomach contents. Another medication may be given to reduce the secretions in the mouth and nose. An intravenous line will be placed into the hand or arm, and an electrolyte solution will be infused. Monitors will be placed to keep track of blood pressure, heart rate, and blood oxygen levels.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Anesthesia",
"     </span>",
"     &nbsp;&mdash;&nbsp;The woman is usually accompanied to an operating room before anesthesia is administered. A spouse or partner can usually stay with the woman in the operating room.",
"    </p>",
"    <p>",
"     There are two types of anesthesia used during cesarean delivery: regional and less commonly, general. For a planned cesarean delivery, regional anesthesia is usually performed. Meeting with the anesthesiologist allows the woman to ask specific questions about anesthesia, and allows the anesthesiologist to identify any medical problems that might affect the type of anesthesia that is recommended.",
"    </p>",
"    <p>",
"     With epidural and spinal anesthesia, the anesthetic is injected near the spine, which numbs the abdomen and legs to allow the surgery to be pain-free while allowing the mother to be awake.",
"    </p>",
"    <p>",
"     General anesthesia induces unconsciousness. This means that the mother will not be awake or aware during the procedure. After the anesthesia is given, the woman will fall asleep within 10 to 20 seconds and a tube will be placed in the throat to assist with breathing. General anesthesia carries a greater risk of complications than epidural or regional anesthesia because of the need for an endotracheal (breathing) tube and because drugs given to the mother affect the infant.",
"     <br/>",
"     <br/>",
"     Women who have general anesthesia will not be awake during the cesarean delivery. Regional anesthesia is generally preferred because it allows the mother to remain awake during the procedure, enjoy support from staff and a family member, experience the birth, and have immediate contact with the infant. It is usually safer than general anesthesia.",
"    </p>",
"    <p>",
"     After the anesthesia is given, a catheter is placed in the bladder to allow urine to drain out during the surgery and reduce the chance of injury to the bladder. The catheter is usually removed within 24 hours after the procedure.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Skin incision",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are two basic types of incision: horizontal (transverse or \"bikini line\") and vertical (midline). Most women have a transverse skin incision, which is made 1 to 2 inches above the pubic hair line. The advantages of this type of incision include less postoperative pain, more rapid healing, and a lower chance that the wound will separate during healing.",
"    </p>",
"    <p>",
"     Less commonly, the woman will have a vertical (\"up and down\") skin incision in the midline of the abdomen. The advantages of this type of incision include rapid access to the uterus (eg, if the baby is in distress or if the woman is bleeding excessively).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Uterine incision",
"     </span>",
"     &nbsp;&mdash;&nbsp;The uterine incision can also be either transverse or vertical. The type of incision depends upon several factors, including the position and size of the fetus, the location of the placenta, and the presence of fibroids. The main consideration is that the incision must be large enough to allow delivery of the fetus without causing trauma.",
"    </p>",
"    <p>",
"     The most common uterine incision is transverse. However, a vertical incision may be required if the baby is breech or sideways, if the placenta is in the lower front of the uterus, or if there are other abnormalities of the uterus.",
"    </p>",
"    <p>",
"     After opening the uterus, the baby is usually removed within seconds. After the baby is delivered, the umbilical cord is clamped and cut and the placenta is removed. The uterus is then closed. The abdominal skin is closed with either metal staples or reabsorbable sutures.",
"    </p>",
"    <p>",
"     After the mother and baby are stable, she or her partner may hold the baby.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      POSTOPERATIVE CARE",
"     </span>",
"    </p>",
"    <p>",
"     After surgery is completed, the woman will be monitored in a recovery area. Pain medication is given, initially through the IV line, and later with oral medications.",
"    </p>",
"    <p>",
"     When the effects of anesthesia have worn off, generally within one to three hours after surgery, the woman is transferred to a postpartum room and encouraged to move around and begin to drink fluids and eat food.",
"    </p>",
"    <p>",
"     Breastfeeding can usually begin anytime after the birth. A pediatrician will examine the baby within the first 24 hours of the delivery. Most women are able to go home within three to four days after delivery. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/63/34805?source=see_link\">",
"      \"Patient information: Deciding to breastfeed (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Staples are usually removed within three to seven days of delivery, while reabsorbable sutures are absorbed by the body and do not need to be removed.",
"    </p>",
"    <p>",
"     The abdominal incision will heal over the next few weeks. During this time, there may be mild cramping, light bleeding or vaginal discharge, incisional pain, and numbness in the skin around the incision site Most women will feel well by six weeks postpartum, but numbness around the incision and occasional aches and pains can last for several months.",
"    </p>",
"    <p>",
"     After going home, the woman should notify her healthcare provider if she develops a fever (temperature greater than 100.4&ordm; F [38&ordm; C]), if pain or bleeding worsens, or there are other concerns.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      FUTURE DELIVERIES",
"     </span>",
"    </p>",
"    <p>",
"     Previously, obstetricians recommended that all women who had a cesarean delivery have the same for all future deliveries. However, this is no longer the case. Most women in the United States who have had one low transverse cesarean delivery choose to have a repeat cesarean delivery, although these women could try to have a vaginal delivery with the next pregnancy. Between 60 and 80 percent of women who try to deliver vaginally after a c-section are successful in delivering vaginally. However, women who have a vaginal birth after cesarean (VBAC) have a less than 1 percent chance that the uterus will rupture during delivery, which could affect the baby's health [",
"     <a class=\"abstract\" href=\"UTD.htm?11/45/11988/abstract/1\">",
"      1",
"     </a>",
"     ]. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/33/27155?source=see_link\">",
"      \"Patient information: Vaginal birth after cesarean delivery (VBAC) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2287322077\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H248132552\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/21/16723?source=see_link\">",
"      Patient information: C-section (cesarean delivery) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/33/15890?source=see_link\">",
"      Patient information: When your baby is overdue (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/62/31714?source=see_link\">",
"      Patient information: Care during pregnancy for women with type 1 or type 2 diabetes (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/13/12499?source=see_link\">",
"      Patient information: Labor and delivery (childbirth) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/15/38129?source=see_link\">",
"      Patient information: Postpartum hemorrhage (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/20/6466?source=see_link\">",
"      Patient information: Placenta previa (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/2/19490?source=see_link\">",
"      Patient information: Shoulder dystocia (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/60/20418?source=see_link\">",
"      Patient information: Vaginal birth after cesarean delivery (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/44/1732?source=see_link\">",
"      Patient information: Having twins (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/15/13555?source=see_link\">",
"      Patient information: Spina bifida (myelomeningocele) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/62/18402?source=see_link\">",
"      Patient information: Breech pregnancy (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H248132561\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/28/7620?source=see_link\">",
"      Patient information: Permanent sterilization procedures for women (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/45/10966?source=see_link\">",
"      Patient information: Care during pregnancy for women with type 1 or 2 diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/3/36916?source=see_link\">",
"      Patient information: Genital herpes (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/29/7635?source=see_link\">",
"      Patient information: HIV and pregnancy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/63/34805?source=see_link\">",
"      Patient information: Deciding to breastfeed (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/33/27155?source=see_link\">",
"      Patient information: Vaginal birth after cesarean delivery (VBAC) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/2/39977?source=see_link\">",
"      Anesthesia for cesarean delivery",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/62/44009?source=see_link\">",
"      Cesarean delivery of the obese woman",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/21/344?source=see_link\">",
"      Cesarean delivery on maternal request",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28535?source=see_link\">",
"      Cervical ripening and induction of labor in women with a prior cesarean delivery",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37862?source=see_link\">",
"      Repeat cesarean delivery",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/ency/article/002911.htm\">",
"      www.nlm.nih.gov/medlineplus/ency/article/002911.htm",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American College of Obstetricians and Gynecologists",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.acog.org/for_patients\">",
"      www.acog.org/For_Patients",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?11/45/11988/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?11/45/11988?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11988/abstract/1\">",
"      ACOG Practice Bulletin #54: vaginal birth after previous cesarean. Obstet Gynecol 2004; 104:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11988/abstract/2\">",
"      Berghella V, Baxter JK, Chauhan SP. Evidence-based surgery for cesarean delivery. Am J Obstet Gynecol 2005; 193:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11988/abstract/3\">",
"      James D. Caesarean section for fetal distress. BMJ 2001; 322:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11988/abstract/4\">",
"      American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 394, December 2007. Cesarean delivery on maternal request. Obstet Gynecol 2007; 110:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11988/abstract/5\">",
"      Minkoff H, Powderly KR, Chervenak F, McCullough LB. Ethical dimensions of elective primary cesarean delivery. Obstet Gynecol 2004; 103:387.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f11_45_11988=[""].join("\n");
var outline_f11_45_11988=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           REASONS FOR CESAREAN DELIVERY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           PLANNING CESAREAN DELIVERY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           MATERNAL REQUEST CESAREAN DELIVERY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           EMERGENCY CESAREAN DELIVERY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           PROCEDURE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           POSTOPERATIVE CARE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           FUTURE DELIVERIES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/10/30880\" title=\"figure 1\">",
"           Illustration of cesarean delivery",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f11_45_11989="ECG first degree AV block I";
var content_f11_45_11989=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67882&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67882&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Single-lead electrocardiogram (ECG) showing first degree atrioventricular (AV) block I",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 113px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electrocardiogram of lead II showing normal sinus rhythm, first degree atrioventricular block with a prolonged PR interval of 0.30 sec, and a QRS complex of normal duration. The tall P waves and P wave duration of approximately 0.12 sec suggest concurrent right atrial enlargement.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_45_11989=[""].join("\n");
var outline_f11_45_11989=null;
var title_f11_45_11990="Clinical manifestations and diagnosis of small intestinal bacterial overgrowth";
var content_f11_45_11990=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of small intestinal bacterial overgrowth",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/45/11990/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/45/11990/contributors\">",
"     Jon A Vanderhoof, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/45/11990/contributors\">",
"     Rosemary J Pauley-Hunter, NP-C, MS, RN",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/45/11990/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/45/11990/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/45/11990/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/45/11990/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/45/11990/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 20, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small intestinal bacterial overgrowth (SIBO) is characterized by nutrient malabsorption associated with an increased number",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    type of bacteria in the upper gastrointestinal tract. Affected patients may be asymptomatic or have one or more symptoms including bloating, abdominal discomfort, watery diarrhea, dyspepsia, and weight loss.",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of SIBO will be reviewed here. The etiology, pathogenesis, and treatment of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/5/2136?source=see_link\">",
"     \"Etiology and pathogenesis of small intestinal bacterial overgrowth\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28454?source=see_link\">",
"     \"Treatment of small intestinal bacterial overgrowth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of small intestinal bacterial overgrowth (SIBO) depend upon the severity of disease, as well as the underlying cause leading to its development. Symptoms may be nonspecific and include bloating, flatulence, abdominal pain, watery diarrhea, dyspepsia, malabsorption, and weight loss or failure to gain weight in children. In severe cases (mostly associated with jejunoileal bypass surgery or short bowel syndrome), patients may present with tetany (resulting from hypocalcemia induced by vitamin D deficiency), night blindness (due to vitamin A deficiency), dermatitis, arthritis, and hepatic injury.",
"   </p>",
"   <p>",
"    SIBO has been implicated in the pathogenesis of irritable bowel syndrome. In addition, one report found an association with rosacea (a skin condition associated with chronic inflammation of the face) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11990/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12697?source=see_link\">",
"     \"Pathophysiology of irritable bowel syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36584?source=see_link\">",
"     \"Rosacea: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most frequent presenting symptoms are abdominal pain, diarrhea, weight loss, bloating, excess flatulence, malabsorption, and anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11990/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Diarrhea was also common in a report of 53 children, although 17 percent had abdominal pain alone [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11990/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Physical examination may reveal scarring associated with past surgery, and abdominal distention with identifiable succussion splash due to palpable soft, fluid-filled loops of bowel [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11990/abstract/6\">",
"     6",
"    </a>",
"    ]. Neuropathy from cobalamin deficiency may be present in advanced cases. Episodic ataxia and delirium after carbohydrate ingestion may result from D-lactic acidosis, which most often occurs in the short bowel syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11990/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18723?source=see_link\">",
"     \"D-Lactic acidosis\"",
"    </a>",
"    .) Metabolic bone disease has been noticed to coexist with confirmed SIBO [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11990/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laboratory examination may show anemia, which is generally macrocytic due to malabsorption of vitamin B12. However, microcytic anemia may result from bleeding from ulcers in stagnant intestinal loops [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11990/abstract/9\">",
"     9",
"    </a>",
"    ]. Micronutrient deficiency and evidence of malnutrition may also be present in advanced cases. Serum folate and vitamin K levels are normal or sometimes increased and urine indicans may be present [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11990/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical suspicion for the disease should be high in patients with known predisposing conditions (",
"    <a class=\"graphic graphic_table graphicRef81285 \" href=\"UTD.htm?9/2/9260\">",
"     table 1",
"    </a>",
"    ). Furthermore, clinical deterioration in such patients (such as in scleroderma or Crohn's disease) may reflect the development of symptoms related to SIBO rather than an exacerbation of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;SIBO should be included in the differential diagnosis of patients who present with abdominal pain, borborygmi, diarrhea, weight loss, macrocytic anemia, abdominal distension with succussion splash, or other stigmata of malabsorption. The diagnosis of suspected malabsorption should be based upon clinical evaluation and judicious diagnostic testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38232?source=see_link\">",
"     \"Clinical features and diagnosis of malabsorption\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An upper gastrointestinal series, including examination of the small bowel, is part of the routine evaluation of the patient with malabsorption. SIBO should be suspected if this study shows hypomotility, partial obstruction, dilatation, diverticula, or other mechanical factors associated with delayed gastrointestinal motility. A small bowel biopsy, while not diagnostic of SIBO, is beneficial in identifying inflammation associated with overgrowth and helps to exclude other causes of malabsorption such as celiac disease. In fact, in the absence of gut inflammation, SIBO may often be asymptomatic. In patients with vitamin B12 deficiency, SIBO may be diagnosed during the last stage of the Schilling test if antibiotic administration normalizes the absorption of vitamin B12. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5130?source=see_link\">",
"     \"Diagnosis and treatment of vitamin B12 and folate deficiency\"",
"    </a>",
"    .) A serum D-lactate level, blood alcohol, and urine indicans in children are other screening studies that may be beneficial in detecting bacterial metabolites or byproducts [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11990/abstract/11\">",
"     11",
"    </a>",
"    ]. Unexplained acidosis may also occur.",
"   </p>",
"   <p>",
"    When suspicion for SIBO is high, some clinicians advocate empiric treatment as a diagnostic test. Rapid resolution of symptoms will occur, although a major drawback to this approach is that treatment may require broad spectrum or multiple antibiotics, with repeated and sometimes cyclic treatment. Antibiotics may be associated with adverse effects, some of which may mimic symptoms of SIBO (such as diarrhea and abdominal discomfort), and therefore careful monitoring is required when therapy is initiated.",
"   </p>",
"   <p>",
"    On the other hand, the demonstration of SIBO in the small intestine by any of the tests described below does not prove a causal relationship to the associated symptoms since some affected patients do not have clinically significant disease. Patients at risk for clinical sequelae related to SIBO usually have associated intestinal inflammation. Inflammation of the small bowel and colon may occur in such patients secondary to reactions from absorbed bacterial antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11990/abstract/6\">",
"     6",
"    </a>",
"    ]. Successful treatment of severe SIBO with ASA preparations and corticosteroids has been reported, an observation consistent with the importance of intestinal inflammation in the etiology of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11990/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sterilization of the gastrointestinal tract should not be the goal of therapy as gut bacteria are important in maintaining normal gut function, normal immune function, and normal digestion of nutrients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11990/abstract/14\">",
"     14",
"    </a>",
"    ]. In addition, bacterial overgrowth may have a beneficial effect in some patients with short bowel syndrome since the degradation of carbohydrates by bacteria may be a source of energy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Jejunal aspirate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gold standard for the diagnosis of bacterial overgrowth has traditionally been the demonstration of excessive bacterial concentrations in a jejunal aspirate, which can be performed during endoscopy or by fluoroscopy with jejunal intubation. Clinically significant bacterial overgrowth is diagnosed when bacterial counts exceed 10(5)",
"    <span class=\"nowrap\">",
"     organisms/mL",
"    </span>",
"    (normal jejunal concentration is &le;10(4)",
"    <span class=\"nowrap\">",
"     organisms/mL).",
"    </span>",
"    Multiple organisms are typically present in varying numbers. Common species include bacteroides, enterococcus, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32004?source=see_link\">",
"     lactobacillus",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef81285 \" href=\"UTD.htm?9/2/9260\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11990/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unfortunately, quantitative culture from jejunal aspirates has several limitations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Very few of the gut bacteria can be identified since there are 400 to 500 species of bacteria in the bowel, most of which cannot be cultured.",
"     </li>",
"     <li>",
"      Culture of anaerobic organisms requires careful microbiologic technique.",
"     </li>",
"     <li>",
"      Contamination from oropharyngeal flora may occur during collection of the specimen.",
"     </li>",
"     <li>",
"      Bacterial overgrowth may be patchy and missed by a single culture, or located in relatively inaccessible sites [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11990/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several other diagnostic tests have been devised for the diagnosis of bacterial overgrowth. Histopathological changes including cryptitis, villous blunting,",
"    <span class=\"nowrap\">",
"     ulcers/erosions,",
"    </span>",
"    intraepithelial lymphocytosis, and eosinophilia have been associated with SIBO. Villous blunting was identified in one study as the only factor found more often in those with SIBO versus controls [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11990/abstract/16\">",
"     16",
"    </a>",
"    ]. The authors suggested that duodenal biopsies can be normal even in the presence of overgrowth in that area.",
"   </p>",
"   <p>",
"    Most breath tests are based upon the detection of analytes (eg, hydrogen or radioactive carbon dioxide) in the breath or urine following the administration of a test dose of a substrate. Bacterial action on the substrate is responsible for production of the analyte.",
"   </p>",
"   <p>",
"    The diagnostic accuracy of these tests has been compared in a variety of clinical conditions associated with SIBO using culture of jejunal aspirates as the gold standard. Compared to properly obtained quantitative jejunal cultures, no test performs perfectly. The sensitivity and specificity are affected by the clinical condition leading to malabsorption; in addition, variability in the timing of collections and the interpretation of results significantly limit their use for routine clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     [14C]-d-xylose breath test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Xylose is a pentose sugar that is catabolized by gram-negative aerobes, which are invariably part of the microflora implicated in SIBO. Bacterial action on the sugar releases the radioactive isotope 14-CO2 which, after absorption, is detectable in breath samples. Normal 14-CO2 release peaks with bacterial action in the colon; by contrast, early peaks indicate the presence of jejunal overgrowth. Only the one gram [14C]-d-xylose test is advocated for use in routine clinical practice by the Clinical Efficacy Committee of the American College of Physicians. Despite this recommendation, it is not commonly performed in clinical practice since it is not widely available and has been largely replaced by hydrogen breath tests (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Breath hydrogen analysis'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Compared to quantitative jejunal cultures, the sensitivity and specificity of the [14C]-d-xylose breath test has been reported to approach 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11990/abstract/17\">",
"     17",
"    </a>",
"    ]; however, lower values for sensitivity and specificity have been found in some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11990/abstract/18\">",
"     18",
"    </a>",
"    ]. Disorders associated with impaired gastric emptying may lead to false negative results, while rapid intestinal emptying may lead to false positive results due to early presentation of the test substrate in the colon. To optimize the diagnostic performance of the [14C]-d-xylose test, advocates recommend the following modifications:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with severe dysmotility syndromes have breath samples taken up to three hours after ingestion of the sugar.",
"     </li>",
"     <li>",
"      Patients undergo testing with the coadministration of intestinal transit markers to serve as a measure of intestinal transit time [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11990/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although administration of 14-C is associated with trivial radiation exposure, it is not routinely recommended for children or fertile women. A similar test based upon 13-C, which does not lead to radiation exposure, is under investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11990/abstract/20\">",
"     20",
"    </a>",
"    ]. The presence of lung disease may interfere with the interpretation of any breath test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Breath hydrogen analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breath hydrogen testing is performed by administering a test dose of carbohydrate (usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    or glucose in a dose of 50 to 75 g for adults), which, in patients with SIBO, is associated with an abnormality in the timing of the rise in breath hydrogen levels. Lactulose is normally metabolized by gut bacteria in the colon; however, in SIBO, an early rise in hydrogen production followed by the later colonic peak suggests SIBO in more proximal segments of the gastrointestinal tract. Glucose is also used as a substrate since, in the presence of SIBO, it may be metabolized to hydrogen in the small bowel lumen prior to absorption.",
"   </p>",
"   <p>",
"    The diagnostic accuracy of the glucose breath hydrogen test was compared to the d-xylose test and culture of the small bowel aspirate. There was found to be no statistically significant difference in accuracy between the studies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11990/abstract/21\">",
"     21",
"    </a>",
"    ]. It is possible to have no rise in hydrogen production during a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    breath hydrogen test if hydrogen is converted to methane or hydrogen sulfide by hydrogen consumptive microbes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11990/abstract/22\">",
"     22",
"    </a>",
"    ]. Concurrent testing with methane may enhance sensitivity. A new stable isotope lactose 13C ureide breath test has been found to have higher specificity and sensitivity than the standard glucose hydrogen breath test [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11990/abstract/23\">",
"     23",
"    </a>",
"    ]. Since the breath tests are simpler to perform, they are a reasonable choice for screening and monitoring of therapy.",
"   </p>",
"   <p>",
"    To improve accuracy of the test:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Certain foods (bread, pasta, fiber) need to be avoided prior to testing because they cause prolonged hydrogen secretion.",
"     </li>",
"     <li>",
"      Cigarette smoking or physical exercise sufficient to produce hyperventilation needs to be avoided for two hours prior to testing.",
"     </li>",
"     <li>",
"      Oral bacteria may lead to an early hydrogen peak; thus, pre-test mouthwashing with an antiseptic should be performed.",
"     </li>",
"     <li>",
"      To ensure accuracy, two consecutive hydrogen measurements may be obtained.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Breath hydrogen testing is safe, easy to perform, and can be used in women of child-bearing age and children. However, the usefulness of the test is limited by its lower sensitivity and specificity than the [14C]-d-xylose test because of the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lung disease may interfere with the interpretation of results.",
"     </li>",
"     <li>",
"      The hydrogen peak occurring from SIBO in the distal small intestine may be difficult to discriminate from the normal peak seen when the test substrate reaches the colon.",
"     </li>",
"     <li>",
"      Rapid delivery of the test substrate to the colon in patients with short bowel syndrome may lead to false positive results [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11990/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      False negatives may occur in 30 to 40 percent of patients due to low anaerobic organism counts [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11990/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bacterial overgrowth should be included in the differential diagnosis of patients who present with abdominal pain, borborygmi, diarrhea, weight loss, macrocytic anemia, abdominal distension with succussion splash, or other stigmata of malabsorption. The diagnosis of suspected malabsorption should be based upon clinical evaluation and judicious diagnostic testing. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38232?source=see_link\">",
"       \"Clinical features and diagnosis of malabsorption\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The gold standard for the diagnosis has traditionally been the demonstration of excessive bacterial concentrations in a jejunal aspirate, which can be performed during endoscopy or by fluoroscopy with jejunal intubation. Several other diagnostic tests have been devised but compared to properly obtained quantitative jejunal cultures, no test performs perfectly. The sensitivity and specificity are affected by the clinical condition leading to malabsorption; in addition, variability in the timing of collections and the interpretation of results significantly limit their use for routine clinical practice. Glucose breath hydrogen testing is most commonly recommended as a diagnostic procedure due to its wide availability. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11990/abstract/1\">",
"      Parodi A, Paolino S, Greco A, et al. Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication. Clin Gastroenterol Hepatol 2008; 6:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11990/abstract/2\">",
"      Sherman P, Lichtman S. Small bowel bacterial overgrowth syndrome. Dig Dis 1987; 5:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11990/abstract/3\">",
"      Fan X, Sellin JH. Review article: Small intestinal bacterial overgrowth, bile acid malabsorption and gluten intolerance as possible causes of chronic watery diarrhoea. Aliment Pharmacol Ther 2009; 29:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11990/abstract/4\">",
"      de Boissieu D, Chaussain M, Badoual J, et al. Small-bowel bacterial overgrowth in children with chronic diarrhea, abdominal pain, or both. J Pediatr 1996; 128:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11990/abstract/5\">",
"      Collins BS, Lin HC. Chronic abdominal pain in children is associated with high prevalence of abnormal microbial fermentation. Dig Dis Sci 2010; 55:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11990/abstract/6\">",
"      Taylor SF, Sondheimer JM, Sokol RJ, et al. Noninfectious colitis associated with short gut syndrome in infants. J Pediatr 1991; 119:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11990/abstract/7\">",
"      Bongaerts GP, Tolboom JJ, Naber AH, et al. Role of bacteria in the pathogenesis of short bowel syndrome-associated D-lactic acidemia. Microb Pathog 1997; 22:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11990/abstract/8\">",
"      Di Stefano M, Veneto G, Malservisi S, Corazza GR. Small intestine bacterial overgrowth and metabolic bone disease. Dig Dis Sci 2001; 46:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11990/abstract/9\">",
"      Giannella RA, Toskes PP. Gastrointestinal bleeding and iron absorption in the experimental blind loop syndrome. Am J Clin Nutr 1976; 29:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11990/abstract/10\">",
"      Gasbarrini A, Lauritano EC, Gabrielli M, et al. Small intestinal bacterial overgrowth: diagnosis and treatment. Dig Dis 2007; 25:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11990/abstract/11\">",
"      Mack DR. D(-)-lactic acid-producing probiotics, D(-)-lactic acidosis and infants. Can J Gastroenterol 2004; 18:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11990/abstract/12\">",
"      Vanderhoof JA, Young RJ, Murray N, Kaufman SS. Treatment strategies for small bowel bacterial overgrowth in short bowel syndrome. J Pediatr Gastroenterol Nutr 1998; 27:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11990/abstract/13\">",
"      Vanderhoof, JA, Young, RJ, Kaufman, SS, et al. Small bowel bacterial overgrowth in pediatric short bowel syndrome: Use of corticosteroids (abstract). Am J Gastroenterol 1999; 94:2741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11990/abstract/14\">",
"      Singh VV, Toskes PP. Small Bowel Bacterial Overgrowth: Presentation, Diagnosis, and Treatment. Curr Treat Options Gastroenterol 2004; 7:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11990/abstract/15\">",
"      Bouhnik Y, Alain S, Attar A, et al. Bacterial populations contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome. Am J Gastroenterol 1999; 94:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11990/abstract/16\">",
"      Lappinga PJ, Abraham SC, Murray JA, et al. Small intestinal bacterial overgrowth: histopathologic features and clinical correlates in an underrecognized entity. Arch Pathol Lab Med 2010; 134:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11990/abstract/17\">",
"      King CE, Toskes PP, Spivey JC, et al. Detection of small intestine bacterial overgrowth by means of a 14C-D-xylose breath test. Gastroenterology 1979; 77:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11990/abstract/18\">",
"      Simr&eacute;n M, Stotzer PO. Use and abuse of hydrogen breath tests. Gut 2006; 55:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11990/abstract/19\">",
"      Lewis SJ, Young G, Mann M, et al. Improvement in specificity of [14C]d-xylose breath test for bacterial overgrowth. Dig Dis Sci 1997; 42:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11990/abstract/20\">",
"      Dellert SF, Nowicki MJ, Farrell MK, et al. The 13C-xylose breath test for the diagnosis of small bowel bacterial overgrowth in children. J Pediatr Gastroenterol Nutr 1997; 25:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11990/abstract/21\">",
"      Stotzer PO, Kilander AF. Comparison of the 1-gram (14)C-D-xylose breath test and the 50-gram hydrogen glucose breath test for diagnosis of small intestinal bacterial overgrowth. Digestion 2000; 61:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11990/abstract/22\">",
"      Strocchi A, Furne J, Ellis C, Levitt MD. Methanogens outcompete sulphate reducing bacteria for H2 in the human colon. Gut 1994; 35:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11990/abstract/23\">",
"      Berthold HK, Schober P, Scheurlen C, et al. Use of the lactose-[13C]ureide breath test for diagnosis of small bowel bacterial overgrowth: comparison to the glucose hydrogen breath test. J Gastroenterol 2009; 44:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11990/abstract/24\">",
"      Riordan SM, McIver CJ, Walker BM, et al. The lactulose breath hydrogen test and small intestinal bacterial overgrowth. Am J Gastroenterol 1996; 91:1795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11990/abstract/25\">",
"      Romagnuolo J, Schiller D, Bailey RJ. Using breath tests wisely in a gastroenterology practice: an evidence-based review of indications and pitfalls in interpretation. Am J Gastroenterol 2002; 97:1113.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4776 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-C2273CD5CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_45_11990=[""].join("\n");
var outline_f11_45_11990=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Jejunal aspirate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      [14C]-d-xylose breath test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Breath hydrogen analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/4776\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4776|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/2/9260\" title=\"table 1\">",
"      Disorders associated with bacterial overgrowth",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38232?source=related_link\">",
"      Clinical features and diagnosis of malabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18723?source=related_link\">",
"      D-Lactic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5130?source=related_link\">",
"      Diagnosis and treatment of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/5/2136?source=related_link\">",
"      Etiology and pathogenesis of small intestinal bacterial overgrowth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12697?source=related_link\">",
"      Pathophysiology of irritable bowel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36584?source=related_link\">",
"      Rosacea: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28454?source=related_link\">",
"      Treatment of small intestinal bacterial overgrowth",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_45_11991="Paraquat poisoning";
var content_f11_45_11991=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Paraquat poisoning",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/45/11991/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/45/11991/contributors\">",
"     James F Winchester, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/45/11991/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/45/11991/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/45/11991/contributors\">",
"     Michele Burns Ewald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/45/11991/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/45/11991/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/45/11991/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paraquat (1,1-dimethyl-4,4'-bipyridylium chloride) is the most important member of the bipyridyl herbicides, a group that also includes diquat, chlormequat, difenzoquat and morfamquat.",
"   </p>",
"   <p>",
"    Soon after the introduction of paraquat in 1962, reported deaths resulted principally from the accidental ingestion of the concentrate. Subsequently, deaths from ingestion have been more commonly due to suicide and homicide [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11991/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Paraquat is a major medical problem in some countries in the Asia-Pacific region, and is responsible for many pesticide-herbicide related case fatalities (over 50 percent) in that region, as well in Europe, Trinidad, Sri Lanka and Samoa. It has been banned in Sri Lanka and some European countries [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11991/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A review of the clinical manifestations and management of paraquat poisoning is presented here. A general approach to drug poisoning is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREPARATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paraquat is available as a liquid concentrate (29 percent), as granules subsequently dissolved in water (2.5 to 10 percent), or as an aerosol (0.2 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TOXICITY AND METABOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paraquat exerts its herbicidal activity by inhibiting the reduction of NADP to NADPH during photosynthesis and forming superoxide, singlet oxygen, hydroxyl, and peroxide radicals [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11991/abstract/4\">",
"     4",
"    </a>",
"    ]. These toxic oxygen species subsequently destroy lipid cell membranes by polymerization of unsaturated lipid compounds [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11991/abstract/5\">",
"     5",
"    </a>",
"    ]. Human tissue toxicity likely results from a similar oxidative mechanism. After oxidative destruction, recruitment of inflammatory cells exacerbates injury [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11991/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lung and kidney are the primary target organs in paraquat toxicity. In the lung, a polyamine transporter protein leads to preferential accumulation in alveolocytes; the high local oxygen tension then generates high levels of toxic oxygen species and subsequent damage [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11991/abstract/7\">",
"     7",
"    </a>",
"    ]. In the kidney, the principal organ of excretion, paraquat is concentrated during excretion, often leading to acute tubular necrosis, which may occur soon after ingestion (within 24 hours). Paraquat-induced renal dysfunction may decrease paraquat excretion, thereby enhancing overall toxicity.",
"   </p>",
"   <p>",
"    Various compounds may ameliorate the toxic effects of paraquat, thereby suggesting different mechanisms of injury:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lipid peroxidation may be enhanced by iron radicals, since removal of iron by the chelating agent deferoxamine reduces toxicity in bacterial preparations or in normal mice, as well as in vitamin E deficient rats [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11991/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vitamin E, a potent antioxidant, may prevent cytotoxicity in cultured cells [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11991/abstract/9\">",
"       9",
"      </a>",
"      ]; however, it has had no effect on clinical outcome.",
"     </li>",
"     <li>",
"      Exogenous glutathione and n-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/1/20504?source=see_link\">",
"       acetylcysteine",
"      </a>",
"      , a donor of glutathione, may protect against injury [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11991/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sulfite or thiosulfate (redox agents) may be protective by reversing oxidized glutathione, which competes with glutathione for peroxide, hydroxyl, and superoxide radicals [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11991/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Animal studies suggest that salicylates help prevent paraquat induced lung, kidney, and liver injury [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11991/abstract/12-14\">",
"       12-14",
"      </a>",
"      ]. The mechanisms may involve interruption of pro-inflammatory factors (NF&kappa;B), scavenging of reactive oxygen species, and inhibition of both myeloperoxidase pathways and platelet aggregation. There is also some evidence that salicylates can chelate bipyridyls.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some of these agents have been administered to patients poisoned with paraquat with varying success. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL EXPOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are principally exposed to paraquat via the skin, lungs, and gastrointestinal tract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Skin and lungs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct exposure via the skin and lungs infrequently results in systemic toxicity. Inhalation and dermal absorption of paraquat is poor, particularly if there are no preexisting skin lesions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systemic reactions are not observed among knapsack paraquat sprayers with heavy skin exposure [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11991/abstract/15\">",
"       15",
"      </a>",
"      ]. Cutaneous absorption appears to vary with skin integrity.",
"      <br/>",
"      <br/>",
"      One study that evaluated the dermal absorption of the closely related chemical diquat reported that 0.4 percent of a topical dose was absorbed from an unoccluded site; 1.4 percent was absorbed from an occluded site; and 3.8 percent was absorbed from an occluded and damaged dermal site [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11991/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inhalation of spray is unlikely to cause systemic toxicity because of its low vapor pressure and large droplets.",
"     </li>",
"     <li>",
"      Inhaled smoke from paraquat-contaminated marijuana is also less able to produce systemic illness; this is due to the low concentration of paraquat, and the thermal-dependent conversion of paraquat to nontoxic bipyridines [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11991/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     GI tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral ingestion of significant amounts of paraquat can cause systemic toxicity as well as direct injury to the gastrointestinal tract. Death may result from multiorgan failure, including severe hepatotoxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxicity can be local, due to direct caustic effects, or systemic, due to absorption via the gastrointestinal tract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Direct local toxicity",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     GI tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major acute local gastrointestinal effects result from the caustic properties of paraquat, particularly the concentrate [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11991/abstract/18\">",
"     18",
"    </a>",
"    ]. Ulceration of the lips, tongue, and pharynx (\"pseudomembrane\") may be observed within one to two days of ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11991/abstract/19\">",
"     19",
"    </a>",
"    ]. Esophageal ulceration may proceed to esophageal perforation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/38/40551?source=see_link\">",
"     \"Caustic esophageal injury in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4473?source=see_link\">",
"     \"Caustic esophageal injury in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Skin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among knapsack paraquat sprayers with heavy skin exposure, skin rashes (particularly on scrotal and intergluteal areas), cracked nails, and epistaxis may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11991/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Lungs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhalation of paraquat-contaminated marijuana may cause local toxic effects on bronchi, possibly resulting in hemoptysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Eyes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corneal exposure to paraquat can cause ulceration and scarring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Systemic toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic toxicity principally results from the oral ingestion of moderate to large amounts of paraquat.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Ingestion of moderate amounts",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following subacute toxic effects may occur with the oral ingestion of amounts of paraquat approximately between 4 to 30 mL of the liquid concentrate:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Buccal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      esophageal ulcerations.",
"     </li>",
"     <li>",
"      Renal failure &ndash; Although reversible, renal failure may occur within two to six days of ingestion, which further impairs paraquat excretion. Proximal tubule dysfunction may be observed [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11991/abstract/20,21\">",
"       20,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hepatotoxicity &ndash; Manifestations include jaundice, hepatic failure and biochemical derangements such as raised transaminases and bilirubin.",
"     </li>",
"     <li>",
"      Metabolic acidosis &ndash; This may be caused by a variety of abnormalities, including myocardial failure (resulting from myocarditis and epicardial hemorrhage with arrhythmias), adrenal gland insufficiency (due to necrosis), systemic hypotension, severe hypoxemia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      renal failure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=see_link\">",
"       \"Approach to the adult with metabolic acidosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pulmonary involvement &ndash; Pulmonary edema may be observed 24 to 48 hours after ingestion; this may evolve to a condition resembling adult respiratory distress syndrome, which may progress to pulmonary fibrosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link\">",
"       \"Acute respiratory distress syndrome: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The exact pulmonary changes depend upon the quantity of paraquat ingested and the time from ingestion. In the first week after ingestion, radiographic findings may include diffuse consolidation, pneumomediastinum with or without pneumothorax and subcutaneous emphysema, and cardiomegaly with widened superior mediastinum [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11991/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Pulmonary fibrosis may develop after a few days. Although this last event is usually irreversible, there have been isolated reports of full recovery (even with severe pulmonary involvement). Death usually occurs within one to two weeks, but may be observed up to six weeks after ingestion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Ingestion of massive amounts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major organ failure, frequently resulting in death, may occur with massive ingestion (greater than 30 mL of concentrate). These include cardiac failure, renal failure (which may be observed within hours of ingestion), hepatic failure, pulmonary edema,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    central nervous system involvement (resulting in convulsions). Death may occur within several hours to a few days.",
"   </p>",
"   <p>",
"    APACHE II scores appear to correlate with both the amount of paraquat ingested, and to clinical outcomes. In one study, an APACHE II score &gt;20 was an accurate predictor of in-hospital mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11991/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     LABORATORY DETECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A qualitative urine test for paraquat, which detects concentrations of 1",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    or above (1 ppm), can be made by adding 2 mL of a 1 percent solution of sodium dithionite in 1 N sodium hydroxide to 10 mL of urine; a blue color indicates the presence of paraquat.",
"   </p>",
"   <p>",
"    Additional modalities provide exact quantitation of concentrations in plasma or urine:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gas chromatography and high pressure liquid chromatography can detect levels of 1 to 2",
"      <span class=\"nowrap\">",
"       microgram/mL",
"      </span>",
"      with some accuracy.",
"     </li>",
"     <li>",
"      Radioimmunoassay can detect and measure levels well below 0.1",
"      <span class=\"nowrap\">",
"       microgram/mL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11991/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fatal outcomes are usually associated with plasma levels greater than 0.2",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    at 24 hours after ingestion and 0.1",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    at 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11991/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to appropriate supportive care, management of paraquat poisoning is directed at removing paraquat from the gastrointestinal tract, increasing its excretion from blood, and preventing cellular damage with selected agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Prevention of gastrointestinal absorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fuller's earth, bentonite, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    have all been employed in paraquat poisonings. Fuller's earth may be administered as a 30 percent suspension, along with magnesium sulfate to produce a catharsis. Bentonite may also be administered as a 6 to 7.5 percent suspension. Activated charcoal may be administered in typical (1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    up to 50 g) doses. We do not routinely recommend gastric lavage, although this modality may be considered if a patient presents immediately after ingestion. Gastrointestinal decontamination, if employed, should be performed as quickly as possible owing to the rapid absorption of paraquat after oral exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Extracorporeal removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extracorporeal removal techniques may be effective, particularly when the paraquat level or ingested dose is moderate to low (ingestion of 4 to 30 mL of concentrated paraquat). Although plasma paraquat concentrations are reduced with hemodialysis or hemoperfusion, redistribution from tissue or continued absorption from the gastrointestinal tract may cause a rebound in plasma concentration in the postdialysis period. In one human study, the rebound after hemoperfusion varied from -7.56% to +69.9 % [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11991/abstract/27\">",
"     27",
"    </a>",
"    ]. Some have therefore utilized continuous arteriovenous or venovenous hemofiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11991/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hemoperfusion provides better clearance of paraquat than hemodialysis, and the use of hemoperfusion within 12 hours of poisoning may reduce mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11991/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. A study of charcoal hemoperfusion in a dedicated pesticide treatment center has reported 50 survivors of 105 patients treated; a more rapid reduction in plasma concentrations in the survival group (compared with the nonsurvivors) was observed [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11991/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Summary and recommendations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Unfortunately, successful outcomes have not been uniformly observed with these modalities when used alone or in combination. This includes hemodialysis or hemoperfusion alone, the combination of hemodialysis and hemoperfusion, and continuous dialysis therapies (despite maintaining low serum concentrations of paraquat) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11991/abstract/29,34-39\">",
"     29,34-39",
"    </a>",
"    ]. Ion-exchange resins are not available for this clinical setting; however, a new zeolite resin tested in vitro shows promise of a high degree of adsorption, although it has not yet been used clinically [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11991/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, prolonged hemoperfusion or hemodialysis with almost continuous treatment periods of up to two to three weeks after an ingestion has been associated with successful clinical outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11991/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Thus, although there is controversy relating to the efficacy of extracorporeal therapy, most clinicians, after first judging the amount ingested, initiate a four to six hour hemodialysis or hemoperfusion treatment soon after the patient is admitted to the hospital. Daily treatment is continued with intermittent assessment of pulmonary function and plasma and urinary concentrations of paraquat.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Ancillary treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of interventions have been tried in severely compromised patients:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although glucocorticoids have been used in the management of patients poisoned with paraquat, evidence of their effectiveness is lacking. Azathioprine, beclomethasone, bleomycin, fluorouracil, and fibrinolytic agents (potassium aminobenzoate) have also been used without benefit.",
"   </p>",
"   <p>",
"    Small, primarily observational studies reported mixed results about the effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    combined with glucocorticoid [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11991/abstract/41-46\">",
"     41-46",
"    </a>",
"    ]. A subsequent systematic review of three randomized trials involving a total of 164 patients with moderate to severe paraquat poisoning found that those treated with a combination of cyclophosphamide and glucocorticoids had a 28 percent lower risk of death (RR 0.72, 95% CI 0.59-0.89) compared to those given standard treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11991/abstract/43,47-49\">",
"     43,47-49",
"    </a>",
"    ]. Standard treatment included gastrointestinal decontamination and either hemodialysis or hemoperfusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Pulmonary transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung transplantation has been performed in at least four patients without success. Serial lung transplant in one patient eventually resulted in a successful transplant, as the first transplant also developed paraquat toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11991/abstract/50\">",
"     50",
"    </a>",
"    ]. However, the patient was ventilator dependent due to progressive toxic myopathy (another feature of paraquat toxicity) and eventually died from bronchopneumonia. Another patient had a successful transplant but died from complications arising from a ruptured bronchial anastomosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11991/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Other measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung radiotherapy is controversial; some have reported success [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11991/abstract/52\">",
"     52",
"    </a>",
"    ], but controlled animal experiments and other clinical studies have failed to find benefit. Superoxide dismutase has been used in several patients without benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11991/abstract/53\">",
"     53",
"    </a>",
"    ]. Deferoxamine [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11991/abstract/32,54\">",
"     32,54",
"    </a>",
"    ], nitric oxide [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11991/abstract/55\">",
"     55",
"    </a>",
"    ], and immunotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11991/abstract/56\">",
"     56",
"    </a>",
"    ] are other possible therapies, but data is limited and further study required.",
"   </p>",
"   <p>",
"    Paraquat antibodies immobilized on agarose-polyacrolein spheres enclosed in hemoperfusion devices have been shown experimentally to bind paraquat avidly from animal blood passing through the devices [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11991/abstract/57\">",
"     57",
"    </a>",
"    ]. Plasmapheresis also has been advocated, but further studies are needed before its effectiveness is proven.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Further information on paraquat can be obtained in the United States from National Pesticide Telecommunications Network at: 1-800-858-7378 or",
"    <a class=\"external\" href=\"file://npic.orst.edu/\">",
"     file://npic.orst.edu/",
"    </a>",
"    (outside the US: 1-806-743-3091), and in the United Kingdom from the International",
"    <span class=\"nowrap\">",
"     Paraquat/Diquat",
"    </span>",
"    Poisoning Registry at New Cross Hospital, London 011-44-171-407-7600. Chemical terrorism concerns should be communicated to the Centers for Disease Control and Prevention (1-800-CDC-INFO).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Paraquat is a bipyridyl herbicides widely used to desiccate crops for harvesting and to kill weeds. Paraquat inhibits the reduction of NADP to NADPH and is highly toxic. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Preparations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Toxicity and metabolism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exposure to paraquat occurs via the skin, lungs, and gastrointestinal tract.",
"      <strong>",
"      </strong>",
"      Direct exposure via the skin and lungs infrequently results in systemic toxicity. Oral ingestion of significant amounts (4 to 30 mL concentrate) of paraquat causes systemic toxicity. The lungs and kidneys are often affected. Massive ingestions (&gt;30 mL concentrate) generally lead to multiorgan failure and death. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical exposure'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management is directed at removing paraquat from the gastrointestinal tract (GI decontamination), increasing its excretion from blood (hemoperfusion), and preventing pulmonary damage with antiinflammatory medications and other agents. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Any patient who has ingested greater than 4 mL of paraquat concentrate should be aggressively managed, including treatment with intestinal decontaminants and daily four to six hour hemoperfusion (or high efficiency hemodialysis) sessions. In addition,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      and glucocorticoids&nbsp;should be given. Treatment with salicylates and n-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/1/20504?source=see_link\">",
"       acetylcysteine",
"      </a>",
"      may offer potential benefit. Hemoperfusion is continued until paraquat is no longer detectable in the blood. Low-inspired oxygen therapy is given until it becomes impractical in the face of hypoxemia.",
"     </li>",
"     <li>",
"      For clinicians without experience managing paraquat poisoning, consultation with a medical toxicologist should be obtained. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Additional resources'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Winchester JF. History of paraquat intoxication. In: Paraquat Poisoning: Mechanisms, Prevention, Treatment, Bismuth C, Hall AH.  (Eds), Marcel Decker, New York 1995. Vol 10, p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/2\">",
"      Stephens BG, Moormeister SK. Homicidal poisoning by paraquat. Am J Forensic Med Pathol 1997; 18:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/3\">",
"      Gawarammana IB, Buckley NA. Medical management of paraquat ingestion. Br J Clin Pharmacol 2011; 72:745.",
"     </a>",
"    </li>",
"    <li>",
"     Lewis CPL, Nemery B. Pathophysiology and biochemical mechanisms of the pulmonary toxicity of paraquat. In: Paraquat Poisoning: Mechanisms, Prevention, Treatment, Bismuth C, Hall AH.  (Eds), Marcel Decker, New York 1995. Vol 10, p.107.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/5\">",
"      Sandy MS, Moldeus P, Ross D, Smith MT. Role of redox cycling and lipid peroxidation in bipyridyl herbicide cytotoxicity. Studies with a compromised isolated hepatocyte model system. Biochem Pharmacol 1986; 35:3095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/6\">",
"      Snider GL. Interstitial pulmonary fibrosis--which cell is the culprit? Am Rev Respir Dis 1983; 127:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/7\">",
"      Rose MS, Smith LL, Wyatt I. Evidence for energy-dependent accumulation of paraquat into rat lung. Nature 1974; 252:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/8\">",
"      van Asbeck BS, Hillen FC, Boonen HC, et al. Continuous intravenous infusion of deferoxamine reduces mortality by paraquat in vitamin E-deficient rats. Am Rev Respir Dis 1989; 139:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/9\">",
"      Watanabe N, Shiki Y, Morisaki N, et al. Cytotoxic effects of paraquat and inhibition of them by vitamin E. Biochim Biophys Acta 1986; 883:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/10\">",
"      Wegener T, Sandhagen B, Chan KW, Saldeen T. N-acetylcysteine in paraquat toxicity: toxicological and histological evaluation in rats. Ups J Med Sci 1988; 93:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/11\">",
"      Yamamoto H. Protection against paraquat-induced toxicity with sulfite or thiosulfate in mice. Toxicology 1993; 79:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/12\">",
"      Dinis-Oliveira RJ, Pontes H, Bastos ML, et al. An effective antidote for paraquat poisonings: the treatment with lysine acetylsalicylate. Toxicology 2009; 255:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/13\">",
"      Dinis-Oliveira RJ, de Pinho PG, Ferreira AC, et al. Reactivity of paraquat with sodium salicylate: formation of stable complexes. Toxicology 2008; 249:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/14\">",
"      Dinis-Oliveira RJ, Sousa C, Remi&atilde;o F, et al. Full survival of paraquat-exposed rats after treatment with sodium salicylate. Free Radic Biol Med 2007; 42:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/15\">",
"      Swan AA. Exposure of spray operators to paraquat. Br J Ind Med 1969; 26:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/16\">",
"      Wester RC, Maibach HI, Bucks DA, Aufrere MB. In vivo percutaneous absorption of paraquat from hand, leg, and forearm of humans. J Toxicol Environ Health 1984; 14:759.",
"     </a>",
"    </li>",
"    <li>",
"     Chemistry and toxicology of paraquat-contaminated marijuana. Final report to the National Institutes for Drug Abuse, June 1978.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/18\">",
"      Cant JS, Lewis DR. Ocular damage due to paraquat and diquat. Br Med J 1968; 3:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/19\">",
"      Stephens DS, Walker DH, Schaffner W, et al. Pseudodiphtheria: prominent pharyngeal membrane associated with fatal paraquat ingestion. Ann Intern Med 1981; 94:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/20\">",
"      Vaziri ND, Ness RL, Fairshter RD, et al. Nephrotoxicity of paraquat in man. Arch Intern Med 1979; 139:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/21\">",
"      Van Vleet TR, Schnellmann RG. Toxic nephropathy: environmental chemicals. Semin Nephrol 2003; 23:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/22\">",
"      Im JG, Lee KS, Han MC, et al. Paraquat poisoning: findings on chest radiography and CT in 42 patients. AJR Am J Roentgenol 1991; 157:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/23\">",
"      Chen KW, Wu MH, Huang JJ, Yu CY. Bilateral spontaneous pneumothoraces, pneumopericardium, pneumomediastinum, and subcutaneous emphysema: a rare presentation of paraquat intoxication. Ann Emerg Med 1994; 23:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/24\">",
"      Huang NC, Lin SL, Hung YM, et al. Severity assessment in acute paraquat poisoning by analysis of APACHE II score. J Formos Med Assoc 2003; 102:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/25\">",
"      Levitt, T. Determination of paraquat in clinical practice using radioimmunoassay. Proc Anal Div Chem Soc 1979; 16:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/26\">",
"      Hart TB, Nevitt A, Whitehead A. A new statistical approach to the prognostic significance of plasma paraquat concentrations. Lancet 1984; 2:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/27\">",
"      Shi Y, Bai Y, Zou Y, et al. The value of plasma paraquat concentration in predicting therapeutic effects of haemoperfusion in patients with acute paraquat poisoning. PLoS One 2012; 7:e40911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/28\">",
"      Pond SM, Johnston SC, Schoof DD, et al. Repeated hemoperfusion and continuous arteriovenous hemofiltration in a paraquat poisoned patient. J Toxicol Clin Toxicol 1987; 25:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/29\">",
"      Koo JR, Kim JC, Yoon JW, et al. Failure of continuous venovenous hemofiltration to prevent death in paraquat poisoning. Am J Kidney Dis 2002; 39:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/30\">",
"      Okonek S, Hofmann A, Henningsen B. Efficacy of gut lavage, hemodialysis, and hemoperfusion in the therapy of paraquat or diquat intoxication. Arch Toxicol 1976; 36:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/31\">",
"      Okonek S, Weilemann LS, Majdandzic J, et al. Successful treatment of paraquat poisoning: activated charcoal per os and \"continuous hemoperfusion\". J Toxicol Clin Toxicol 1982; 19:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/32\">",
"      Lheureux P, Leduc D, Vanbinst R, Askenasi R. Survival in a case of massive paraquat ingestion. Chest 1995; 107:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/33\">",
"      Hong SY, Yang JO, Lee EY, Kim SH. Effect of haemoperfusion on plasma paraquat concentration in vitro and in vivo. Toxicol Ind Health 2003; 19:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/34\">",
"      Mascie-Taylor BH, Thompson J, Davison AM. Haemoperfusion ineffective for paraquat removal in life-threatening poisoning. Lancet 1983; 1:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/35\">",
"      Van de Vyver FL, Giuliano RA, Paulus GJ, et al. Hemoperfusion-hemodialysis ineffective for paraquat removal in life-threatening poisoning? J Toxicol Clin Toxicol 1985; 23:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/36\">",
"      Hampson EC, Pond SM. Failure of haemoperfusion and haemodialysis to prevent death in paraquat poisoning. A retrospective review of 42 patients. Med Toxicol Adverse Drug Exp 1988; 3:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/37\">",
"      Maini R. Removal of paraquat from blood by haemoperfusion over sorbent materials. Br Med J 1975; 3:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/38\">",
"      Widdop, B, Medd, RK, Braithwaite, RA, Vale, JA. Haemoperfusion in the treatment of paraquat poisoning. Proc Eur Soc Artif Organs 1975; 2:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/39\">",
"      Gelfand MC, Winchester JF, Knepshield JH, et al. Treatment of severe drug overdosage with charcoal hemoperfusion. Trans Am Soc Artif Intern Organs 1977; 23:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/40\">",
"      Walcarius A, Mouchotte R. Efficient in vitro paraquat removal via irreversible immobilization into zeolite particles. Arch Environ Contam Toxicol 2004; 46:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/41\">",
"      Addo E, Poon-King T. Leucocyte suppression in treatment of 72 patients with paraquat poisoning. Lancet 1986; 1:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/42\">",
"      Vale JA, Meredith TJ, Buckley BM. Paraquat poisoning. Lancet 1986; 1:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/43\">",
"      Lin JL, Leu ML, Liu YC, Chen GH. A prospective clinical trial of pulse therapy with glucocorticoid and cyclophosphamide in moderate to severe paraquat-poisoned patients. Am J Respir Crit Care Med 1999; 159:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/44\">",
"      Perri&euml;ns JH, Benimadho S, Kiauw IL, et al. High-dose cyclophosphamide and dexamethasone in paraquat poisoning: a prospective study. Hum Exp Toxicol 1992; 11:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/45\">",
"      Botella de Maglia J, Belenguer Tar&iacute;n JE. [Paraquat poisoning. A study of 29 cases and evaluation of the effectiveness of the \"Caribbean scheme\"]. Med Clin (Barc) 2000; 115:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/46\">",
"      Eddleston M, Wilks MF, Buckley NA. Prospects for treatment of paraquat-induced lung fibrosis with immunosuppressive drugs and the need for better prediction of outcome: a systematic review. QJM 2003; 96:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/47\">",
"      Afzali S, Gholyaf M. The effectiveness of combined treatment with methylprednisolone and cyclophosphamide in oral paraquat poisoning. Arch Iran Med 2008; 11:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/48\">",
"      Lin JL, Lin-Tan DT, Chen KH, Huang WH. Repeated pulse of methylprednisolone and cyclophosphamide with continuous dexamethasone therapy for patients with severe paraquat poisoning. Crit Care Med 2006; 34:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/49\">",
"      Li LR, Sydenham E, Chaudhary B, You C. Glucocorticoid with cyclophosphamide for paraquat-induced lung fibrosis. Cochrane Database Syst Rev 2012; 7:CD008084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/50\">",
"      Cooper, JD, The Toronto Lung Transplant Group. Sequential bilateral lung transplantation for paraquat poisonings case report. J Thorac Cardiovasc Surg 1985; 89:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/51\">",
"      Kamholz S, Veith FJ, Mollenkopf F, et al. Single lung transplantation in paraquat intoxication. N Y State J Med 1984; 84:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/52\">",
"      Webb DB, Williams MV, Davies BH, James KW. Resolution after radiotherapy of severe pulmonary damage due to paraquat poisoning. Br Med J (Clin Res Ed) 1984; 288:1259.",
"     </a>",
"    </li>",
"    <li>",
"     Connolly ME, Davies DS, Draffan GH, et al. Clinical experience with paraquat poisoning. In: Clinical Aspects of Paraquat Poisoning, Fletcher K.  (Ed), Imperial Chemical Industries, London 1975. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/54\">",
"      Nagano N, Yagi M, Nishikori K. Protective effects of antioxidants on paraquat-induced acute renal failure in mice. Jpn J Pharmacol 1992; 59:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/55\">",
"      K&ouml;ppel C, von Wissmann C, Barckow D, et al. Inhaled nitric oxide in advanced paraquat intoxication. J Toxicol Clin Toxicol 1994; 32:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/56\">",
"      Wright, AF, Green, TP, Dale, P, Smith, LL. Monoclonal-antibody does not protect mice from paraquat toxicity. Vet Hum Toxicol 1987; 29(suppl 2):102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11991/abstract/57\">",
"      Azhari R, Margel S, Labes A, Haviv Y. Specific removal of paraquat by hemoperfusion through antiparaquat conjugated agarose-polyacrolein microsphere beads. J Biomed Mater Res 1987; 21:25.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 337 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-31C67D9254-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_45_11991=[""].join("\n");
var outline_f11_45_11991=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREPARATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TOXICITY AND METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL EXPOSURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Skin and lungs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      GI tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Direct local toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - GI tract",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Skin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Lungs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Eyes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Systemic toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Ingestion of moderate amounts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Ingestion of massive amounts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      LABORATORY DETECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Prevention of gastrointestinal absorption",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Extracorporeal removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Ancillary treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Pulmonary transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Other measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=related_link\">",
"      Acute respiratory distress syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=related_link\">",
"      Approach to the adult with metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/38/40551?source=related_link\">",
"      Caustic esophageal injury in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4473?source=related_link\">",
"      Caustic esophageal injury in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=related_link\">",
"      General approach to drug poisoning in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_45_11992="Pathogenesis of and risk factors for pelvic inflammatory disease";
var content_f11_45_11992=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of and risk factors for pelvic inflammatory disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/45/11992/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/45/11992/contributors\">",
"     Charles H Livengood, III, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/45/11992/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/45/11992/contributors\">",
"     Noreen A Hynes, MD, MPH, DTM&amp;H",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/45/11992/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/45/11992/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/45/11992/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic inflammatory disease (PID) refers to acute infection of the upper genital tract structures in women, involving any or all of the uterus, oviducts, and ovaries; this is often accompanied by involvement of the neighboring pelvic organs. By definition, PID is a community-acquired infection initiated by a sexually transmitted agent, distinguishing it from pelvic infections caused by medical procedures, pregnancy, and other primary abdominal processes.",
"   </p>",
"   <p>",
"    Pelvic inflammatory disease in the United States annually accounts for about 2.5 million outpatient visits, 200,000 hospitalizations, and 100,000 surgical procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/1\">",
"     1",
"    </a>",
"    ]. It is the most frequent gynecologic cause for emergency department visits",
"    <span class=\"nowrap\">",
"     (350,000/year)",
"    </span>",
"    and incurs an annual total expense of almost $2 billion [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, costs of PID in the US have decreased in the last decade [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of and risk factors for PID will be reviewed here. The clinical features, diagnosis, treatment, and sequelae of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1032?source=see_link\">",
"     \"Clinical features and diagnosis of pelvic inflammatory disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35832?source=see_link\">",
"     \"Treatment of pelvic inflammatory disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vaginal flora of most normal, healthy women includes a variety of potentially pathogenic bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/4\">",
"     4",
"    </a>",
"    ]. Among these are species of streptococci, staphylococci, Enterobacteriaceae (most commonly Klebsiella spp, Escherichia coli, and Proteus spp), and a variety of anaerobes. Compared with the dominant hydrogen peroxide-producing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32004?source=see_link\">",
"     Lactobacillus",
"    </a>",
"    acidophilus, these organisms are present in low numbers, and ebb and flow under the influence of hormonal changes (pregnancy, degree of estrogenization), contraceptive method, sexual activity, and other as yet unknown forces.",
"   </p>",
"   <p>",
"    Complete disruption of the vaginal ecosystem can occur, in which anaerobic bacteria assume predominance over the desirable strains of lactobacilli. This condition is known as bacterial vaginosis, which is not associated with an inflammatory response [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/5\">",
"     5",
"    </a>",
"    ]. Bacterial vaginosis affects 15 to 30 percent of American women, one-half of whom are asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/6\">",
"     6",
"    </a>",
"    ]. Its significance is not clearly understood but when found in pregnancy, bacterial vaginosis was an independent risk factor for preterm delivery of a low birthweight infant in a study of 10,397 women of whom 16 percent had the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/7\">",
"     7",
"    </a>",
"    ]. An intermediate situation in which H202-producing lactobacilli and anaerobes coexist in roughly equal numbers is called a transitional flora.",
"   </p>",
"   <p>",
"    The endocervical canal functions as a barrier protecting the normally sterile upper genital tract from the organisms of the dynamic vaginal ecosystem. Disturbance of this barrier provides vaginal bacteria with access to the upper genital organs via canalicular routes, infecting the endometrium, then endosalpinx, ovarian cortex, pelvic peritoneum, and their underlying stroma. This is the clinical entity of PID.",
"   </p>",
"   <p>",
"    Patients with PID can present with clinical disease at any point along the continuum (eg, endometritis with normal tubes, ovaries, and peritoneum) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/8\">",
"     8",
"    </a>",
"    ]. This observation has required reevaluation of many time-honored concepts of PID, which relied upon the presence of gross salpingitis by direct visualization to establish the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1032?source=see_link\">",
"     \"Clinical features and diagnosis of pelvic inflammatory disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Up to 75 percent of cases occur within seven days of menses, during which time the quality of the cervical mucus favors the ascension of vaginal organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/9\">",
"     9",
"    </a>",
"    ]. Epidemiologic data suggest that all community-acquired agents causing disturbance of the endocervical barrier are sexually transmitted (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initiating pathogens in PID include Neisseria gonorrhoeae and Chlamydia trachomatis, although in many cases the etiology of PID is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Neisseria gonorrhoeae",
"    </span>",
"    &nbsp;&mdash;&nbsp;N. gonorrhoeae was the first identified cause of PID. Following a dramatic decline after the advent of penicillin, the incidence of gonorrhea in the United States rebounded to about one million reported cases annually by the mid-1970s, and the Centers for Disease Control and Prevention (CDC) estimated that only about one-third of cases were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/20/38217?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical manifestations of Neisseria gonorrhoeae infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of gonorrhea in the United States has steadily declined since that time despite the simultaneous arrival of beta-lactamase-producing gonococci from West Africa and East Asia in 1978, the evolution of chromosomally mediated multidrug resistant strains in the early 1980s, and reports that more than one-third of United States isolates currently carry some form of drug resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/11\">",
"     11",
"    </a>",
"    ]. In light of rising rates of drug resistance, fluoroquinolone use is no longer recommended for the treatment of gonococcal infections [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/3/19514?source=see_link\">",
"     \"Treatment of uncomplicated gonococcal infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 15 percent of women acquiring endocervical gonorrhea go on to develop PID [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Factors differentiating these cases from those with a more benign course are undefined. However, it is common for endocervical gonorrhea to be asymptomatic, which often leads to no treatment or delay in treatment.",
"   </p>",
"   <p>",
"    N. gonorrhoeae accounts for approximately one-third of cases of PID overall: somewhat more in the southeastern United States, less in the western United States, and much less in western Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/13,15,16\">",
"     13,15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Chlamydia trachomatis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chlamydia trachomatis serovars D-K began to be recognized as an initiator of PID in the mid-1970s. Genital chlamydia infections are now the most common bacterial sexually transmissible disease and the most common reportable infectious disease, with about four million new cases occurring annually in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. They account for about one-third of cases of PID overall, more in the western United States and much more in Western Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/19\">",
"     19",
"    </a>",
"    ]. The geographic distribution of Chlamydia is the converse of that for the gonococcus.",
"   </p>",
"   <p>",
"    As with the gonococcus, about 15 percent of endocervical chlamydia infections produce PID, with the remaining infections being asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/20\">",
"     20",
"    </a>",
"    ]. At our institution, for example, 50 percent of positive chlamydia tests derive from cervices described as normal on examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Screening in young women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paradigms to identify whom to test for chlamydia have proven to lack universality, with the exception that women aged 16 to 24 years account for most cases. In one report of 150,000 such women, those at lowest risk still had a 6 percent prevalence of genital chlamydia infection, which accounted for 17 percent of infections in this sample [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/21\">",
"     21",
"    </a>",
"    ]. Furthermore, if only those with one or more identified risk factors had been tested, 60 percent of cases would have been missed. Annual screening more than five years decreased the prevalence of genital chlamydia infection by 42 percent.",
"   </p>",
"   <p>",
"    Similar findings were noted in a large HMO population [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/22\">",
"     22",
"    </a>",
"    ]. Annual screening and treatment of at risk 18 to 34 year-old women reduced the prevalence of PID by 56 percent (8 versus 18 per 10,000) woman-months in those managed traditionally by risk and symptomatic assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/13/8408?source=see_link\">",
"     \"Screening for Chlamydia trachomatis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Annual screening of sexually active adolescent girls and young women for chlamydia is recommended by the United States Preventive Services Task force and other professional organizations [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. However, only 20 percent of eligible young women who receive health care through health maintenance organizations are screened [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Screening rates can be increased through clinical practice improvement interventions (eg, involvement of practice leaders, team building, and monitoring of progress) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/27\">",
"     27",
"    </a>",
"    ]. In one study, pediatric clinics that were randomly assigned to receive such interventions for 16 to 18 months had a greater increase in screening rates than those that were assigned to provide usual care (5 to 65 percent versus 14 to 21 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/27\">",
"     27",
"    </a>",
"    ]. The USPSTF clinical practice guideline for screening for chlamydial infection, as well as other USPSTF guidelines, can be accessed through the website for the Agency for Healthcare Research and Quality at",
"    <a class=\"external\" href=\"file://www.ahrq.gov/clinic/uspstfix.htm\">",
"     www.ahrq.gov/clinic/uspstfix.htm",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other initiating pathogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other agents that initiate PID, while almost certainly sexually transmitted and probably infectious, remain obscure. Bacterial vaginosis (BV) is more common among women with PID but, in the most comprehensive pathogenetic study to date, was shown not to be responsible alone for PID [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/29\">",
"     29",
"    </a>",
"    ]. Another study of 1179 women found that BV did not increase risk of PID during three years of prospective follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/30\">",
"     30",
"    </a>",
"    ]. However, in another study, PID risk was increased two-fold among those with the highest colony counts of BV-associated organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Investigations of various mycoplasma species, such as Mycoplasma hominis, have been fueled by the ability of these organisms to cause urethritis in the male. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31177?source=see_link\">",
"     \"Mycoplasma hominis, Mycoplasma genitalium, and Ureaplasma urealyticum infections\"",
"    </a>",
"    .) M. genitalium has been identified by nucleic acid amplification in clinical cases of non-chlamydial, non-gonococcal PID, and infection with this pathogen has been associated with tubal infertility [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/32\">",
"     32",
"    </a>",
"    ]. However, in a large community-based prospective cohort study of 2378 female college students, the prevalence of M. genitalium at baseline (3.3 percent) and the incidence of this infection (0.9 percent) over 12 months of follow-up was low, despite testing via polymerase chain reaction assays [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/33\">",
"     33",
"    </a>",
"    ]. Since the incidence and prevalence of M. genitalium was less than half that of chlamydia, the researchers concluded that M. genitalium was unlikely to be a major risk factor for PID.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Mixed infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regardless of the initiating event, the microbiology of PID, especially for clinical purposes, should be viewed and treated as a mixed (facultative and anaerobic) polymicrobial infection. Older studies isolated groups A and B streptococci (rarely enterococci), E. coli, Klebsiella spp, Proteus mirabilis, Haemophilus spp,",
"    <span class=\"nowrap\">",
"     Bacteroides/Prevotella",
"    </span>",
"    spp, Peptococcus, and Peptostreptococcus spp [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/15,34,35\">",
"     15,34,35",
"    </a>",
"    ]. A more recent study with comprehensive microbiologic methodology in 102 patients confirmed the older findings and emphasized the association of H. influenzae and Streptococcus pyogenes with clinically severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/29\">",
"     29",
"    </a>",
"    ]. These studies found that, among cases of PID initiated by the gonococcus, a mixed polymicrobial infection was seen in approximately 35 percent. Another study, which employed particularly stringent microbiologic techniques, identified other organisms in more than 50 percent of patients with gonococcal PID [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/36\">",
"     36",
"    </a>",
"    ]. Microbiologic findings at different levels of the genital tract of a given patient with PID often show poor correlation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/15,29,35-37\">",
"     15,29,35-37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Celibate women are not at risk for PID [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/38\">",
"     38",
"    </a>",
"    ], and women with longstanding monogamous relationships rarely develop PID. On the other hand, women with multiple partners are at greatest risk. The clinical status of the partner, age, previous PID, and race are other important risk factors for PID. The frequency is also affected by the method of contraceptive used.",
"   </p>",
"   <p>",
"    In one case control study among sexually active, inner city adolescents with and without PID, younger age at first intercourse, older sex partners, prior involvement with a child protection agency, prior suicide attempt, alcohol use before intercourse, and current C. trachomatis infection were all significant risk factors for the development of PID [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/39\">",
"     39",
"    </a>",
"    ]. The number of total sexual partners, history of rape, prior PID, or other STD (eg, syphilis, hepatitis B, or HIV) were not different between the girls with PID and the sexually active controls in this report.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Multiple partners",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of multiple partners was illustrated in a report that compared 712 women hospitalized for PID to 2719 controls [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/40\">",
"     40",
"    </a>",
"    ]. The risk for PID was increased 3.4 times by four or more sexual partners during the last six months, and 3.2 times by intercourse with a single partner six or more times per week [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/40\">",
"     40",
"    </a>",
"    ]. Other studies have confirmed the importance of multiple partners with an increase in frequency of PID ranging from 4.6- to 20-fold [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. One report, however, did not confirm a role for coital frequency [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Status of the partner",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately one-half of men with gonococcal or chlamydial urethritis are asymptomatic. Having a symptomatic (dysuria, urethral discharge) male partner greatly increases a woman's risk of PID [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;PID occurs in highest frequency among those 15 to 25 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/14,43\">",
"     14,43",
"    </a>",
"    ]; the incidence in women older than the age of 35 is only one-seventh that in younger women [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/44\">",
"     44",
"    </a>",
"    ]. The initiators of PID in both the United States and Europe, particularly Chlamydia, are densely concentrated among adolescent and young adult women, with a prevalence around 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/45-47\">",
"     45-47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recurrence of genital chlamydia infection is also a function of age. In one series, for example, the risk of recurrence was eightfold (at 54 percent) and fivefold (at 30 percent) greater among women whose first infection occurred at &lt;15 years and 15 to 19 years, respectively, compared to those whose first infection occurred older than age 30 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Previous PID",
"    </span>",
"    &nbsp;&mdash;&nbsp;Previous PID increased the risk for subsequent episodes by a factor of 2.3 in one report [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/41\">",
"     41",
"    </a>",
"    ], and approximately one in four women with PID will suffer recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/49\">",
"     49",
"    </a>",
"    ]. However, these data must be used cautiously in practice. Every episode of abdominal pain in a woman whose medical record indicates that she has had PID is not PID.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Contraceptive method",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although earlier data suggested that the choice of contraceptive method may affect risk of PID, this was not supported by a large cross-sectional study in 563 women with PID; in this study, no hormonal or barrier contraceptive method was related to a reduction in upper genital tract disease among women with clinical PID [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/50\">",
"     50",
"    </a>",
"    ]. However, other data (see below) support a role for barrier contraception in the prevention of PID.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Barrier contraception",
"    </span>",
"    &nbsp;&mdash;&nbsp;Barrier contraception protects against PID [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/51\">",
"     51",
"    </a>",
"    ]. Condoms are the most effective, preventing 50 percent of endocervical gonococcal and chlamydial infections; the addition of nonoxynol-9 confers 25 percent more protection [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/52\">",
"     52",
"    </a>",
"    ]. One large study suggested that inconsistent condom use is associated with greater risk for PID than both consistent condom use and no condom use [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/53\">",
"     53",
"    </a>",
"    ]. Unfortunately, according to survey data reported by the Centers for Disease Control and Prevention from 2002 to 2007, only 31 percent of never-married women aged 20 to 24 years consistently use condoms [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Oral contraceptives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral contraceptives (OCs) have a complex interaction with PID. Several studies have shown that OC use nearly doubles the prevalence of both chlamydial and gonococcal infection of the cervix [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/55\">",
"     55",
"    </a>",
"    ]. However, OC use has traditionally been associated with a 50 percent reduction in PID risk [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Resolution of this apparent quandary is emerging. Among OC users with cervical infection, asymptomatic endometritis is fourfold more common than among their counterparts not using OCs [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/57\">",
"     57",
"    </a>",
"    ], although gross salpingitis is reduced fivefold [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/58\">",
"     58",
"    </a>",
"    ]. Thus, women using OCs appear to develop PID in response to cervical initiating agents about as frequently as other women, but the severity of the infection &mdash; with respect to both symptoms and tissue damage &mdash; is substantially diminished.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Intrauterine device and tubal ligation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modern intrauterine devices cause little, if any, increased risk for PID [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/45,59,60\">",
"     45,59,60",
"    </a>",
"    ]. The risk of PID is primarily limited to the first three weeks after IUD insertion and is uncommon thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/60\">",
"     60",
"    </a>",
"    ]. No evidence suggests that IUDs should be removed in women diagnosed with acute PID [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, long-term indwelling IUDs have been associated with pelvic actinomycosis, a rare disease that can present as a pelvic mass with weight loss and constitutional symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/61\">",
"     61",
"    </a>",
"    ]. In a study of 475 isolates of actinomyces species, 30 percent of the clinical specimens originated in association with IUDs [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The decision to treat a patient for possible pelvic actinomycosis is influenced by the presence or absence of clinical symptoms, since actinomyces are part of normal vaginal flora. Thus, the identification of this organism on any cervical smears should not prompt antibiotic therapy or IUD removal, unless there are associated symptoms, such as fever, abdominal pain, abnormal vaginal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/63\">",
"     63",
"    </a>",
"    ], or abnormal rectovaginal exam. Antibiotics that are commonly used in the treatment of PID (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , beta-lactams, fluoroquinolones) also have activity against actinomyces, although the treatment duration is longer (three to six months). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35832?source=see_link\">",
"     \"Treatment of pelvic inflammatory disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tubal ligation may protect the distal oviducts from involvement, but the clinical syndrome of PID is otherwise unaffected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;PID occurs significantly more commonly among African-Americans [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/41\">",
"     41",
"    </a>",
"    ]. It may be more common among women who use vaginal douching [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/64\">",
"     64",
"    </a>",
"    ]. However, there is a higher frequency of other risk factors for PID among women who employ this practice, and a causative relationship has not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11992/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/14/26850?source=see_link\">",
"       \"Patient information: Pelvic inflammatory disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2538513\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pelvic inflammatory disease (PID) is a community-acquired infection initiated by a sexually transmitted agent, distinguishing it from pelvic infections caused by medical procedures, pregnancy, and other primary abdominal processes. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anatomically, PID refers to acute infection of the upper genital tract structures in women, involving any or all of the uterus, oviducts, and ovaries and sometimes other surrounding pelvic organs. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initiating pathogens in pelvic inflammatory disease include Neisseria gonorrhoeae and Chlamydia trachomatis account for an estimated one-third of all cases of pelvic inflammatory disease, although in the majority of cases the etiology of PID is unknown. Regardless of the initiating event, the microbiology of PID should be viewed and treated as a mixed (facultative and anaerobic) polymicrobial infection. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main risk factor for pelvic inflammatory disease is having intercourse with multiple sex partners. The choice of contraceptive method does not clearly affect the risk of pelvic infection, though consistent use of condoms may offer significant reduction of risk. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/1\">",
"      Washington AE, Katz P. Cost of and payment source for pelvic inflammatory disease. Trends and projections, 1983 through 2000. JAMA 1991; 266:2565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/2\">",
"      Curtis KM, Hillis SD, Kieke BA Jr, et al. Visits to emergency departments for gynecologic disorders in the United States, 1992-1994. Obstet Gynecol 1998; 91:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/3\">",
"      Rein DB, Kassler WJ, Irwin KL, Rabiee L. Direct medical cost of pelvic inflammatory disease and its sequelae: decreasing, but still substantial. Obstet Gynecol 2000; 95:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/4\">",
"      Galask RP, Larsen B, Ohm MJ. Vaginal flora and its role in disease entities. Clin Obstet Gynecol 1976; 19:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/5\">",
"      Platz-Christensen JJ, Mattsby-Baltzer I, Thomsen P, Wiqvist N. Endotoxin and interleukin-1 alpha in the cervical mucus and vaginal fluid of pregnant women with bacterial vaginosis. Am J Obstet Gynecol 1993; 169:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/6\">",
"      Fleury FJ. Adult vaginitis. Clin Obstet Gynecol 1981; 24:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/7\">",
"      Hillier SL, Nugent RP, Eschenbach DA, et al. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. The Vaginal Infections and Prematurity Study Group. N Engl J Med 1995; 333:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/8\">",
"      Paavonen J, Aine R, Teisala K, et al. Comparison of endometrial biopsy and peritoneal fluid cytologic testing with laparoscopy in the diagnosis of acute pelvic inflammatory disease. Am J Obstet Gynecol 1985; 151:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/9\">",
"      Eschenbach DA. Acute pelvic inflammatory disease: etiology, risk factors and pathogenesis. Clin Obstet Gynecol 1976; 19:147.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Public Health Service. V.D. fact sheet, 1976. Publication No. (CDC) 77-8195, USPHS; 1976.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/11\">",
"      Morse SA, Trees DL. Prevalence and treatment of multi-drug resistant Neisseria gonorrhoeae. Infect Med 1995; 12:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/12\">",
"      Centers for Disease Control and Prevention (CDC). Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep 2007; 56:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/13\">",
"      Rendtroff RC, Curran JW, Chandler RW, et al. Economic consequences of gonorrhea in women: experience from an Urban hospital. J Am Vener Dis Assoc 1974; 1:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/14\">",
"      Forslin L, Falk V, Danielsson D. Changes in the incidence of acute gonococcal and nongonococcal salpingitis. A five-year study from an urban area of central Sweden. Br J Vener Dis 1978; 54:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/15\">",
"      Eschenbach DA, Buchanan TM, Pollock HM, et al. Polymicrobial etiology of acute pelvic inflammatory disease. N Engl J Med 1975; 293:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/16\">",
"      Treharne JD, Ripa KT, M&aring;rdh PA, et al. Antibodies to Chlamydia trachomatis in acute salpingitis. Br J Vener Dis 1979; 55:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/17\">",
"      Recommendations of the International Task Force for Disease Eradication. MMWR Recomm Rep 1993; 42:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/18\">",
"      Centers for Disease Control and Prevention (CDC). Ten leading nationally notifiable infectious diseases--United States, 1995. MMWR Morb Mortal Wkly Rep 1996; 45:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/19\">",
"      Bowie WR, Jones H. Acute pelvic inflammatory disease in outpatients: association with Chlamydia trachomatis and Neisseria gonorrhoeae. Ann Intern Med 1981; 95:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/20\">",
"      Arya OP, Mallinson H, Goddard AD. Epidemiological and clinical correlates of chlamydial infection of the cervix. Br J Vener Dis 1981; 57:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/21\">",
"      Mosure DJ, Berman S, Fine D, et al. Genital Chlamydia infections in sexually active female adolescents: do we really need to screen everyone? J Adolesc Health 1997; 20:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/22\">",
"      Scholes D, Stergachis A, Heidrich FE, et al. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med 1996; 334:1362.",
"     </a>",
"    </li>",
"    <li>",
"     United States Preventive Service Task Force. Chlamydial infection: Screening 2001. In: Guide to Clinical Preventive Services, International Medical Publishing Co, Alexandria, VA 2001. p.332.",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Guidelines for Health Supervision, Third Ed, Stein M (Ed), American Academy of Pediatrics, Elk Grove, IL 1997.",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Guidelines for Women's Health Care. American College of Obstetricians and Gynecologists, Washington, DC 1996.",
"    </li>",
"    <li>",
"     American Medical Association. AMA Guidelines for Adolescent Preventive Services (GAPS), Elster A, Kuznets N (Eds), Williams &amp; Wilkins, Baltimore, MD 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/27\">",
"      Shafer MA, Tebb KP, Pantell RH, et al. Effect of a clinical practice improvement intervention on Chlamydial screening among adolescent girls. JAMA 2002; 288:2846.",
"     </a>",
"    </li>",
"    <li>",
"     National Committee on Quality Assurance. State of managed care quality report. National Committee for Quality Assurance, Washington, DC 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/29\">",
"      Soper DE, Brockwell NJ, Dalton HP, Johnson D. Observations concerning the microbial etiology of acute salpingitis. Am J Obstet Gynecol 1994; 170:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/30\">",
"      Ness RB, Hillier SL, Kip KE, et al. Bacterial vaginosis and risk of pelvic inflammatory disease. Obstet Gynecol 2004; 104:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/31\">",
"      Ness RB, Kip KE, Hillier SL, et al. A cluster analysis of bacterial vaginosis-associated microflora and pelvic inflammatory disease. Am J Epidemiol 2005; 162:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/32\">",
"      Haggerty CL. Evidence for a role of Mycoplasma genitalium in pelvic inflammatory disease. Curr Opin Infect Dis 2008; 21:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/33\">",
"      Oakeshott P, Aghaizu A, Hay P, et al. Is Mycoplasma genitalium in women the \"New Chlamydia?\" A community-based prospective cohort study. Clin Infect Dis 2010; 51:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/34\">",
"      Thompson SE 3rd, Hager WD, Wong KH, et al. The microbiology and therapy of acute pelvic inflammatory disease in hospitalized patients. Am J Obstet Gynecol 1980; 136:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/35\">",
"      Chow AW, Malkasian KL, Marshall JR, Guze LB. The bacteriology of acute pelvic inflammatory disease. Am J Obstet Gynecol 1975; 122:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/36\">",
"      Sweet RL, Draper DL, Hadley WK. Etiology of acute salpingitis: influence of episode number and duration of symptoms. Obstet Gynecol 1981; 58:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/37\">",
"      Sweet RL, Mills J, Hadley KW, et al. Use of laparoscopy to determine the microbiologic etiology of acute salpingitis. Am J Obstet Gynecol 1979; 134:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/38\">",
"      Stemmer W. Uber die ursachen von eileiterentzundungen. Gentral fur Gynnak 1941; 65:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/39\">",
"      Suss AL, Homel P, Hammerschlag M, Bromberg K. Risk factors for pelvic inflammatory disease in inner-city adolescents. Sex Transm Dis 2000; 27:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/40\">",
"      Lee NC, Rubin GL, Grimes DA. Measures of sexual behavior and the risk of pelvic inflammatory disease. Obstet Gynecol 1991; 77:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/41\">",
"      Flesh G, Weiner JM, Corlett RC Jr, et al. The intrauterine contraceptive device and acute salpingitis: a multifactor analysis. Am J Obstet Gynecol 1979; 135:402.",
"     </a>",
"    </li>",
"    <li>",
"     Rein MF. Epidemiology of gonococcal infection. In: The Gonococcus, Roberts RB (Ed), Wiley and Sons, New York 1977. p.1.",
"    </li>",
"    <li>",
"     Westrom, L, Mardh PA. Epidemiology, etiology, and prognosis of acute salpingitis: A study of 1,457 laparoscopically verified cases. In: Nongonococcal Urethritis and Related Diseases, Hobson D, Holmes KK (Eds), Am Soc Microbiol, Washington DC 1977. p.84.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/44\">",
"      Westr&ouml;m L. Incidence, prevalence, and trends of acute pelvic inflammatory disease and its consequences in industrialized countries. Am J Obstet Gynecol 1980; 138:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/45\">",
"      Centers for Disease Control and Prevention, Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/46\">",
"      Biro FM, Rosenthal SL, Kiniyalocts M. Gonococcal and chlamydial genitourinary infections in symptomatic and asymptomatic adolescent women. Clin Pediatr (Phila) 1995; 34:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/47\">",
"      Lan J, Melgers I, Meijer CJ, et al. Prevalence and serovar distribution of asymptomatic cervical Chlamydia trachomatis infections as determined by highly sensitive PCR. J Clin Microbiol 1995; 33:3194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/48\">",
"      Hillis SD, Nakashima A, Marchbanks PA, et al. Risk factors for recurrent Chlamydia trachomatis infections in women. Am J Obstet Gynecol 1994; 170:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/49\">",
"      Westr&ouml;m L. Effect of acute pelvic inflammatory disease on fertility. Am J Obstet Gynecol 1975; 121:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/50\">",
"      Ness RB, Soper DE, Holley RL, et al. Hormonal and barrier contraception and risk of upper genital tract disease in the PID Evaluation and Clinical Health (PEACH) study. Am J Obstet Gynecol 2001; 185:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/51\">",
"      Eschenbach DA, Harnisch JP, Holmes KK. Pathogenesis of acute pelvic inflammatory disease: role of contraception and other risk factors. Am J Obstet Gynecol 1977; 128:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/52\">",
"      Niruthisard S, Roddy RE, Chutivongse S. Use of nonoxynol-9 and reduction in rate of gonococcal and chlamydial cervical infections. Lancet 1992; 339:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/53\">",
"      Ness RB, Randall H, Richter HE, et al. Condom use and the risk of recurrent pelvic inflammatory disease, chronic pelvic pain, or infertility following an episode of pelvic inflammatory disease. Am J Public Health 2004; 94:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/54\">",
"      Gavin L, MacKay AP, Brown K, et al. Sexual and reproductive health of persons aged 10-24 years - United States, 2002-2007. MMWR Surveill Summ 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/55\">",
"      Louv WC, Austin H, Perlman J, Alexander WJ. Oral contraceptive use and the risk of chlamydial and gonococcal infections. Am J Obstet Gynecol 1989; 160:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/56\">",
"      Rubin GL, Ory HW, Layde PM. Oral contraceptives and pelvic inflammatory disease. Am J Obstet Gynecol 1982; 144:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/57\">",
"      Ness RB, Keder LM, Soper DE, et al. Oral contraception and the recognition of endometritis. Am J Obstet Gynecol 1997; 176:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/58\">",
"      W&oslash;lner-Hanssen P, Svensson L, M&aring;rdh PA, Westr&ouml;m L. Laparoscopic findings and contraceptive use in women with signs and symptoms suggestive of acute salpingitis. Obstet Gynecol 1985; 66:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/59\">",
"      Lee NC, Rubin GL, Borucki R. The intrauterine device and pelvic inflammatory disease revisited: new results from the Women's Health Study. Obstet Gynecol 1988; 72:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/60\">",
"      Grimes DA. Intrauterine device and upper-genital-tract infection. Lancet 2000; 356:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/61\">",
"      Lee YC, Min D, Holcomb K, et al. Computed tomography guided core needle biopsy diagnosis of pelvic actinomycosis. Gynecol Oncol 2000; 79:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/62\">",
"      Hall V, Talbot PR, Stubbs SL, Duerden BI. Identification of clinical isolates of actinomyces species by amplified 16S ribosomal DNA restriction analysis. J Clin Microbiol 2001; 39:3555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/63\">",
"      Lippes J. Pelvic actinomycosis: a review and preliminary look at prevalence. Am J Obstet Gynecol 1999; 180:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/64\">",
"      W&oslash;lner-Hanssen P, Eschenbach DA, Paavonen J, et al. Association between vaginal douching and acute pelvic inflammatory disease. JAMA 1990; 263:1936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11992/abstract/65\">",
"      Rosenberg MJ, Phillips RS. Does douching promote ascending infection? J Reprod Med 1992; 37:930.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7580 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.7.204.202-C708E0D7D2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_45_11992=[""].join("\n");
var outline_f11_45_11992=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2538513\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Neisseria gonorrhoeae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Chlamydia trachomatis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Screening in young women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other initiating pathogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Mixed infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Multiple partners",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Status of the partner",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Previous PID",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Contraceptive method",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Barrier contraception",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Oral contraceptives",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Intrauterine device and tubal ligation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2538513\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1032?source=related_link\">",
"      Clinical features and diagnosis of pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/20/38217?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical manifestations of Neisseria gonorrhoeae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31177?source=related_link\">",
"      Mycoplasma hominis, Mycoplasma genitalium, and Ureaplasma urealyticum infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/14/26850?source=related_link\">",
"      Patient information: Pelvic inflammatory disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/13/8408?source=related_link\">",
"      Screening for Chlamydia trachomatis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35832?source=related_link\">",
"      Treatment of pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/3/19514?source=related_link\">",
"      Treatment of uncomplicated gonococcal infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_45_11993="Estimation of blood glucose control in diabetes mellitus";
var content_f11_45_11993=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Estimation of blood glucose control in diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/45/11993/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/45/11993/contributors\">",
"     David K McCulloch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/45/11993/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/45/11993/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/45/11993/contributors\">",
"     Joseph I Wolfsdorf, MB, BCh",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/45/11993/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/45/11993/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/45/11993/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The demonstration that the development of microvascular complications in patients with type 1 diabetes can be slowed by treating hyperglycemia has led to increased use of intensive insulin regimens to attain strict glycemic control (",
"    <a class=\"graphic graphic_figure graphicRef73143 \" href=\"UTD.htm?18/21/18781\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef82664 \" href=\"UTD.htm?42/55/43901\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The efficacy of these regimens requires an accurate method to estimate the degree to which this is achieved. It is helpful to first review some basic concepts before discussing the utility of measurements of hemoglobin A1C (HbA1c) and serum fructosamine to assess glycemic control.",
"   </p>",
"   <p>",
"    There are three useful measurements for defining glycemic control:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean blood glucose concentration has often been measured in clinical trials as the mean of values obtained before breakfast, mid-morning, before lunch, mid-afternoon, before dinner, and before sleep each day. Clinically, this can be replaced with or supplemented by the more simple measurement of A1C. In some cases, however, there is a disparity between the A1C values and mean blood glucose values (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Recommendations in type 1 diabetes'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      The degree to which blood glucose concentrations fluctuate within the same day can be formally measured as the mean amplitude of glycemic excursions [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The degree to which blood glucose concentrations fluctuate from day to day can be formally measured as the mean of daily differences [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mean blood glucose has received the greatest attention. However, as will be discussed below, a given mean blood glucose value may be associated with different mean glycemic excursions and mean daily differences (",
"    <a class=\"graphic graphic_figure graphicRef55747 \" href=\"UTD.htm?7/3/7231\">",
"     figure 3",
"    </a>",
"    ). The approach to improving blood glucose control may be different depending upon whether an elevated mean blood glucose is associated with large fluctuations or not.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ESTIMATION OF MEAN BLOOD GLUCOSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been known since the 1970s that glucose can attach to many proteins via a nonenzymatic, post-translational process [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/6\">",
"     6",
"    </a>",
"    ]. This occurs in two stages (",
"    <a class=\"graphic graphic_figure graphicRef80716 \" href=\"UTD.htm?22/4/22606\">",
"     figure 4",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A reversible reaction leads to the formation of an aldimine (or Schiff base).",
"     </li>",
"     <li>",
"      This is followed by an Amadori rearrangement to form an irreversible ketoamine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A transient elevation in blood glucose concentration can lead to the formation of a large quantity of aldimines. This reaction reverses if the concentration returns to normal. However, formation of the ketoamine is irreversible because glucose remains permanently attached to the protein until it is metabolized. This sequence is important in understanding and interpreting assays that measure glycated proteins. The large majority of commercially available assays of glycated hemoglobin only measure the stable ketoamine and do not measure the labile (aldimine) fraction. Therefore, they reflect long-term (two to three months) average glycemia, relatively unaffected by recent acute fluctuations in glucose levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Hemoglobin A1C",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most widely used clinical test is measurement of glycated hemoglobin (also called A1C, hemoglobin A1C, glycohemoglobin, or HbA1C). Hemoglobin formed in new red blood cells enters the circulation with minimal glucose attached. However, red cells are freely permeable to glucose. As a result, glucose becomes irreversibly attached to hemoglobin at a rate dependent upon the prevailing blood glucose concentration. Approximately 1 percent of erythrocytes are destroyed every day, while an equal number of new ones are formed. Thus, the average amount of A1C changes in a dynamic way and indicates the mean blood glucose concentration over the life span of the red cell [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Although the A1C reflects mean blood glucose over the entire 120 day life span of the red blood cell, it correlates best with mean blood glucose over the previous 8 to 12 weeks (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?12/54/13153?source=see_link\">",
"     calculator 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This relationship has been demonstrated in several studies that have calculated average glucose on the basis of frequently measured, usually capillary, glucose levels [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/7,9-11\">",
"     7,9-11",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Diabetes Control and Complications Trial (DCCT) estimated the mean blood glucose concentrations derived from seven measurements a day (before and 90 minutes after each of the three major meals, and before bedtime), performed once every three months, and compared the average glucose concentration with A1C values in patients with type 1 diabetes (",
"      <a class=\"graphic graphic_figure graphicRef62980 \" href=\"UTD.htm?0/57/926\">",
"       figure 5",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/9\">",
"       9",
"      </a>",
"      ]. Non-DCCT investigators noted a relatively strong correlation between the limited glucose sampling and A1C values and translated the A1C values into a comparable average glucose level.",
"     </li>",
"     <li>",
"      A much smaller study captured average glucose by using continuous glucose monitoring (CGM) over three months in 25 participants (type 1 and type 2 diabetics and nondiabetic subjects) and compared the calculated average glucose levels to the A1C at three months [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A large international study (A1C-Derived Average Glucose or ADAG study) calculated average glucose levels in 507 subjects (268 type 1, 159 type 2, and 80 nondiabetic), using a combination of CGM and self-monitoring of blood glucose testing, and established a reliable regression equation that can be used to translate A1C results into an estimated average glucose value [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Assay'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies suggest that A1C values may also be helpful in the diagnosis of impaired glucose tolerance or overt diabetes mellitus, being simpler to perform and to repeat than the oral glucose tolerance test. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38758?source=see_link\">",
"     \"Diagnosis of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Assay",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, the results of the DCCT could not be extrapolated widely because of differences in methodology and a lack of standardization among laboratories [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/13\">",
"     13",
"    </a>",
"    ]. The National Glycohemoglobin Standardization Program (NGSP) has standardized more than 99 percent of the assays used in the United States to the DCCT standard [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/14\">",
"     14",
"    </a>",
"    ]. A strict quality control program has improved precision and accuracy of assays in the US and many international assays.",
"   </p>",
"   <p>",
"    In addition, a new reference method has been established that will provide for even more reliable worldwide standardization of all A1C assays [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/15\">",
"     15",
"    </a>",
"    ]. With this new reference system, A1C results will be reported globally in SI (Systeme International) units",
"    <span class=\"nowrap\">",
"     (mmol/mol)",
"    </span>",
"    and derived NGSP units (the same values as reported currently as percent of total hemoglobin) using a master equation. An estimated average glucose (eAG), calculated from the A1C result and based upon the results of the ADAG study described above, will be included in the report (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?12/54/13153?source=see_link\">",
"     calculator 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The eAG",
"    <span class=\"nowrap\">",
"     (mg/dL",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    is a more relevant term for patients who self-monitor blood glucose. If there are differences in the eAG derived from the A1C result and the meter-calculated average glucose, further exploration is required. As an example, if the eAG is higher than the patient&rsquo;s meter calculated average glucose, it is possible that fingerstick testing is not being performed at times when the blood glucose is highest, eg, after meals. If the eAG is lower than the meter average, a patient may be having undetected periods of low blood glucose, most often nocturnal hypoglycemia. In such cases, the timing of fingerstick blood glucose monitoring requires adjustment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Sources of error",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the international standardization of the A1C assay has decreased potential technical errors in interpreting A1C results, there are other biological and patient-specific factors that may cause misleading results [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A1C values are influenced by red cell survival. Thus, falsely high values in relation to a mean blood glucose values can be obtained when red cell turnover is low, resulting in a disproportionate number of older red cells. This problem can occur in patients with iron, vitamin B12, or folate deficiency anemia.",
"     </li>",
"     <li>",
"      On the other hand, rapid red cell turnover leads to a greater proportion of younger red cells and falsely low A1C values. Examples include patients with hemolysis or anemia and those treated for iron, vitamin B12, or folate deficiency, and patients treated with erythropoietin [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/17-20\">",
"       17-20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Depending upon the methodology, the values may be high in patients with abnormal hemoglobins (such as HbF and HbS) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/21\">",
"       21",
"      </a>",
"      ]. However, many methods for measuring A1C are no longer affected by hemoglobin variants. The National Glycohemoglobin Standardization Program (NGSP) website (",
"      <a class=\"external\" href=\"file://www.ngsp.org/\">",
"       www.ngsp.org",
"      </a>",
"      ) contains current information about substances that interfere with A1C test results. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/13/4306?source=see_link\">",
"       \"Interactive diabetes case 8: Discordant values for A1C and home blood glucose values\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A1C values may be falsely elevated or decreased in those with chronic kidney disease. False elevations may be due in part to analytical interference from carbamylated hemoglobin formed in the presence of elevated concentrations of urea, leading to false elevations in the A1C level with some assays. False decreases in measured A1C may occur with hemodialysis and altered red cell turnover, especially in the setting of erythropoietin treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7865?source=see_link&amp;anchor=H2#H2\">",
"       \"Management of hyperglycemia in diabetics with end-stage renal disease\", section on 'Monitoring glycemic control'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22323466\">",
"    <span class=\"h3\">",
"     Racial variation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have shown that A1C concentrations are higher in some ethnic groups (African American, Hispanic, Asian) than in white persons with similar plasma glucose concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/22-26\">",
"     22-26",
"    </a>",
"    ]. The differences are evident across the spectrum of glycemia, from normal glucose tolerance to prediabetes to diabetes and are independent of assay method. In one cross-sectional study, A1C was 0.13 to 0.47 percentage points higher in black than in white persons, with the difference increasing as glucose intolerance worsened [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/27\">",
"     27",
"    </a>",
"    ]. However, all of these studies estimated mean glucose levels on the basis of very limited measurements, usually a single fasting glucose level or oral glucose tolerance test. This leaves open the possibility that if measured appropriately, ie, with frequent enough glucose measurements over time, mean glucose levels might be different between different racial groups and the putative different A1C levels between races reflect different mean glucose levels. This scenario has been supported by a cross-sectional study in which differences in HbA1c between races was paralleled by other, independent measures of chronic glycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/25\">",
"     25",
"    </a>",
"    ]. This finding supports differences in glucose levels as the reason for different levels of HbA1c in different",
"    <span class=\"nowrap\">",
"     racial/ethnic",
"    </span>",
"    groups. However, until more definitive studies are performed, whether A1C differs among races for the same mean glucose levels remains an open question.",
"   </p>",
"   <p>",
"    Even if differences in A1C between races do exist, the differences appear to be small and have not been shown to significantly modify the association between A1C and cardiovascular outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/28\">",
"     28",
"    </a>",
"    ], retinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/29-31\">",
"     29-31",
"    </a>",
"    ], or nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/30\">",
"     30",
"    </a>",
"    ]. In a cross-sectional study using the National Health and Nutrition Examination Survey (NHANES 2005 to 2008), the prevalence of retinopathy actually increased at a lower A1C level in blacks compared with whites (5.5 to 5.9 versus 6.0 to 6.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If a difference does exist, potential mechanisms include genetic differences in intracellular glycation, glucose transport across the erythrocyte membrane, or in erythrocyte survival [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Fructosamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many proteins other than hemoglobin also undergo nonenzymatic glycation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/34\">",
"     34",
"    </a>",
"    ], leading to the formation of advanced glycosylation end products which may play a direct role in the development of diabetic microvascular complications (",
"    <a class=\"graphic graphic_figure graphicRef80716 \" href=\"UTD.htm?22/4/22606\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=see_link&amp;anchor=H2#H2\">",
"     \"Glycemic control and vascular complications in type 1 diabetes mellitus\", section on 'Pathogenesis'",
"    </a>",
"    .) The serum concentration of some of these proteins can also be used to estimate glycemic control. The term fructosamine has been applied to the ketoamines formed in this process.",
"   </p>",
"   <p>",
"    Several methods are available for measuring serum fructosamine [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/34\">",
"     34",
"    </a>",
"    ]. Some of the assays are cheaper and easier to perform than the A1C assay. There is generally a good correlation between serum fructosamine and A1C values [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. There are, however, several potential problems with the use of serum fructosamine measurements:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The within-subject variation for serum fructosamine is higher than that for A1C; as a result, serum fructosamine concentrations must change more before a significant change can be said to have occurred [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The turnover of serum albumin is more rapid than that of hemoglobin (28 days versus 120 days). Thus, serum fructosamine values reflect mean blood glucose values over a much shorter period of time (one to two weeks).",
"     </li>",
"     <li>",
"      Serum fructosamine values must be adjusted if the serum albumin concentration is abnormal [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/40\">",
"       40",
"      </a>",
"      ]. Furthermore, falsely low values in relation to mean blood glucose values will occur with rapid albumin turnover as occurs in patients with protein-losing enteropathy or the nephrotic syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These limitations plus the lack of necessity of following changes in mean blood glucose concentrations every one to two weeks means that A1C is usually preferable for estimating mean blood glucose concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     WITHIN-DAY GLUCOSE VARIATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The range over which blood glucose concentrations vary within a day has been used to define one type of \"unstable diabetes\" [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/4\">",
"     4",
"    </a>",
"    ]. A useful approximation of these fluctuations in patients who do blood glucose monitoring can be obtained by measuring the blood glucose before and 90 minutes after meals for several days. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29641?source=see_link\">",
"     \"Blood glucose self-monitoring in management of adults with diabetes mellitus\"",
"    </a>",
"    .) While unstable within-day glucose variation may increase the risk of hypoglycemia, it does not appear to be an additional factor in the development of microvascular complications over and above the average blood glucose level as measured by A1C [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     1,5-Anhydroglucitol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of serum 1,5-anhydroglucitol (1,5-AG), a naturally occurring dietary polyol, is another method that provides information on daily glycemic variations [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. During euglycemia, 1,5-AG is filtered and is completely reabsorbed by the kidneys; as a result, serum concentrations remain stable. However, renal reabsorption of 1,5-AG is competitively inhibited by glucose. Within 24 hours of a rise in serum glucose to &gt;180",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (10",
"    <span class=\"nowrap\">",
"     mmol/L,",
"    </span>",
"    the renal threshold for glucose excretion), serum 1,5-AG concentrations fall as urinary losses increase [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Thus, serum 1,5-AG measurements reflect blood glucose values over the past 24 hours, whereas A1C and fructosamine measurements reflect values over two to three months and one to two weeks, respectively.",
"   </p>",
"   <p>",
"    In addition, serum 1,5-AG may reflect postprandial glycemic excursions better than A1C [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/45,48\">",
"     45,48",
"    </a>",
"    ]. However, there are no data to suggest that complementary measurement of 1,5-AG (GlycoMark assay) improves glycemic control or complications of diabetes more than measurement of A1C alone. Thus, we do not typically measure 1,5-AG concentrations. In patients who have high A1C values despite excellent fasting and preprandial blood glucose levels, we prefer to test blood glucose one to two hours after meals and adjust medication accordingly.",
"   </p>",
"   <p>",
"    Optimal therapy of postprandial hyperglycemia (",
"    <a class=\"graphic graphic_figure graphicRef55747 \" href=\"UTD.htm?7/3/7231\">",
"     figure 3",
"    </a>",
"    ) requires changes in either the nutrition prescription or the insulin regimen. As an example, a large meal containing a lot of quickly absorbed carbohydrate that is low in soluble fiber will cause substantial postprandial hyperglycemia. Changing the overall distribution of carbohydrate (eating somewhat less with each meal and more with between meal snacks) and increasing the intake of soluble fiber should dampen the glycemic excursions after meals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/2/25641?source=see_link\">",
"     \"Nutritional considerations in type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/18/14634?source=see_link\">",
"     \"Nutritional considerations in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Altering the insulin regimen and using an adjustable premeal algorithm also may be helpful. Large postprandial rises in blood glucose levels can be minimized by increasing the time between the injection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    (which begins to act within 20 to 30 minutes after subcutaneous injection) and the beginning of the meal. The availability of monomeric rapidly absorbed insulin analogues, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17160?source=see_link\">",
"     insulin lispro",
"    </a>",
"    , which have a much more rapid onset of action and larger peak effect than regular insulin, reduces the lag time between injection and onset of action to approximately 15 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=see_link\">",
"     \"General principles of insulin therapy in diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=see_link\">",
"     \"Insulin therapy in adults with type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DAY-TO-DAY GLUCOSE VARIATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extent to which blood glucose concentrations vary at the same time each day is another useful measure of overall glycemic control [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/5\">",
"     5",
"    </a>",
"    ]. For patients who test their own blood glucose at the same times every day, this variability can be evaluated simply by scanning down columns of blood glucose measurements over several days. The usual explanation for large daily fluctuations is an erratic lifestyle in terms of eating or exercise habits. These problems should be corrected before increasing the insulin dose. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/8/4232?source=see_link&amp;anchor=H2#H2\">",
"     \"Cases illustrating problems with intensive insulin therapy for diabetes mellitus\", section on 'Lack of control due to diet'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of continuous glucose monitoring devices can make the identification of within-day and between-day variation easier. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29641?source=see_link\">",
"     \"Blood glucose self-monitoring in management of adults with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS IN TYPE 1 DIABETES",
"    </span>",
"    &nbsp;&mdash;&nbsp;We measure A1C every three months in patients with type 1 diabetes. The goal must be correlated with the normal range for the assay in the particular laboratory, although the National Glycohemoglobin Standardization Program (NGSP) has largely standardized the values for much of the world. For patients who do blood glucose monitoring, both the patient's technique and the meter's reliability should be checked periodically. It is then useful to compare an average of the 50 or so most recent blood glucose readings with the A1C value obtained at that visit (",
"    <a class=\"graphic graphic_figure graphicRef62980 \" href=\"UTD.htm?0/57/926\">",
"     figure 5",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the A1C value is",
"      <strong>",
"       higher",
"      </strong>",
"      than expected, it is possible that the patient is falsifying his or her blood glucose results or has made an effort to improve glycemic control in the two weeks before the appointment. Another explanation is that the blood glucose concentrations are much higher at times between blood tests (such as between meals). Finally, some of the factors discussed above, which can falsely elevate the A1C, should be excluded (such as abnormal hemoglobins, untreated iron deficiency, or renal failure).",
"     </li>",
"     <li>",
"      If the A1C value is",
"      <strong>",
"       lower",
"      </strong>",
"      than expected, it is possible that the blood glucose is low for long periods of time when the patient is not testing (such as undetected nocturnal hypoglycemia). Other possibilities include reduced red cell survival (such as hemolysis) or conditions in which a disproportionate number of red cells are young (as with chronic bleeding, venisection, treatment of anemia).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the patient is interested in improving glycemic control by intensifying his or her diabetes regimen, then attention must be paid to the blood glucose patterns to detect problems of within-day and between-day variability. These fluctuations should be corrected before increasing the insulin regimen.",
"   </p>",
"   <p>",
"    The DCCT found an inverse relationship between the A1C value and the incidence of developing diabetic retinopathy in patients with type 1 diabetes (",
"    <a class=\"graphic graphic_figure graphicRef82664 \" href=\"UTD.htm?42/55/43901\">",
"     figure 2",
"    </a>",
"    ). The risk of retinopathy was near its lowest level in patients with A1C values of approximately 7 to 7.5 percent. There is a continued relative risk reduction of retinopathy with A1C levels less than 7.5 percent, similar in magnitude to the reduction at higher A1C levels; however, the absolute risk of retinopathy is low (",
"    <a class=\"graphic graphic_figure graphicRef59452 \" href=\"UTD.htm?5/41/5789\">",
"     figure 6",
"    </a>",
"    ). Thus, increasing the intensity of glycemic control should only be considered if recurrent severe hypoglycemia is not occurring. In general, we aim for an A1C value of 7 percent or less. This approach is consistent with that of the American Diabetes Association (ADA), which recommends a target of less than 7 percent for most patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=see_link\">",
"     \"Glycemic control and vascular complications in type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS IN TYPE 2 DIABETES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although similar general considerations apply to patients with type 2 diabetes, there is less variability in blood glucose concentrations in this disorder. As a result, the fasting blood glucose concentration correlates fairly well with the A1C value and can be used with the A1C to estimate glycemic control [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some authors have argued that nonfasting blood glucose measurements are a better marker of blood glucose control than fasting values [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/9,51\">",
"     9,51",
"    </a>",
"    ]. However, the effectiveness of self-monitoring of blood glucose in terms of improving glycemic control in patients with type 2 diabetes is less clear than for type 1 diabetes. Self-blood glucose monitoring should not be regarded as an intervention that in its own right will be associated with improved glycemic control. Rather, it is a tool that gives invaluable information with which motivated and well-educated patients can modify their behavior and improve their glycemic control (and A1C values) safely. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29641?source=see_link&amp;anchor=H4#H4\">",
"     \"Blood glucose self-monitoring in management of adults with diabetes mellitus\", section on 'Type 2 diabetes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Improving glycemic control is often more difficult in patients with type 2 diabetes because of obesity and insulin resistance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28986?source=see_link\">",
"     \"Management of persistent hyperglycemia in type 2 diabetes mellitus\"",
"    </a>",
"    .) The frequency of blood glucose monitoring is usually less than for type 1 diabetes, but can vary considerably depending upon the stage of the disease, the targets being set, and the treatments being used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11332?source=see_link\">",
"     \"Case illustrating blood glucose monitoring in type 2 diabetes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal level of glycemic control to prevent microvascular complications in patients with type 2 diabetes is not clear. The United Kingdom Prospective Diabetes Study (UKPDS) showed that intensive therapy (mean A1C value of 7 percent) with oral hypoglycemic drugs or insulin resulted in a decreased risk of microvascular complications compared to conventional therapy with diet (mean A1C value of 7.9 percent) (",
"    <a class=\"graphic graphic_figure graphicRef52273 \" href=\"UTD.htm?36/32/37389\">",
"     figure 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/52\">",
"     52",
"    </a>",
"    ]. Subanalysis of the UKPDS showed no evidence of a threshold effect of A1C; a 1 percent reduction in A1C was associated with a 35 percent reduction in microvascular endpoints. Finally, long-term follow-up of UKPDS revealed a benefit of intensive therapy compared with conventional therapy, with A1C levels of 7 versus 7.9 percent during the trial, on cardiovascular events [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several trials [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/54,55\">",
"     54,55",
"    </a>",
"    ] have examined the effects of even lower A1C levels than achieved during UKPDS on cardiovascular outcomes. The randomly assigned intensive groups achieved lower A1C levels than the control groups (approximately 6.5 compared with 7.5 percent) and microvascular outcomes, which were secondary outcomes, were reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. However, these trials had either no effect on cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/55\">",
"     55",
"    </a>",
"    ] or were associated with higher overall and cardiovascular mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/54\">",
"     54",
"    </a>",
"    ]. Thus, the trials that achieved A1C levels of approximately 6.5 percent had lower microvascular disease but either no better or worse cardiovascular effects. These trials are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=see_link&amp;anchor=H10#H10\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\", section on 'Intensive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On balance and taking the results of the UKPDS and the more recent large clinical trials into account, we recommend that the target A1C value should be 7 percent or lower for most patients. The goal should be set somewhat higher for older patients and those with comorbid conditions or a limited life expectancy in whom the risk of hypoglycemia may outweigh the potential benefit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=see_link\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28986?source=see_link\">",
"     \"Management of persistent hyperglycemia in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PATIENT FEEDBACK",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults, immediate patient feedback at clinician visits about A1C values may improve glycemic control [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. These studies used rapid A1C assays, but it may also be feasible to measure A1C several days before routine office visits so that the results are available at the time of the visit. In a randomized trial of immediate (fingerstick point-of-care testing at office visits) or conventional (venipuncture with follow-up days after visit) feedback in children under 18 years of age, immediate feedback resulted in improvement in A1C after three months, which was not sustained at 6 or 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11993/abstract/61\">",
"     61",
"    </a>",
"    ]. There were no significant differences between the groups with regard to frequency of treatment changes to insulin dosing, dietary, exercise, or blood glucose monitoring recommendations. Point-of-care testing was less painful and, therefore, more acceptable to children, and immediate feedback resulted in more efficient patient-clinician communication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=see_link\">",
"       \"Patient information: Type 1 diabetes (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=see_link\">",
"       \"Patient information: Type 2 diabetes (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/14/227?source=see_link\">",
"       \"Patient information: Hemoglobin A1C tests (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=see_link\">",
"       \"Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22323804\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most widely used clinical test to estimate blood glucose control is measurement of glycated hemoglobin (also called A1C, hemoglobin A1C, glycohemoglobin, or HbA1C). A1C reflects mean blood glucose over the entire 120 day life span of the red blood cell, but it correlates best with mean blood glucose over the previous 8 to 12 weeks. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Hemoglobin A1C'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As part of an effort to provide worldwide standardization of all A1C assays, A1C results will be reported globally in International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) units",
"      <span class=\"nowrap\">",
"       (mmol/mol)",
"      </span>",
"      and derived NGSP units (the same values as reported currently as percent of total hemoglobin) using a master equation. An estimated average glucose (eAG), calculated from the A1C result, will be included in the report (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?12/54/13153?source=see_link\">",
"       calculator 1",
"      </a>",
"      ). The eAG is a more relevant term for patients who self-monitor blood glucose. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Hemoglobin A1C'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the international standardization of the A1C assay has decreased potential technical errors in interpreting A1C results, there are other biological and patient-specific factors that may cause misleading results. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Sources of error'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The extent to which blood glucose concentrations vary at the same time each day is another useful measure of overall glycemic control. For patients who test their own blood glucose at the same times every day, this variability can be evaluated simply by scanning down columns of blood glucose measurements over several days. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Day-to-day glucose variations'",
"      </a>",
"      above.) The use of continuous glucose monitoring devices can make the identification of within-day and between-day variation easier. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29641?source=see_link&amp;anchor=H13#H13\">",
"       \"Blood glucose self-monitoring in management of adults with diabetes mellitus\", section on 'Continuous glucose monitoring'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/1\">",
"      The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/2\">",
"      Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 1993; 341:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/3\">",
"      Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993; 329:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/4\">",
"      Service FJ, Molnar GD, Rosevear JW, et al. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 1970; 19:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/5\">",
"      Molnar GD, Taylor WF, Ho MM. Day-to-day variation of continuously monitored glycaemia: a further measure of diabetic instability. Diabetologia 1972; 8:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/6\">",
"      Bunn HF, Haney DN, Gabbay KH, Gallop PM. Further identification of the nature and linkage of the carbohydrate in hemoglobin A1c. Biochem Biophys Res Commun 1975; 67:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/7\">",
"      Nathan DM, Singer DE, Hurxthal K, Goodson JD. The clinical information value of the glycosylated hemoglobin assay. N Engl J Med 1984; 310:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/8\">",
"      Goldstein DE. Is glycosylated hemoglobin clinically useful? N Engl J Med 1984; 310:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/9\">",
"      Rohlfing CL, Wiedmeyer HM, Little RR, et al. Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care 2002; 25:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/10\">",
"      Svendsen PA, Lauritzen T, S&oslash;egaard U, Nerup J. Glycosylated haemoglobin and steady-state mean blood glucose concentration in Type 1 (insulin-dependent) diabetes. Diabetologia 1982; 23:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/11\">",
"      Nathan DM, Turgeon H, Regan S. Relationship between glycated haemoglobin levels and mean glucose levels over time. Diabetologia 2007; 50:2239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/12\">",
"      Nathan DM, Kuenen J, Borg R, et al. Translating the A1C assay into estimated average glucose values. Diabetes Care 2008; 31:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/13\">",
"      Little RR, Wiedmeyer HM, England JD, et al. Interlaboratory comparison of glycohemoglobin results: College of American Pathologists Survey data. Clin Chem 1991; 37:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/14\">",
"      Steffes MW, Sacks DB. Measurement of circulating glucose concentrations: the time is now for consistency among methods and types of samples. Clin Chem 2005; 51:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/15\">",
"      Hanas R, John G, International HBA1c Consensus Committee. 2010 consensus statement on the worldwide standardization of the hemoglobin A1C measurement. Diabetes Care 2010; 33:1903.",
"     </a>",
"    </li>",
"    <li>",
"     National Glycohemoglobin Standardization Program (NGSP) website, which contains up to date information about substances that interfere with glycohemoglobin (HbA1c) test results. file://www.ngsp.org (Accessed on November 04, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/17\">",
"      Panzer S, Kronik G, Lechner K, et al. Glycosylated hemoglobins (GHb): an index of red cell survival. Blood 1982; 59:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/18\">",
"      Polgreen PM, Putz D, Stapleton JT. Inaccurate glycosylated hemoglobin A1C measurements in human immunodeficiency virus-positive patients with diabetes mellitus. Clin Infect Dis 2003; 37:e53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/19\">",
"      Brown JN, Kemp DW, Brice KR. Class effect of erythropoietin therapy on hemoglobin A(1c) in a patient with diabetes mellitus and chronic kidney disease not undergoing hemodialysis. Pharmacotherapy 2009; 29:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/20\">",
"      Ng JM, Cooke M, Bhandari S, et al. The effect of iron and erythropoietin treatment on the A1C of patients with diabetes and chronic kidney disease. Diabetes Care 2010; 33:2310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/21\">",
"      Roberts WL, Safar-Pour S, De BK, et al. Effects of hemoglobin C and S traits on glycohemoglobin measurements by eleven methods. Clin Chem 2005; 51:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/22\">",
"      Saaddine JB, Fagot-Campagna A, Rolka D, et al. Distribution of HbA(1c) levels for children and young adults in the U.S.: Third National Health and Nutrition Examination Survey. Diabetes Care 2002; 25:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/23\">",
"      Herman WH, Ma Y, Uwaifo G, et al. Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care 2007; 30:2453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/24\">",
"      Herman WH, Dungan KM, Wolffenbuttel BH, et al. Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. J Clin Endocrinol Metab 2009; 94:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/25\">",
"      Selvin E, Steffes MW, Ballantyne CM, et al. Racial differences in glycemic markers: a cross-sectional analysis of community-based data. Ann Intern Med 2011; 154:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/26\">",
"      Herman WH, Cohen RM. Racial and ethnic differences in the relationship between HbA1c and blood glucose: implications for the diagnosis of diabetes. J Clin Endocrinol Metab 2012; 97:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/27\">",
"      Ziemer DC, Kolm P, Weintraub WS, et al. Glucose-independent, black-white differences in hemoglobin A1c levels: a cross-sectional analysis of 2 studies. Ann Intern Med 2010; 152:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/28\">",
"      Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010; 362:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/29\">",
"      Tsugawa Y, Mukamal KJ, Davis RB, et al. Should the hemoglobin A(1c) diagnostic cutoff differ between blacks and whites?: a cross-sectional study. Ann Intern Med 2012; 157:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/30\">",
"      Selvin E, Ning Y, Steffes MW, et al. Glycated hemoglobin and the risk of kidney disease and retinopathy in adults with and without diabetes. Diabetes 2011; 60:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/31\">",
"      Bower JK, Brancati FL, Selvin E. No ethnic differences in the association of glycated hemoglobin with retinopathy: the national health and nutrition examination survey 2005-2008. Diabetes Care 2013; 36:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/32\">",
"      Cohen RM, Holmes YR, Chenier TC, Joiner CH. Discordance between HbA1c and fructosamine: evidence for a glycosylation gap and its relation to diabetic nephropathy. Diabetes Care 2003; 26:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/33\">",
"      Cohen RM, Franco RS, Khera PK, et al. Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c. Blood 2008; 112:4284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/34\">",
"      Armbruster DA. Fructosamine: structure, analysis, and clinical usefulness. Clin Chem 1987; 33:2153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/35\">",
"      Vlassara H. Protein glycation in the kidney: role in diabetes and aging. Kidney Int 1996; 49:1795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/36\">",
"      Baker JR, Metcalf PA, Holdaway IM, Johnson RN. Serum fructosamine concentration as measure of blood glucose control in type I (insulin dependent) diabetes mellitus. Br Med J (Clin Res Ed) 1985; 290:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/37\">",
"      Pandya, HC, Livingstone, S, Colgan, ME, et al. Serum fructosamine as an index of glycaemia: Comparison with glycated haemoglobin in diabetic and non-diabetic individuals. Pract Diabetes 1987; 4:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/38\">",
"      Narbonne H, Renacco E, Pradel V, et al. Can fructosamine be a surrogate for HbA(1c) in evaluating the achievement of therapeutic goals in diabetes? Diabetes Metab 2001; 27:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/39\">",
"      Howey JE, Bennet WM, Browning MC, et al. Clinical utility of assays of glycosylated haemoglobin and serum fructosamine compared: use of data on biological variation. Diabet Med 1989; 6:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/40\">",
"      Howey JE, Browning MC, Fraser CG. Assay of serum fructosamine that minimizes standardization and matrix problems: use to assess components of biological variation. Clin Chem 1987; 33:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/41\">",
"      Ashby JP, Frier BM. Is serum fructosamine a clinically useful test? Diabet Med 1988; 5:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/42\">",
"      Kilpatrick ES, Rigby AS, Atkin SL. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 2006; 29:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/43\">",
"      Kishimoto M, Yamasaki Y, Kubota M, et al. 1,5-Anhydro-D-glucitol evaluates daily glycemic excursions in well-controlled NIDDM. Diabetes Care 1995; 18:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/44\">",
"      McGill JB, Cole TG, Nowatzke W, et al. Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: a U.S. trial of the GlycoMark assay. Diabetes Care 2004; 27:1859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/45\">",
"      Dungan KM, Buse JB, Largay J, et al. 1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care 2006; 29:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/46\">",
"      Buse JB, Freeman JL, Edelman SV, et al. Serum 1,5-anhydroglucitol (GlycoMark ): a short-term glycemic marker. Diabetes Technol Ther 2003; 5:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/47\">",
"      Dungan KM. 1,5-anhydroglucitol (GlycoMark) as a marker of short-term glycemic control and glycemic excursions. Expert Rev Mol Diagn 2008; 8:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/48\">",
"      Stettler C, Stahl M, Allemann S, et al. Association of 1,5-anhydroglucitol and 2-h postprandial blood glucose in type 2 diabetic patients. Diabetes Care 2008; 31:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/49\">",
"      Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 1994; 43:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/50\">",
"      Howe-Davies S, Simpson RW, Turner RC. Control of maturity-onset diabetes by monitoring fasting blood glucose and body weight. Diabetes Care 1980; 3:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/51\">",
"      Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 1997; 20:1822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/52\">",
"      Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/53\">",
"      Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/54\">",
"      Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/55\">",
"      ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/56\">",
"      ACCORD Study Group, ACCORD Eye Study Group, Chew EY, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/57\">",
"      Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010; 376:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/58\">",
"      Beulens JW, Patel A, Vingerling JR, et al. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia 2009; 52:2027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/59\">",
"      Cagliero E, Levina EV, Nathan DM. Immediate feedback of HbA1c levels improves glycemic control in type 1 and insulin-treated type 2 diabetic patients. Diabetes Care 1999; 22:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/60\">",
"      Thaler LM, Ziemer DC, Gallina DL, et al. Diabetes in urban African-Americans. XVII. Availability of rapid HbA1c measurements enhances clinical decision-making. Diabetes Care 1999; 22:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11993/abstract/61\">",
"      Agus MS, Alexander JL, Wolfsdorf JI. Utility of immediate hemoglobin A1c in children with type I diabetes mellitus. Pediatr Diabetes 2010; 11:450.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1807 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-A7177AF1CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_45_11993=[""].join("\n");
var outline_f11_45_11993=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22323804\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ESTIMATION OF MEAN BLOOD GLUCOSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Hemoglobin A1C",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Assay",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Sources of error",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22323466\">",
"      - Racial variation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Fructosamine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      WITHIN-DAY GLUCOSE VARIATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      1,5-Anhydroglucitol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DAY-TO-DAY GLUCOSE VARIATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      RECOMMENDATIONS IN TYPE 1 DIABETES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RECOMMENDATIONS IN TYPE 2 DIABETES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PATIENT FEEDBACK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22323804\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1807\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1807|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/21/18781\" title=\"figure 1\">",
"      Nephropathy and control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/55/43901\" title=\"figure 2\">",
"      Retinopathy and HbA1c",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/3/7231\" title=\"figure 3\">",
"      Patterns of glycemic control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/4/22606\" title=\"figure 4\">",
"      Glycosylation of proteins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/57/926\" title=\"figure 5\">",
"      MBG and HbA1c",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/41/5789\" title=\"figure 6\">",
"      Hypoglycemia and HbA1c",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/32/37389\" title=\"figure 7\">",
"      Microvascular endpoint and control",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?12/54/13153?source=related_link\" title=\"calculator 1\">",
"      Calculator: Glycemic assessment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29641?source=related_link\">",
"      Blood glucose self-monitoring in management of adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11332?source=related_link\">",
"      Case illustrating blood glucose monitoring in type 2 diabetes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/8/4232?source=related_link\">",
"      Cases illustrating problems with intensive insulin therapy for diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38758?source=related_link\">",
"      Diagnosis of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=related_link\">",
"      General principles of insulin therapy in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=related_link\">",
"      Glycemic control and vascular complications in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=related_link\">",
"      Glycemic control and vascular complications in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=related_link\">",
"      Initial management of blood glucose in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=related_link\">",
"      Insulin therapy in adults with type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/13/4306?source=related_link\">",
"      Interactive diabetes case 8: Discordant values for A1C and home blood glucose values",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7865?source=related_link\">",
"      Management of hyperglycemia in diabetics with end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28986?source=related_link\">",
"      Management of persistent hyperglycemia in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/2/25641?source=related_link\">",
"      Nutritional considerations in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/18/14634?source=related_link\">",
"      Nutritional considerations in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=related_link\">",
"      Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/14/227?source=related_link\">",
"      Patient information: Hemoglobin A1C tests (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=related_link\">",
"      Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=related_link\">",
"      Patient information: Type 1 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=related_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_45_11994="Prevention of spontaneous preterm birth";
var content_f11_45_11994=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention of spontaneous preterm birth",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/45/11994/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/45/11994/contributors\">",
"     Errol R Norwitz, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/45/11994/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/45/11994/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/45/11994/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/45/11994/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/45/11994/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Twelve percent of births in the United States occur before 37 weeks and are considered preterm. Approximately 20 percent of preterm deliveries are iatrogenic; they are performed due to medical or obstetrical complications that are believed to put the health of the mother or fetus in jeopardy (eg, intrauterine growth restriction, preeclampsia, placenta previa, nonreassuring antenatal fetal testing). The remaining 80 percent of preterm deliveries are spontaneous, related to preterm labor or preterm premature rupture of the membranes.",
"   </p>",
"   <p>",
"    Potential interventions for reducing the incidence of spontaneous preterm birth can be classified as primary (aimed at all women), secondary (aimed at eliminating or reducing risk in women with a previous preterm birth), or tertiary (aimed at preterm infants) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/1\">",
"     1",
"    </a>",
"    ]. While the ability of obstetrical care providers to identify women at risk for preterm birth has improved over the past three decades, application of primary and secondary interventions has not reduced the incidence of preterm delivery, which has actually increased. In the vast majority of cases, it is beyond the capabilities of obstetric medicine to prevent preterm delivery. Neonatal outcome, however, has improved during this interval as a result of widespread use of antenatal glucocorticoids and advances in neonatal care (eg, exogenous surfactant treatment, new methods of mechanical ventilation).",
"   </p>",
"   <p>",
"    Strategies for the prevention of spontaneous preterm labor and delivery will be reviewed here. Other issues relating to preterm labor and birth are discussed separately (partial list):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32393?source=see_link\">",
"       \"Pathogenesis of spontaneous preterm birth\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35898?source=see_link\">",
"       \"Risk factors for preterm labor and delivery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/51/15159?source=see_link\">",
"       \"Fetal fibronectin for prediction of preterm labor and delivery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35674?source=see_link\">",
"       \"Inhibition of acute preterm labor\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IDENTIFICATION OF RISK FACTORS FOR PRETERM BIRTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;In theory, identification of risk factors for preterm delivery before conception or in early pregnancy provides an opportunity for intervention to prevent this complication (",
"    <a class=\"graphic graphic_table graphicRef56785 \" href=\"UTD.htm?9/27/9660\">",
"     table 1",
"    </a>",
"    ). However, many preterm births occur among women with no risk factors and there are few interventions that have been proven to prolong pregnancy in women at risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35898?source=see_link\">",
"     \"Risk factors for preterm labor and delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     POTENTIALLY EFFECTIVE INTERVENTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Supplemental progesterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progesterone supplementation to reduce spontaneous preterm birth has been studied in a variety of high risk populations. The best evidence is for a reduction in risk of preterm birth in women with a history of prior preterm birth or a short cervix on ultrasound examination. It may be effective after an episode of arrested preterm labor, but the evidence is less robust. There is no evidence that progesterone supplementation is beneficial in other settings (eg, multiple gestation, preterm premature rupture of membranes) or that it reduces the risk of perinatal death.",
"   </p>",
"   <p>",
"    The use of progesterone to reduce the risk of spontaneous preterm birth is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5657?source=see_link\">",
"     \"Progesterone supplementation to reduce the risk of spontaneous preterm birth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Inhibition of acute preterm labor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tocolytic therapy of an acute episode of idiopathic preterm labor often abolishes contractions temporarily, but does not remove the underlying stimulus that initiated the process of parturition or reverse parturitional changes in the uterus. The net effect is that tocolytics are unlikely to prolong pregnancy by weeks or months. However, delivery can often be delayed for at least 48 hours so that glucocorticoids given to the mother can achieve their maximum effect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35674?source=see_link\">",
"     \"Inhibition of acute preterm labor\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Diagnosis and treatment of asymptomatic bacteriuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant women with asymptomatic bacteriuria should be treated with antibiotics to reduce the risk of preterm birth. A meta-analysis of 14 randomized trials comparing antibiotic treatment with placebo or no treatment in pregnant women with asymptomatic bacteriuria demonstrated that antibiotic treatment was effective in clearing asymptomatic bacteriuria (OR 0.07, 95% CI 0.05-0.10), reducing the incidence of pyelonephritis (OR 0.24, 95% CI 0.19-0.32), and reducing preterm delivery and delivery of low-birth-weight infants (OR 0.60, 95% CI 0.45-0.80) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A first trimester urine culture should be performed on all pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/3,4\">",
"     3,4",
"    </a>",
"    ], and regular antenatal screening is recommended for women at high-risk of asymptomatic bacteriuria (eg, women with sickle cell trait, recurrent urinary tract infections, diabetes mellitus, underlying renal disease). Reliance on symptoms to prompt screening is inadequate because symptoms such as frequency and nocturia are often attributed to the state of pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/40/43657?source=see_link\">",
"     \"Urinary tract infections and asymptomatic bacteriuria in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Smoking cessation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cigarette smoking has a modest dose-dependent relationship with preterm birth [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. This effect can be explained, in part, by increased rates of smoking-related complications of pregnancy, such as placental abruption, placenta previa, premature rupture of membranes, and intrauterine growth restriction. However, the association remains after adjustment is made for these possible confounding factors, suggesting there may be a direct effect of cigarette smoking on spontaneous preterm labor and delivery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27482?source=see_link\">",
"     \"Smoking and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Smoking cessation should always be encouraged for its general health benefits. It is likely that smokers who decrease or stop cigarette smoking will reduce their risk of preterm birth, but this has not been proven.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Avoidance of cocaine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, cocaine has been detected in approximately 60 percent of women in preterm labor who have positive toxicology tests [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/9\">",
"     9",
"    </a>",
"    ]. Health care providers should attempt to identify maternal cocaine use, provide information on the maternal and fetal risks associated with using cocaine, and help patients to stop using this drug. It is likely that this will reduce their risk of preterm birth, but this has not been proven. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6346?source=see_link\">",
"     \"Overview of illicit drug use in pregnant women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Decrease the rate of multiple gestation from ART",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple births are six times more likely to be preterm than singleton births [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/10\">",
"     10",
"    </a>",
"    ]. The incidence of multiple gestation (especially higher-order multiple pregnancies) has increased in the past two decades, largely due to the increasing availability and success of assisted reproduction techniques (ART).",
"   </p>",
"   <p>",
"    Strategies to prevent multiple conceptions resulting from ART include a firm diagnosis of infertility before initiating ART, limiting the number of pre-embryos that are transferred in each ART cycle, and, as a last resort, the judicious use of multifetal pregnancy reduction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/27/43449?source=see_link\">",
"     \"Strategies to control the rate of high order multiple gestation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Cervical cerclage",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is evidence that cerclage can reduce the risk of recurrent preterm",
"    <span class=\"nowrap\">",
"     birth/pregnancy",
"    </span>",
"    loss in women with a prior preterm",
"    <span class=\"nowrap\">",
"     birth/pregnancy",
"    </span>",
"    loss. The selection of appropriate candidates for cerclage is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4457?source=see_link\">",
"     \"Cervical insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H450759\">",
"    <span class=\"h2\">",
"     Pessary",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial reported a significant decrease in preterm birth in women with a short cervix on ultrasound examination who were managed with a cervical pessary. These data are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21017?source=see_link&amp;anchor=H7012170#H7012170\">",
"     \"Transvaginal ultrasound assessment of the cervix and prediction of spontaneous preterm birth\", section on 'Singleton, no prior preterm birth'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4457?source=see_link&amp;anchor=H26#H26\">",
"     \"Cervical insufficiency\", section on 'Pessary'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Reduce occupational fatigue",
"    </span>",
"    &nbsp;&mdash;&nbsp;We feel that a woman with an uncomplicated pregnancy who is employed where there are no greater potential hazards than those encountered in routine daily life may continue to work without interruption until the onset of labor. Nevertheless, the physical demands of the woman's job should be considered, especially in women at high risk of preterm delivery.",
"   </p>",
"   <p>",
"    A meta-analysis of 21 studies including a total of 146,457 women identified a high cumulative work fatigue score as the strongest work-related risk factor for preterm birth (OR 1.63, 95% CI 1.33-1.98) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/11\">",
"     11",
"    </a>",
"    ]. The results of this analysis are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef51860 \" href=\"UTD.htm?29/10/29867\">",
"     table 2",
"    </a>",
"    ). Similar findings were reported in a subsequent large European case-control study that noted employed women were at higher risk of preterm birth if they worked longer than 42",
"    <span class=\"nowrap\">",
"     hours/week,",
"    </span>",
"    stood more than six",
"    <span class=\"nowrap\">",
"     hours/day,",
"    </span>",
"    or had low job satisfaction [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effects of reducing occupational fatigue have not been evaluated in randomized trials. Maternity legislation in many European countries has regulated work schedules and working conditions for pregnant women; however, none of the European countries except France have experienced a reduction in preterm birth rates [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/13\">",
"     13",
"    </a>",
"    ]. Nevertheless, paid maternity leave, guaranteed job protection, and regulation of hazardous working conditions remain desirable societal goals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Nutritional intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with adequate nutrition and a normal body-mass index have better pregnancy outcomes than other women, which suggests that nutritional interventions may have a role in preventing preterm birth. Randomized trials have provided evidence that some dietary interventions increase the length of gestation, but the evidence is not conclusive and these supplements cannot be recommended at this time.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       N-3 fatty acid supplements",
"      </strong>",
"      &mdash; Low consumption of n-3 fatty acids (eg, fish oil) has been associated with a higher rate of preterm birth [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/14\">",
"       14",
"      </a>",
"      ]. N-3 fatty acid supplements may induce uterine quiescence by favoring production of noninflammatory cytokines and weak eicosanoids over production of proinflammatory cytokines and eicosanoids causing uterine contractions [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/15\">",
"       15",
"      </a>",
"      ]. When this hypothesis was evaluated, however, dietary intervention did not significantly reduce the maternal or fetal blood concentration of a variety of biomarkers associated with inflammation [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/16\">",
"       16",
"      </a>",
"      ]. The following randomized trials exemplify this area of research:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A meta-analysis of six randomized trials involving 2783 women compared pregnancy outcome after supplementation with fish oil (and other prostaglandin precursors) versus",
"      <span class=\"nowrap\">",
"       placebo/no",
"      </span>",
"      treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/17\">",
"       17",
"      </a>",
"      ]. Women allocated to receive fish oil had a lower risk of giving birth before 34 weeks of gestation (RR 0.69, 95% CI 0.49-0.99; two trials, 860 women), but the proportion delivering before 37 completed weeks was similar for both groups. These results were largely due to one large multicenter trial (Fish Oil Trials In Pregnancy [FOTIP]) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/18,19\">",
"       18,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      After this meta-analysis, a randomized trial including 852 women with a history of preterm birth found the combination of omega-3 fatty acid and progesterone supplements was no more effective than progesterone supplementation alone (spontaneous preterm birth rate &lt;37 weeks in",
"      <span class=\"nowrap\">",
"       omega-3/progesterone",
"      </span>",
"      group 32.9 percent versus 35.6 percent in",
"      <span class=\"nowrap\">",
"       placebo/progesterone",
"      </span>",
"      group; RR 0.92, 95% CI 0.77-1.11) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/20\">",
"       20",
"      </a>",
"      ]. There were no significant differences in preterm birth &lt;32 or 35 weeks either.",
"     </li>",
"     <li>",
"      Supplementation with docosahexaenoic acid (n-3 long chain polyunsaturated fatty acid) increased gestation by a mean of six days in women who received it in fortified eggs from 24 to 28 weeks of gestation until parturition (133 mg in fortified eggs versus 33 mg in unfortified eggs) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Fish consumption",
"      </strong>",
"      &mdash; The effect of fish oil supplements on preterm birth has been studied in randomized trials and no benefit was found, as discussed above. The effect of fish consumption of length of gestation has only been evaluated in observational studies, which have reported discordant results [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/14,22-27\">",
"       14,22-27",
"      </a>",
"      ]. In these studies, the benefits of fish consumption may be confounded by socioeconomic class, avoidance of more harmful foods that fish replaces, beneficial effects of nutrients in fish other than n-3 fatty acids,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      other attributes that are discordant between fish consumers and nonconsumers. Two representative studies are illustrated below:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial reported a diet low in saturated fat and cholesterol and enriched with polyunsaturated fatty acids (fish, low-fat meats and dairy products, oils, whole grains, fruits, vegetables, legumes) markedly reduced the rate of preterm birth in low-risk pregnancies compared with controls consuming their usual diet (preterm birth",
"      <span class=\"nowrap\">",
"       1/141",
"      </span>",
"      versus",
"      <span class=\"nowrap\">",
"       11/149;",
"      </span>",
"      mean gestational age at delivery 281 versus 277 days) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, a prospective observational cohort study including 2109 pregnant women examined the association between seafood intake and length of gestation and preterm delivery and reported seafood intake was not associated with length of gestation or risk of preterm birth after adjustment for maternal and child factors [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Avoiding under-nutrition",
"      </strong>",
"      &mdash; There is some evidence supporting the hypothesis that maternal under-nutrition in pregnancy results in preterm birth [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/28\">",
"       28",
"      </a>",
"      ]. In sheep, moderate maternal undernutrition around the time of conception results in accelerated maturation of the fetal hypothalamic-pituitary-adrenal axis, a precocious fetal cortisol surge, and preterm birth [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. In Gambian women, pregnancies conceived during the rainy season when food is scarce were significantly shorter than those conceived when food was more plentiful [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/31\">",
"       31",
"      </a>",
"      ]. Observations of shorter gestational length with early pregnancy exposure to the Dutch famine also support this hypothesis [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/32\">",
"       32",
"      </a>",
"      ]. Thus, focusing on dietary events around the time of conception may be important in prevention of some cases of preterm birth.",
"      <br/>",
"      <br/>",
"      Systematic reviews have found that isocaloric protein supplements [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/33\">",
"       33",
"      </a>",
"      ],balanced",
"      <span class=\"nowrap\">",
"       protein/energy",
"      </span>",
"      supplements [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/34\">",
"       34",
"      </a>",
"      ], and high protein supplements [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/34\">",
"       34",
"      </a>",
"      ] do not reduce the rate of preterm delivery. Most studies show that vitamin supplements during pregnancy do not reduce the risk of preterm birth [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/35-41\">",
"       35-41",
"      </a>",
"      ], although they have other benefits. There may be potential benefits of micronutrient supplementation in specific subpopulations of pregnant women, such as those who are undernourished or HIV infected [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/42\">",
"       42",
"      </a>",
"      ]; this topic is discussed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/44/28362?source=see_link&amp;anchor=H9#H9\">",
"       \"Nutrition in pregnancy\", section on 'Dietary components'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Avoiding a short interpregnancy interval",
"    </span>",
"    &nbsp;&mdash;&nbsp;The highest risk of preterm birth appears to be in women with an interpregnancy interval of less than six months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/63/13302?source=see_link\">",
"     \"Interpregnancy interval and pregnancy outcome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30579651\">",
"    <span class=\"h2\">",
"     Avoidance or treatment of malaria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malaria in pregnant women can result in several adverse maternal and fetal outcomes, including preterm birth. Treatment to prevent infection can reduce the frequency of preterm birth [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/33/16921?source=see_link\">",
"     \"Overview of malaria in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20695?source=see_link\">",
"     \"Treatment and prevention of malaria in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     UNPROVEN INTERVENTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Diagnosis and treatment of genital tract infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lower genital tract infection has been associated with preterm delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/46-52\">",
"     46-52",
"    </a>",
"    ]. Such infection may serve as a marker of upper genital tract infection or may lead to direct migration of organisms to the decidua, fetal membranes, and amniotic fluid. Nevertheless, most studies have not shown a reduction in preterm birth after treatment of asymptomatic vaginal or cervical infection.",
"   </p>",
"   <p>",
"    Evidence against the effectiveness of screening for and treating asymptomatic lower genital tract infection is summarized below by organism:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Chlamydia, gonorrhea, syphilis",
"      </strong>",
"      &mdash; There is no evidence that treatment of chlamydia, gonorrhea, or syphilis prolongs gestation. The only controlled trial that evaluated the effect of treatment of chlamydia on gestational duration did not show a reduction in preterm birth [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/53\">",
"       53",
"      </a>",
"      ]. However, screening for and treatment of these infections is recommended to prevent other maternal and neonatal sequelae. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42728?source=see_link\">",
"       \"Genital Chlamydia trachomatis infections in women\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/35/26166?source=see_link\">",
"       \"Diagnosis of gonococcal infections\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/3/19514?source=see_link\">",
"       \"Treatment of uncomplicated gonococcal infections\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4057?source=see_link\">",
"       \"Syphilis in pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Bacterial vaginosis, Ureaplasma, group B streptococcus (GBS)",
"      </strong>",
"      &mdash; Prospective controlled trials and meta-analyses have reported either a modest or no effect of antibiotic treatment on prolonging gestation in asymptomatic women who screened positive for bacterial vaginosis [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/54-58\">",
"       54-58",
"      </a>",
"      ], Ureaplasma urealyticum [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/59,60\">",
"       59,60",
"      </a>",
"      ], or GBS [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/61\">",
"       61",
"      </a>",
"      ], although these studies are undoubtedly confounded by recolonization or reinfection after therapy and intercurrent use of nonprotocol antibiotics. GBS screening in late pregnancy and chemoprophylaxis for prevention of early onset neonatal GBS infection is recommended. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19354?source=see_link\">",
"       \"Chemoprophylaxis for the prevention of neonatal group B streptococcal disease\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Women with bacterial vaginosis and a previous preterm birth may benefit from bacterial vaginosis screening and treatment, but there are insufficient data to recommend this as a routine practice. This subject is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30602?source=see_link&amp;anchor=H18#H18\">",
"       \"Bacterial vaginosis\", section on 'Pregnant women'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Trichomonas",
"      </strong>",
"      &mdash; Treatment of asymptomatic Trichomonas infection is not recommended during pregnancy because it does not prevent, and may even increase, the risk of preterm delivery [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/62\">",
"       62",
"      </a>",
"      ]. In one large trial, 617 women with culture proven asymptomatic infection at 16 to 23 weeks of gestation were randomly assigned to receive either two doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      (2 g) or placebo 48 hours apart [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/62\">",
"       62",
"      </a>",
"      ]. All women were retreated with the same regimen at 24 to 29 weeks of gestation. Trichomonas resolved in 93 percent of metronidazole treated women and 35 percent of the placebo group. The rate of preterm birth was higher in treated than control women (19 versus 11 percent, relative risk 1.8; 95% CI 1.2-2.7), primarily related to an increased frequency of spontaneous preterm labor (10.2 versus 3.5 percent, relative risk 3.0; 95% CI 1.5- 5.9). This outcome was unexpected. The authors commented that the regimen of metronidazole administered was not a standard one and speculated that other bacteria may have increased in density during metronidazole treatment. Since extensive culturing was not performed, the presence of other infections was not determined. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36633?source=see_link&amp;anchor=H9#H9\">",
"       \"Approach to women with symptoms of vaginitis\", section on 'Vaginal culture'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Positive gram stain of vaginal smear",
"      </strong>",
"      &mdash; One exception to these negative studies was a multicenter trial in which all pregnant women presenting for a routine prenatal visit at 15 to 19 weeks of gestation were screened for bacterial vaginosis, vaginal candidiasis, and T. vaginalis by Gram stain of a vaginal smear [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/63\">",
"       63",
"      </a>",
"      ]. The women were then randomly assigned to an intervention group (Gram stain results provided to care-giver and positive results treated with appropriate antibiotics) or a control group (Gram stain results not released to care-giver, usual care). Women in the intervention group had a significantly lower rate of spontaneous preterm birth than controls (3 versus 5 percent). This is surprising since over 70 percent of preterm births occurred in women with normal Gram stains. Given the low overall rate of preterm birth in this study, it is not clear whether such findings can be extrapolated to other populations.",
"      <br/>",
"      <br/>",
"      The results of this trial need to be confirmed before any practice changes can be recommended. Of particular concern, other trials that randomly assigned women at high risk of preterm birth to antibiotic therapy or no antibiotic therapy found that antibiotic therapy had no, or a deleterious, effect (see",
"      <a class=\"local\" href=\"#H26\">",
"       'Antibiotics'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Treatment of periodontal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of treatment of periodontal disease on preterm birth is unclear, given discordant results among randomized controlled trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10578899\">",
"    <span class=\"h3\">",
"     Scaling and root planing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a meta-analysis of seven randomized trials on the effect of periodontal disease treatment on preterm birth, scaling",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    root planing was beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/64\">",
"     64",
"    </a>",
"    ]. Using a random effects model, this type of treatment of periodontal disease during pregnancy resulted in a significant reduction of preterm birth (OR 0.55, 95% CI 0.35-0.86) and a strong trend in reduction of low birthweight infants (OR 0.48, 95% CI 0.23-1.00). However, we are not convinced that this analysis proves that treatment of periodontal disease reduces the risk of preterm birth, given that the unadjusted data showed no effect, there was no effort to address the important issue of publication bias, and there was moderate heterogeneity among the trials. The available trials used varying criteria to diagnose periodontal disease and to define adverse outcomes. Moreover, they generally did not adequately adjust for confounders or have adequate sample size to detect significant differences in pregnancy outcomes.",
"   </p>",
"   <p>",
"    After publication of this meta-analysis, results of the Maternal Oral Therapy to Reduce Obstetric Risk Study were published and showed that periodontal therapy did",
"    <strong>",
"     not",
"    </strong>",
"    reduce the incidence of preterm delivery before 37, 35, or 32 weeks of gestation, weight for gestational age, or neonatal morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/65\">",
"     65",
"    </a>",
"    ]. This is the largest randomized controlled trial of the effects of maternal periodontal disease treatment on preterm birth rates; over 1800 pregnant women with periodontal disease were randomly assigned to receive treatment before 24 weeks of gestation or postpartum. Treatment consisted of up to four sessions of supra- and sub-gingival scaling and root planing using hand and ultrasonic instruments, full mouth tooth polishing, and oral hygiene instruction.",
"   </p>",
"   <p>",
"    Two subsequent large randomized trials of pregnant women with periodontal disease had a similar design and also found that treatment did",
"    <strong>",
"     not",
"    </strong>",
"    result in a significant improvement in any pregnancy outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. One of these, the Periodontal Infections and Prematurity Study (PIPS) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/67\">",
"     67",
"    </a>",
"    ], found that treatment might increase the risk of indicated preterm birth; this requires further study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10578911\">",
"    <span class=\"h3\">",
"     Antimicrobial mouth wash",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single-blind trial randomly assigned pregnant women at 6 to 20 weeks of gestation with periodontal disease who refused dental care to use an alcohol-free antimicrobial mouth rinse (n = 81) or to rinse with water (n = 165) twice daily, in addition to tooth brushing [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/68\">",
"     68",
"    </a>",
"    ]. The incidence of preterm birth &lt;35 weeks was significantly lower in the group using the antimicrobial rinse (5.6 versus 21.9 percent; RR 0.26 95% CI 0.096&ndash;0.70). The antimicrobial rinse group had no change or modest improvement in periodontal health during pregnancy, while the untreated group had worsening of the disease. These results are the only evidence of a role for topical oral antimicrobial therapy in reducing preterm birth in women with periodontal disease during pregnancy, and need to be confirmed. Given the presence of persistent periodontal disease despite treatment and the lack of benefit reported in trials of scaling and root planing or antibiotic prophylaxis (see",
"    <a class=\"local\" href=\"#H26\">",
"     'Antibiotics'",
"    </a>",
"    below), a true dramatic reduction in preterm birth from antimicrobial rinsing seems unlikely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10578936\">",
"    <span class=\"h3\">",
"     Discussion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periodontal disease could cause preterm birth if pathogens or inflammatory cytokines from the mother's mouth enter her blood and are transported across the placenta to the fetal compartment. It is also possible that periodontal infection is not a direct cause of preterm birth, but rather a marker of individuals who exhibit an excessive local or systemic inflammatory response to bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/69-72\">",
"     69-72",
"    </a>",
"    ]. Such individuals may also hyperrespond to vaginal bacteria with enhanced production of cytokines that lead to preterm labor or rupture of membranes. Even if there is a causal association, the benefit of treatment of periodontal disease during pregnancy to prevent sequelae in the index pregnancy has not been proven. Although controlled trials have reported that treatment in pregnancy significantly improved periodontal health in the treatment group, periodontal disease was not cured and many patients demonstrated progression of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At this time, there are inadequate data on which to make conclusions about pregnancy complications resulting from periodontal disease or the obstetrical benefits of its treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/73-75\">",
"     73-75",
"    </a>",
"    ]. More prospective trials are needed in both low and high risk populations. Nevertheless, good oral health is desirable so periodontal disease should be treated as a component of good dental hygiene [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/53/20313?source=see_link\">",
"     \"Complications, diagnosis, and treatment of odontogenic infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Assessment of uterine activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although an increase in uterine activity is a prerequisite for labor, randomized trials and a meta-analysis have shown that self-measurement of the frequency of uterine contractions by",
"    <span class=\"nowrap\">",
"     self-palpation/detection",
"    </span>",
"    of signs of labor or through use of a home uterine monitor does not lead to a reduction in the rate of preterm delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. Moreover, such an approach increases the frequency of unscheduled antenatal visits [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/78\">",
"     78",
"    </a>",
"    ]. The American College of Obstetricians and Gynecologists (ACOG) does not recommend use of home uterine activity monitoring as a screening strategy for prediction or prevention of preterm birth [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Bed rest and hospitalization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bed rest is often recommended for women at increased risk for preterm birth [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/80\">",
"     80",
"    </a>",
"    ]. While bed rest improves uteroplacental blood flow and can lead to a slight increase in birth weight, there is no evidence that it decreases the incidence of preterm delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/81-83\">",
"     81-83",
"    </a>",
"    ]. Although underpowered, the only randomized trial attempting to determine whether hospitalization of women with arrested preterm labor improved outcome found hospitalized women had similar outcomes to those discharged home [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/84\">",
"     84",
"    </a>",
"    ]. Moreover, exercise does not appear to increase the risk of preterm birth in healthy women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/30/7657?source=see_link\">",
"     \"Recommendations for exercise during pregnancy and the postpartum period\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bedrest appears to increase the risk of thromboembolic events, and has clear negative psychosocial effects [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/85,86\">",
"     85,86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Abstinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coitus is not a risk factor for preterm birth; therefore, abstinence after pregnancy has been achieved has no role in strategies for prevention of preterm birth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35898?source=see_link\">",
"     \"Risk factors for preterm labor and delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Prophylactic tocolytic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic tocolytic therapy for prevention of preterm birth is not effective, although few randomized trials have been conducted [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24135?source=see_link\">",
"     \"Management of pregnant women after inhibition of acute preterm labor\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    By comparison, pharmacological therapy is the cornerstone of management for acute preterm labor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35674?source=see_link\">",
"     \"Inhibition of acute preterm labor\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Randomized trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials have shown that broad spectrum antibiotic therapy administered to asymptomatic women (pregnant or nonpregnant) without known infection does not prevent preterm labor or birth, and may increase the risk [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/89-92\">",
"     89-92",
"    </a>",
"    ]. Three representative trials are illustrated below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment during pregnancy (fFN positive subjects) &mdash; In one trial, 715 women at high risk for preterm birth because of positive fFN test results (but no contractions) were randomly assigned to receive either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      (250 mg orally three times per day) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      (250 mg orally four times per day) or placebo pills for 10 days [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/89\">",
"       89",
"      </a>",
"      ]. There was no difference between groups in the rate of preterm birth before 37 weeks, less than 35 weeks, or less than 32 weeks of gestation. Moreover, women with a prior spontaneous preterm delivery who took antibiotics had a higher rate of repeat spontaneous preterm delivery at less than 37 weeks than those taking placebo (47 versus 24 percent).",
"     </li>",
"     <li>",
"      Treatment between pregnancies &mdash; In another trial, 241 postpartum women who had a spontaneous preterm birth between 16 and 34 weeks of gestation were randomly assigned to receive a course of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      (two doses of 1 g four days",
"      <span class=\"nowrap\">",
"       apart)/",
"       <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"        metronidazole",
"       </a>",
"      </span>",
"      (750 mg daily for one week) or placebo every four months until they became pregnant again [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/90,93\">",
"       90,93",
"      </a>",
"      ]. Antibiotic treatment did not reduce the risk of preterm birth in the subsequent pregnancy, and may have increased the risk. However, the antibiotic regimen did prevent the acquisition and promoted the resolution, but not the eradication, of bacterial colonization [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/94\">",
"       94",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      HIV infected women &mdash; A third trial randomly assigned 2661 mostly HIV positive women to receive a course of antibiotics or placebo at 20 to 24 weeks of gestation and then again during labor [",
"      <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/91\">",
"       91",
"      </a>",
"      ]. The antibiotic regimen was",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      250 mg plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      250 mg three times daily for seven days antepartum and metronidazole 250 mg plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      500 mg every four hours beginning at the onset of labor and continuing until delivery. Antibiotic therapy did not significantly reduce the incidence of preterm birth, low birth weight, or histologic chorioamnionitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Meta-analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of 17 randomized trials including diverse groups of high risk women confirmed these findings [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/95\">",
"     95",
"    </a>",
"    ]. This analysis involved 12 trials that identified women at risk by abnormal vaginal flora, three that selected women at risk based on a previous preterm birth, and two that recruited women with a positive fetal fibronectin test result. There was no significant association between antibiotic treatment and reduction in preterm birth regardless of the criteria used to assess risk, the antimicrobial drug administered, or gestational age at time of treatment (overall combined random effect for delivery at less than 37 weeks RR 1.03, 95% CI 0.86&ndash;1.24).",
"   </p>",
"   <p>",
"    Antibiotic therapy is also not effective as an adjunct to tocolysis for prolongation of pregnancy in the setting of intact membranes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35674?source=see_link&amp;anchor=H54#H54\">",
"     \"Inhibition of acute preterm labor\", section on 'Antibiotic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This population is different from that with threatened preterm birth in the setting of preterm premature rupture of membranes, where broad-spectrum antibiotics significantly prolong latency and improve perinatal outcome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15866?source=see_link\">",
"     \"Preterm premature rupture of membranes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Enhanced prenatal care",
"    </span>",
"    &nbsp;&mdash;&nbsp;The absence of prenatal care has been consistently identified as a risk factor for preterm labor and delivery, but it is less clear whether this association is causal or a marker of other factors that contribute to preterm birth. Retrospective studies cannot be adequately controlled to adjust for these confounding factors, while prospective randomized trials (no prenatal care versus standard care) would be unethical. Therefore, the only well-designed studies on the effect of prenatal care on preterm birth compare standard to enhanced care (ie, some combination of patient education, case management, home visits, nutrition counseling, and extra prenatal visits and cervical examinations).",
"   </p>",
"   <p>",
"    To investigate whether enhanced prenatal care can decrease the incidence of preterm birth, the March of Dimes Multicenter Prematurity Prevention Trial conducted a randomized, controlled trial of 2395 women with singleton or multiple gestations at high-risk of preterm birth [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/77\">",
"     77",
"    </a>",
"    ]. The women were randomly assigned to either standard of care or an enhanced care intervention (more frequent prenatal visits, improved patient education regarding symptoms and signs of preterm labor, and weekly pelvic examinations after 20 to 24 weeks of gestation). There was no significant difference between the two groups in spontaneous preterm delivery rates. A meta-analysis that included three trials of women with singleton pregnancies also found no clear evidence that specialized antenatal clinics reduced preterm births [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Regular prenatal care should be encouraged and improves perinatal outcome in women with underlying medical disorders (eg, diabetes, chronic hypertension, thyroid disease) or pregnancy-related conditions (eg, preeclampsia); however, the March of Dimes trial suggests enhanced care is unlikely to decrease the incidence of preterm birth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Social support and relaxation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intervention trials that provided enhanced social support (defined as emotional support and tangible assistance) have not clearly shown a benefit in terms of gestational length [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/97-99\">",
"     97-99",
"    </a>",
"    ]. In particular, the two largest randomized trials concluded a program of social support did not reduce the overall rate of preterm delivery or low birth weight [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/98,99\">",
"     98,99",
"    </a>",
"    ]. One of the trials included over 6000 teenagers [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/98\">",
"     98",
"    </a>",
"    ] and the other included over 2000 high risk Latin American women [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are limited data on other interventions for reducing stress in pregnant women (eg, relaxation or mind-body therapies [eg, meditation, massage, yoga, breathing exercises, music therapy, aromatherapy]). Available trials are small and of poor quality; clear effects on birth outcome have not been proven [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6593355\">",
"    <span class=\"h2\">",
"     Thyroid hormone",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a single randomized trial of 115 pregnant euthyroid women with thyroid peroxidase antibodies,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"     levothyroxine",
"    </a>",
"    therapy significantly reduced the rate of preterm birth (RR 0.28; 95% CI 0.10-0.80) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/45/11994/abstract/101\">",
"     101",
"    </a>",
"    ]. Before thyroid antibody assessment or treatment can be considered in euthyroid women with history of preterm birth, further study is needed to confirm these findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/52/35650?source=see_link\">",
"       \"Patient information: Preterm labor (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Risk factors for preterm birth may be classified as nonmodifiable or modifiable factors (",
"      <a class=\"graphic graphic_table graphicRef56785 \" href=\"UTD.htm?9/27/9660\">",
"       table 1",
"      </a>",
"      ). Identification of risk factors for preterm delivery before conception or early in pregnancy may provide an opportunity for intervention to prevent this complication; however, most preterm births occur among women with no risk factors and the number of effective interventions is limited. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Identification of risk factors for preterm birth'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the vast majority of cases, it is beyond the capabilities of obstetric medicine to prevent preterm birth. As such, every effort should be made to optimize perinatal outcome in the event of a premature delivery, including administering antenatal corticosteroids and transferring the patient to a tertiary care center. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For asymptomatic women who have had a previous preterm birth, we recommend progesterone supplementation to decrease the risk of recurrent preterm birth (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5657?source=see_link\">",
"       \"Progesterone supplementation to reduce the risk of spontaneous preterm birth\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      We also recommend progesterone supplementation for women with a shortened cervix (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5657?source=see_link\">",
"       \"Progesterone supplementation to reduce the risk of spontaneous preterm birth\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Progesterone is not useful for preventing preterm birth in multiple gestations or premature rupture of membranes.",
"     </li>",
"     <li>",
"      Given antibiotic treatment of asymptomatic bacteriuria reduces the incidence of preterm delivery and low-birth-weight infants, we recommend screening pregnant women for asymptomatic bacteriuria (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis and treatment of asymptomatic bacteriuria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Smoking cessation and avoidance of illicit drugs should be encouraged for their general health benefits. It is likely that decreasing or stopping cigarette smoking and cocaine use in pregnancy will reduce the risk of preterm birth in users. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Smoking cessation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Avoidance of cocaine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Utilizing strategies to prevent multiple gestations resulting from assisted reproduction should decrease the number of preterm births related to multiple gestation. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Decrease the rate of multiple gestation from ART'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of asymptomatic Trichomonas vaginalis infection does not prevent, and may even increase, the risk of preterm delivery. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis and treatment of asymptomatic bacteriuria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with periodontal disease are at increased risk of preterm delivery. Periodontal disease should be treated as a component of good dental hygiene, but there are inadequate data to suggest treatment for prevention of preterm birth. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Treatment of periodontal disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Home uterine monitoring and self-palpation of uterine contractions, bed rest, abstinence, prophylactic tocolytics, prophylactic antibiotic therapy, enhanced prenatal care, and social support have not been proven useful for preventing preterm birth. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Unproven interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An interpregnancy interval greater than six months may reduce the risk of preterm birth. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Avoiding a short interpregnancy interval'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cervical cerclage, reduction in occupational",
"      <span class=\"nowrap\">",
"       stress/physical",
"      </span>",
"      exertion, and nutritional intervention may be beneficial in selected women. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Cervical cerclage'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Reduce occupational fatigue'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Nutritional intervention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with short cervical length appear to benefit from treatment with vaginal progesterone, a cerclage, or a pessary. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Supplemental progesterone'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Cervical cerclage'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H450759\">",
"       'Pessary'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/1\">",
"      Iams JD, Romero R, Culhane JF, Goldenberg RL. Primary, secondary, and tertiary interventions to reduce the morbidity and mortality of preterm birth. Lancet 2008; 371:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/2\">",
"      Smaill F. Antibiotics for asymptomatic bacteriuria in pregnancy. Cochrane Database Syst Rev 2001; :CD000490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/3\">",
"      Connolly A, Thorp JM Jr. Urinary tract infections in pregnancy. Urol Clin North Am 1999; 26:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/4\">",
"      Uncu Y, Uncu G, Esmer A, Bilgel N. Should asymptomatic bacteriuria be screened in pregnancy? Clin Exp Obstet Gynecol 2002; 29:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/5\">",
"      Shiono PH, Klebanoff MA, Rhoads GG. Smoking and drinking during pregnancy. Their effects on preterm birth. JAMA 1986; 255:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/6\">",
"      Cnattingius S, Forman MR, Berendes HW, et al. Effect of age, parity, and smoking on pregnancy outcome: a population-based study. Am J Obstet Gynecol 1993; 168:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/7\">",
"      Harlow BL, Frigoletto FD, Cramer DW, et al. Determinants of preterm delivery in low-risk pregnancies. The RADIUS Study Group. J Clin Epidemiol 1996; 49:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/8\">",
"      Kyrklund-Blomberg NB, Cnattingius S. Preterm birth and maternal smoking: risks related to gestational age and onset of delivery. Am J Obstet Gynecol 1998; 179:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/9\">",
"      Ney JA, Dooley SL, Keith LG, et al. The prevalence of substance abuse in patients with suspected preterm labor. Am J Obstet Gynecol 1990; 162:1562.",
"     </a>",
"    </li>",
"    <li>",
"     www.marchofdimes.com/peristats (Accessed on October 04, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/11\">",
"      Mozurkewich EL, Luke B, Avni M, Wolf FM. Working conditions and adverse pregnancy outcome: a meta-analysis. Obstet Gynecol 2000; 95:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/12\">",
"      Saurel-Cubizolles MJ, Zeitlin J, Lelong N, et al. Employment, working conditions, and preterm birth: results from the Europop case-control survey. J Epidemiol Community Health 2004; 58:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/13\">",
"      Berkowitz GS, Papiernik E. Working conditions, maternity legislation, and preterm birth. Semin Perinatol 1995; 19:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/14\">",
"      Olsen SF, Secher NJ. Low consumption of seafood in early pregnancy as a risk factor for preterm delivery: prospective cohort study. BMJ 2002; 324:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/15\">",
"      Spong CY. Prediction and prevention of recurrent spontaneous preterm birth. Obstet Gynecol 2007; 110:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/16\">",
"      Khoury J, Henriksen T, Seljeflot I, et al. Effects of an antiatherogenic diet during pregnancy on markers of maternal and fetal endothelial activation and inflammation: the CARRDIP study. BJOG 2007; 114:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/17\">",
"      Makrides M, Duley L, Olsen SF. Marine oil, and other prostaglandin precursor, supplementation for pregnancy uncomplicated by pre-eclampsia or intrauterine growth restriction. Cochrane Database Syst Rev 2006; :CD003402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/18\">",
"      Olsen SF, Secher NJ, Tabor A, et al. Randomised clinical trials of fish oil supplementation in high risk pregnancies. Fish Oil Trials In Pregnancy (FOTIP) Team. BJOG 2000; 107:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/19\">",
"      Olsen SF, S&oslash;rensen JD, Secher NJ, et al. Randomised controlled trial of effect of fish-oil supplementation on pregnancy duration. Lancet 1992; 339:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/20\">",
"      Harper M, Thom E, Klebanoff MA, et al. Omega-3 fatty acid supplementation to prevent recurrent preterm birth: a randomized controlled trial. Obstet Gynecol 2010; 115:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/21\">",
"      Smuts CM, Huang M, Mundy D, et al. A randomized trial of docosahexaenoic acid supplementation during the third trimester of pregnancy. Obstet Gynecol 2003; 101:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/22\">",
"      Khoury J, Henriksen T, Christophersen B, Tonstad S. Effect of a cholesterol-lowering diet on maternal, cord, and neonatal lipids, and pregnancy outcome: a randomized clinical trial. Am J Obstet Gynecol 2005; 193:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/23\">",
"      Olsen SF, &Oslash;sterdal ML, Salvig JD, et al. Duration of pregnancy in relation to seafood intake during early and mid pregnancy: prospective cohort. Eur J Epidemiol 2006; 21:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/24\">",
"      Guldner L, Monfort C, Rouget F, et al. Maternal fish and shellfish intake and pregnancy outcomes: a prospective cohort study in Brittany, France. Environ Health 2007; 6:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/25\">",
"      Oken E, Kleinman KP, Olsen SF, et al. Associations of seafood and elongated n-3 fatty acid intake with fetal growth and length of gestation: results from a US pregnancy cohort. Am J Epidemiol 2004; 160:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/26\">",
"      Rogers I, Emmett P, Ness A, Golding J. Maternal fish intake in late pregnancy and the frequency of low birth weight and intrauterine growth retardation in a cohort of British infants. J Epidemiol Community Health 2004; 58:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/27\">",
"      Klebanoff MA, Harper M, Lai Y, et al. Fish consumption, erythrocyte fatty acids, and preterm birth. Obstet Gynecol 2011; 117:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/28\">",
"      Villar J, G&uuml;lmezoglu AM, de Onis M. Nutritional and antimicrobial interventions to prevent preterm birth: an overview of randomized controlled trials. Obstet Gynecol Surv 1998; 53:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/29\">",
"      Bloomfield FH, Oliver MH, Hawkins P, et al. A periconceptional nutritional origin for noninfectious preterm birth. Science 2003; 300:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/30\">",
"      Kumarasamy V, Mitchell MD, Bloomfield FH, et al. Effects of periconceptional undernutrition on the initiation of parturition in sheep. Am J Physiol Regul Integr Comp Physiol 2005; 288:R67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/31\">",
"      Rayco-Solon P, Fulford AJ, Prentice AM. Maternal preconceptional weight and gestational length. Am J Obstet Gynecol 2005; 192:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/32\">",
"      Stein Z, Susser M. The Dutch famine, 1944-1945, and the reproductive process. I. Effects on six indices at birth. Pediatr Res 1975; 9:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/33\">",
"      Kramer MS. Isocaloric balanced protein supplementation in pregnancy. Cochrane Database Syst Rev 2000; :CD000118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/34\">",
"      Ota E, Tobe-Gai R, Mori R, Farrar D. Antenatal dietary advice and supplementation to increase energy and protein intake. Cochrane Database Syst Rev 2012; 9:CD000032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/35\">",
"      Vahratian A, Siega-Riz AM, Savitz DA, Thorp JM Jr. Multivitamin use and the risk of preterm birth. Am J Epidemiol 2004; 160:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/36\">",
"      Rumbold A, Crowther CA. Vitamin C supplementation in pregnancy. Cochrane Database Syst Rev 2005; :CD004072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/37\">",
"      Rumbold A, Crowther CA. Vitamin E supplementation in pregnancy. Cochrane Database Syst Rev 2005; :CD004069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/38\">",
"      Fawzi WW, Msamanga GI, Urassa W, et al. Vitamins and perinatal outcomes among HIV-negative women in Tanzania. N Engl J Med 2007; 356:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/39\">",
"      Spinnato JA 2nd, Freire S, Pinto e Silva JL, et al. Antioxidant supplementation and premature rupture of the membranes: a planned secondary analysis. Am J Obstet Gynecol 2008; 199:433.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/40\">",
"      Hauth JC, Clifton RG, Roberts JM, et al. Vitamin C and E supplementation to prevent spontaneous preterm birth: a randomized controlled trial. Obstet Gynecol 2010; 116:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/41\">",
"      Thorp JM, Camargo CA, McGee PL, et al. Vitamin D status and recurrent preterm birth: a nested case-control study in high-risk women. BJOG 2012; 119:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/42\">",
"      Catov JM, Bodnar LM, Ness RB, et al. Association of periconceptional multivitamin use and risk of preterm or small-for-gestational-age births. Am J Epidemiol 2007; 166:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/43\">",
"      Luntamo M, Kulmala T, Mbewe B, et al. Effect of repeated treatment of pregnant women with sulfadoxine-pyrimethamine and azithromycin on preterm delivery in Malawi: a randomized controlled trial. Am J Trop Med Hyg 2010; 83:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/44\">",
"      Wolfe EB, Parise ME, Haddix AC, et al. Cost-effectiveness of sulfadoxine-pyrimethamine for the prevention of malaria-associated low birth weight. Am J Trop Med Hyg 2001; 64:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/45\">",
"      Garner P, G&uuml;lmezoglu AM. Drugs for preventing malaria-related illness in pregnant women and death in the newborn. Cochrane Database Syst Rev 2003; :CD000169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/46\">",
"      Hillier SL, Nugent RP, Eschenbach DA, et al. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. The Vaginal Infections and Prematurity Study Group. N Engl J Med 1995; 333:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/47\">",
"      Edwards LE, Barrada MI, Hamann AA, Hakanson EY. Gonorrhea in pregnancy. Am J Obstet Gynecol 1978; 132:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/48\">",
"      Martin DH, Koutsky L, Eschenbach DA, et al. Prematurity and perinatal mortality in pregnancies complicated by maternal Chlamydia trachomatis infections. JAMA 1982; 247:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/49\">",
"      Andrews WW, Goldenberg RL, Mercer B, et al. The Preterm Prediction Study: association of second-trimester genitourinary chlamydia infection with subsequent spontaneous preterm birth. Am J Obstet Gynecol 2000; 183:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/50\">",
"      Regan JA, Chao S, James LS. Premature rupture of membranes, preterm delivery, and group B streptococcal colonization of mothers. Am J Obstet Gynecol 1981; 141:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/51\">",
"      Goldenberg RL, Andrews WW, Goepfert AR, et al. The Alabama Preterm Birth Study: umbilical cord blood Ureaplasma urealyticum and Mycoplasma hominis cultures in very preterm newborn infants. Am J Obstet Gynecol 2008; 198:43.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/52\">",
"      Cotch MF, Pastorek JG 2nd, Nugent RP, et al. Trichomonas vaginalis associated with low birth weight and preterm delivery. The Vaginal Infections and Prematurity Study Group. Sex Transm Dis 1997; 24:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/53\">",
"      Martin DH, Eschenbach DA, Cotch MF, et al. Double-Blind Placebo-Controlled Treatment Trial of Chlamydia trachomatis Endocervical Infections in Pregnant Women. Infect Dis Obstet Gynecol 1997; 5:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/54\">",
"      Leitich H, Brunbauer M, Bodner-Adler B, et al. Antibiotic treatment of bacterial vaginosis in pregnancy: a meta-analysis. Am J Obstet Gynecol 2003; 188:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/55\">",
"      Guise JM, Mahon SM, Aickin M, et al. Screening for bacterial vaginosis in pregnancy. Am J Prev Med 2001; 20:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/56\">",
"      Carey JC, Klebanoff MA, Hauth JC, et al. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 2000; 342:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/57\">",
"      Brocklehurst P, Hannah M, McDonald H. Interventions for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev 2000; :CD000262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/58\">",
"      Kurkinen-R&auml;ty M, Vuopala S, Koskela M, et al. A randomised controlled trial of vaginal clindamycin for early pregnancy bacterial vaginosis. BJOG 2000; 107:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/59\">",
"      Eschenbach DA, Nugent RP, Rao AV, et al. A randomized placebo-controlled trial of erythromycin for the treatment of Ureaplasma urealyticum to prevent premature delivery. The Vaginal Infections and Prematurity Study Group. Am J Obstet Gynecol 1991; 164:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/60\">",
"      Raynes-Greenow CH, Roberts CL, Bell JC, et al. Antibiotics for ureaplasma in the vagina in pregnancy. Cochrane Database Syst Rev 2004; :CD003767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/61\">",
"      Klebanoff MA, Regan JA, Rao AV, et al. Outcome of the Vaginal Infections and Prematurity Study: results of a clinical trial of erythromycin among pregnant women colonized with group B streptococci. Am J Obstet Gynecol 1995; 172:1540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/62\">",
"      Klebanoff MA, Carey JC, Hauth JC, et al. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. N Engl J Med 2001; 345:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/63\">",
"      Kiss H, Petricevic L, Husslein P. Prospective randomised controlled trial of an infection screening programme to reduce the rate of preterm delivery. BMJ 2004; 329:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/64\">",
"      Polyzos NP, Polyzos IP, Mauri D, et al. Effect of periodontal disease treatment during pregnancy on preterm birth incidence: a metaanalysis of randomized trials. Am J Obstet Gynecol 2009; 200:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/65\">",
"      Offenbacher S, Beck JD, Jared HL, et al. Effects of periodontal therapy on rate of preterm delivery: a randomized controlled trial. Obstet Gynecol 2009; 114:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/66\">",
"      Newnham JP, Newnham IA, Ball CM, et al. Treatment of periodontal disease during pregnancy: a randomized controlled trial. Obstet Gynecol 2009; 114:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/67\">",
"      Macones GA, Parry S, Nelson DB, et al. Treatment of localized periodontal disease in pregnancy does not reduce the occurrence of preterm birth: results from the Periodontal Infections and Prematurity Study (PIPS). Am J Obstet Gynecol 2010; 202:147.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/68\">",
"      Jeffcoat M, Parry S, Gerlach RW, et al. Use of alcohol-free antimicrobial mouth rinse is associated with decreased incidence of preterm birth in a high-risk population. Am J Obstet Gynecol 2011; 205:382.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/69\">",
"      Kornman KS, di Giovine FS. Genetic variations in cytokine expression: a risk factor for severity of adult periodontitis. Ann Periodontol 1998; 3:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/70\">",
"      Galbraith GM, Steed RB, Sanders JJ, Pandey JP. Tumor necrosis factor alpha production by oral leukocytes: influence of tumor necrosis factor genotype. J Periodontol 1998; 69:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/71\">",
"      Kornman KS, Crane A, Wang HY, et al. The interleukin-1 genotype as a severity factor in adult periodontal disease. J Clin Periodontol 1997; 24:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/72\">",
"      Boggess KA, Moss K, Madianos P, et al. Fetal immune response to oral pathogens and risk of preterm birth. Am J Obstet Gynecol 2005; 193:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/73\">",
"      Xiong X, Buekens P, Fraser WD, et al. Periodontal disease and adverse pregnancy outcomes: a systematic review. BJOG 2006; 113:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/74\">",
"      McGaw T. Periodontal disease and preterm delivery of low-birth-weight infants. J Can Dent Assoc 2002; 68:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/75\">",
"      Boggess KA, Society for Maternal-Fetal Medicine Publications Committee. Maternal oral health in pregnancy. Obstet Gynecol 2008; 111:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/76\">",
"      Silk H, Douglass AB, Douglass JM, Silk L. Oral health during pregnancy. Am Fam Physician 2008; 77:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/77\">",
"      Multicenter randomized, controlled trial of a preterm birth prevention program. Collaborative Group on Preterm Birth Prevention. Am J Obstet Gynecol 1993; 169:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/78\">",
"      Urquhart C, Currell R, Harlow F, Callow L. Home uterine monitoring for detecting preterm labour. Cochrane Database Syst Rev 2012; 5:CD006172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/79\">",
"      Committee on Practice Bulletins&mdash;Obstetrics, The American College of Obstetricians and Gynecologists. Practice bulletin no. 130: prediction and prevention of preterm birth. Obstet Gynecol 2012; 120:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/80\">",
"      Fox NS, Gelber SE, Kalish RB, Chasen ST. The recommendation for bed rest in the setting of arrested preterm labor and premature rupture of membranes. Am J Obstet Gynecol 2009; 200:165.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/81\">",
"      Goldenberg RL, Cliver SP, Bronstein J, et al. Bed rest in pregnancy. Obstet Gynecol 1994; 84:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/82\">",
"      Sosa C, Althabe F, Beliz&aacute;n J, Bergel E. Bed rest in singleton pregnancies for preventing preterm birth. Cochrane Database Syst Rev 2004; :CD003581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/83\">",
"      Sciscione AC. Maternal activity restriction and the prevention of preterm birth. Am J Obstet Gynecol 2010; 202:232.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/84\">",
"      Yost NP, Bloom SL, McIntire DD, Leveno KJ. Hospitalization for women with arrested preterm labor: a randomized trial. Obstet Gynecol 2005; 106:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/85\">",
"      Kovacevich GJ, Gaich SA, Lavin JP, et al. The prevalence of thromboembolic events among women with extended bed rest prescribed as part of the treatment for premature labor or preterm premature rupture of membranes. Am J Obstet Gynecol 2000; 182:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/86\">",
"      Crowther CA, Han S. Hospitalisation and bed rest for multiple pregnancy. Cochrane Database Syst Rev 2010; :CD000110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/87\">",
"      Whitworth M, Quenby S. Prophylactic oral betamimetics for preventing preterm labour in singleton pregnancies. Cochrane Database Syst Rev 2008; :CD006395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/88\">",
"      Khanprakob T, Laopaiboon M, Lumbiganon P, Sangkomkamhang US. Cyclo-oxygenase (COX) inhibitors for preventing preterm labour. Cochrane Database Syst Rev 2012; 10:CD007748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/89\">",
"      Andrews WW, Sibai BM, Thom EA, et al. Randomized clinical trial of metronidazole plus erythromycin to prevent spontaneous preterm delivery in fetal fibronectin-positive women. Obstet Gynecol 2003; 101:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/90\">",
"      Andrews WW, Goldenberg RL, Hauth JC, et al. Interconceptional antibiotics to prevent spontaneous preterm birth: a randomized clinical trial. Am J Obstet Gynecol 2006; 194:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/91\">",
"      Goldenberg RL, Mwatha A, Read JS, et al. The HPTN 024 Study: the efficacy of antibiotics to prevent chorioamnionitis and preterm birth. Am J Obstet Gynecol 2006; 194:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/92\">",
"      Shennan A, Crawshaw S, Briley A, et al. A randomised controlled trial of metronidazole for the prevention of preterm birth in women positive for cervicovaginal fetal fibronectin: the PREMET Study. BJOG 2006; 113:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/93\">",
"      Tita AT, Cliver SP, Goepfert AR, et al. Clinical trial of interconceptional antibiotics to prevent preterm birth: subgroup analyses and possible adverse antibiotic-microbial interaction. Am J Obstet Gynecol 2007; 197:367.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/94\">",
"      Tita AT, Cliver SP, Goepfert AR, et al. Impact of interconception antibiotics on the endometrial microbial flora. Am J Obstet Gynecol 2007; 196:226.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/95\">",
"      Simcox R, Sin WT, Seed PT, et al. Prophylactic antibiotics for the prevention of preterm birth in women at risk: a meta-analysis. Aust N Z J Obstet Gynaecol 2007; 47:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/96\">",
"      Whitworth m, Quenby S, Cockerill, et al. Specialised antenatal clinics for women with a pregnancy at high risk of preterm birth (excluding multiple pregnancy) to improve maternal and infant outcomes. Cochrane Database Syst Rev 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/97\">",
"      Orr ST. Social support and pregnancy outcome: a review of the literature. Clin Obstet Gynecol 2004; 47:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/98\">",
"      Rogers MM, Peoples-Sheps MD, Suchindran C. Impact of a social support program on teenage prenatal care use and pregnancy outcomes. J Adolesc Health 1996; 19:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/99\">",
"      Villar J, Farnot U, Barros F, et al. A randomized trial of psychosocial support during high-risk pregnancies. The Latin American Network for Perinatal and Reproductive Research. N Engl J Med 1992; 327:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/100\">",
"      Khianman B, Pattanittum P, Thinkhamrop J, Lumbiganon P. Relaxation therapy for preventing and treating preterm labour. Cochrane Database Syst Rev 2012; 8:CD007426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/45/11994/abstract/101\">",
"      Negro R, Formoso G, Mangieri T, et al. Levothyroxine treatment in euthyroid pregnant women with autoimmune thyroid disease: effects on obstetrical complications. J Clin Endocrinol Metab 2006; 91:2587.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6780 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-4554544F47-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_45_11994=[""].join("\n");
var outline_f11_45_11994=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IDENTIFICATION OF RISK FACTORS FOR PRETERM BIRTH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      POTENTIALLY EFFECTIVE INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Supplemental progesterone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Inhibition of acute preterm labor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Diagnosis and treatment of asymptomatic bacteriuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Avoidance of cocaine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Decrease the rate of multiple gestation from ART",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cervical cerclage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H450759\">",
"      Pessary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Reduce occupational fatigue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Nutritional intervention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Avoiding a short interpregnancy interval",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30579651\">",
"      Avoidance or treatment of malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      UNPROVEN INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Diagnosis and treatment of genital tract infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Treatment of periodontal disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10578899\">",
"      - Scaling and root planing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10578911\">",
"      - Antimicrobial mouth wash",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10578936\">",
"      - Discussion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Assessment of uterine activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Bed rest and hospitalization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Abstinence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Prophylactic tocolytic drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Randomized trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Meta-analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Enhanced prenatal care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Social support and relaxation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6593355\">",
"      Thyroid hormone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6780\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6780|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/27/9660\" title=\"table 1\">",
"      Preterm birth risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/10/29867\" title=\"table 2\">",
"      Work and pregnancy outcome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36633?source=related_link\">",
"      Approach to women with symptoms of vaginitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30602?source=related_link\">",
"      Bacterial vaginosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4457?source=related_link\">",
"      Cervical insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19354?source=related_link\">",
"      Chemoprophylaxis for the prevention of neonatal group B streptococcal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/53/20313?source=related_link\">",
"      Complications, diagnosis, and treatment of odontogenic infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/35/26166?source=related_link\">",
"      Diagnosis of gonococcal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/51/15159?source=related_link\">",
"      Fetal fibronectin for prediction of preterm labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42728?source=related_link\">",
"      Genital Chlamydia trachomatis infections in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35674?source=related_link\">",
"      Inhibition of acute preterm labor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/63/13302?source=related_link\">",
"      Interpregnancy interval and pregnancy outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24135?source=related_link\">",
"      Management of pregnant women after inhibition of acute preterm labor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/44/28362?source=related_link\">",
"      Nutrition in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6346?source=related_link\">",
"      Overview of illicit drug use in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/33/16921?source=related_link\">",
"      Overview of malaria in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32393?source=related_link\">",
"      Pathogenesis of spontaneous preterm birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/52/35650?source=related_link\">",
"      Patient information: Preterm labor (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15866?source=related_link\">",
"      Preterm premature rupture of membranes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5657?source=related_link\">",
"      Progesterone supplementation to reduce the risk of spontaneous preterm birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/30/7657?source=related_link\">",
"      Recommendations for exercise during pregnancy and the postpartum period",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35898?source=related_link\">",
"      Risk factors for preterm labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27482?source=related_link\">",
"      Smoking and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/27/43449?source=related_link\">",
"      Strategies to control the rate of high order multiple gestation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4057?source=related_link\">",
"      Syphilis in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21017?source=related_link\">",
"      Transvaginal ultrasound assessment of the cervix and prediction of spontaneous preterm birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20695?source=related_link\">",
"      Treatment and prevention of malaria in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/3/19514?source=related_link\">",
"      Treatment of uncomplicated gonococcal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/40/43657?source=related_link\">",
"      Urinary tract infections and asymptomatic bacteriuria in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_45_11995="Causes male sexual dysfunction";
var content_f11_45_11995=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F61756&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F61756&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical clues to causes of male sexual dysfunction",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Finding",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cause",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Rapid onset",
"       </td>",
"       <td>",
"        Psychogenic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Genitourinary trauma - eg, radical prostatectomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Nonsustained erection",
"       </td>",
"       <td>",
"        Anxiety",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vascular steal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Depression or use of certain drugs",
"       </td>",
"       <td>",
"        Depression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drug-induced",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Complete loss of nocturnal erections",
"       </td>",
"       <td>",
"        Vascular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurologic disease",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_45_11995=[""].join("\n");
var outline_f11_45_11995=null;
var title_f11_45_11996="Graded prognostic assessment for brain metastases breast cancer";
var content_f11_45_11996=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F54755&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F54755&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Graded prognostic assessment for brain metastases from breast cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Prognostic factor",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"5\">",
"        GPA scoring criteria",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Patient score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        0",
"       </td>",
"       <td class=\"subtitle3\">",
"        0.5",
"       </td>",
"       <td class=\"subtitle3\">",
"        1.0",
"       </td>",
"       <td class=\"subtitle3\">",
"        1.5",
"       </td>",
"       <td class=\"subtitle3\">",
"        2.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Breast cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        KPS",
"       </td>",
"       <td>",
"        &le;50",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        70-80",
"       </td>",
"       <td>",
"        90-100",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Subtype*",
"       </td>",
"       <td>",
"        Basal",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        Luminal A",
"       </td>",
"       <td>",
"        HER2",
"       </td>",
"       <td>",
"        Luminal B",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Age, years",
"       </td>",
"       <td>",
"        &ge;60",
"       </td>",
"       <td>",
"        &lt;60",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td align=\"right\" colspan=\"6\">",
"        <strong>",
"         Sum total:",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Median survival (months) by GPA: 0-1.0 = 3.4; 1.5-2.0 = 7.7; 2.5-3.0 = 15.1; 3.5-4.0 = 25.3.",
"    <div class=\"footnotes\">",
"     * Basal: triple negative; Luminal A: ER/PR positive, HER2 negative; Luminal B: triple positive; HER2: ER/PR negative, HER2 positive.",
"     <br>",
"      GPA: graded prognostic assessment; ER: estrogen receptor; HER2: human epidermal growth factor receptor 2; KPS: Karnofsky performance score; PR: progesterone receptor.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     From: Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: An accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2012: 30:419. Reprinted with permission. Copyright &copy; 2012 American Society of Clinical Oncology. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_45_11996=[""].join("\n");
var outline_f11_45_11996=null;
var title_f11_45_11997="Guidelines for implementation of developmental screening";
var content_f11_45_11997=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79718&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79718&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for implementation of developmental-behavioral screening in primary care",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Save time",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        At all well-visits, use validated accurate measures to accomplish both screening and surveillance tasks (ie, to elicit and address parents' concerns and track developmental milestones, monitor psychosocial risk and protective factors, etc)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use screens focused on protective factors and psychosocial risk at birth, 12 months, and annually thereafter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ask parents to complete the screens before the visit (have forms distributed in the waiting or exam room, or mailed out before the visit)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Administer screens for autism spectrum disorder (eg, the Modified Checklist of Autism in Toddlers) at 18 months and at 24 to 30 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use electronic applications (so that parents can complete measures at home or on an office computer). Online screening services offer automated scoring and can generate billing/procedure codes, summary reports, and letters of referral.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Make follow-up appointments when autism or behavioral/mental health screens are needed and ask the parents to complete the forms before the visit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Check literacy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If printed screens are used, make sure that whoever hands out the screens asks parents which language they prefer and whether they would like to complete the form on their own or have someone go through it with them",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Be prepared to address the various outcomes of screening (see text for details)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Prepare for developmental promotion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Parents often request additional information on child-rearing issues (eg, toilet training, temper tantrums, etc). See table: \"Resources for developmental/behavioral concerns.\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Know the resources in your community that promote early childhood development",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Make use of Internet resources. See tables: \"Educational resources for developmental-behavioral concerns\" and \"Service resources for children with developmental-behavioral concerns.\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Make initial contacts with your local Early Intervention agency and public school system to facilitate and improve the flow of information (eg, two-way consent forms)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Maintain a current list of telephone numbers for local service providers (eg, speech-language centers, school psychologists, parent training classes, etc). See table: \"Service resources for children with developmental-behavioral concerns.\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Engage office staff by helping them to understand the value of early detection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Office staff play a critical role in screening and surveillance (by assisting with completion of screening measures; entering results into the child's record; determining requisite billing/coding procedures; and encouraging families to follow through with clinician recommendations). Office staff need to understand why early detection is critical and should be sufficiently empowered to take charge of the implementation process.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Refer and don't defer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Have a low threshold for referring children with possible developmental delays, especially if there are psychosocial risk factors. Such children can be referred for Early Intervention assessment or child development programs such as Head Start even without an established diagnosis of developmental disability.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data compiled from:",
"     <br>",
"      <ol>",
"       <li>",
"        Glascoe FP. Collaborating with parents: using parents' evaluations of developmental status to detect and address developmental and behavioral problems, PEDSTest.com, LLC, Nolensville, TN, 2002.",
"       </li>",
"       <li>",
"        Glascoe FP. www.pedstest.com. Nolensville, TN: PEDStest.com, LLC, 2011.",
"       </li>",
"       <li>",
"        King TM, Glascoe FP. Developmental surveillance of infants and young children in pediatric primary care. Curr Opin Pediatr 2003; 15:624.4.",
"       </li>",
"       <li>",
"        Squires J, Nickel RE, Eisert D. Early detection of developmental problems: strategies for monitoring young children in the practice setting. J Dev Behav Pediatr 1996; 17:420.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_45_11997=[""].join("\n");
var outline_f11_45_11997=null;
var title_f11_45_11998="Siedel test";
var content_f11_45_11998=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F67497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F67497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Positive Seidel's test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A small perforation will cause a clearing of the dense fluorescein that appears to be streaming away from the perforation site.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_45_11998=[""].join("\n");
var outline_f11_45_11998=null;
var title_f11_45_11999="Spurling test";
var content_f11_45_11999=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F52401&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F52401&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Spurling test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 379px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Spurling test is performed by applying downward pressure to the patient's head with the patient's neck extended and rotated toward the involved side. This neck position narrows the intervertebral foramina on the affected side and reproduces the radiating pain if there is pathology at the root or foramen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jason E Decker, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_45_11999=[""].join("\n");
var outline_f11_45_11999=null;
